{"100-1.\n\u4e00\u4f4d58\u6b72\u5a66\u5973\uff0c\u56e0\u70ba\u5169\u908a\u5c0f\u817f\u7600\u9752\u53ca\u816b\u8139\u75bc\u75db\u61c9\u8a3a\uff0c\u62bd\u8840\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d20 12.1 g/dL\uff0c\u767d\u8840\u7403 8,290/\u03bcL\uff0c\u8840\u5c0f\u677f 225,000/\u03bcL\uff0cPT 11.3\"(\u6b63\u5e388.0-12.2)\uff0cINR 1.02\uff0caPTT 77.3\"(\u6b63\u5e3826.9-36.3)\u3002\u5c07\u75c5\u4eba\u8207\u6b63\u5e38\u4e4b\u8840\u6f3f\u4ee51:1\u505a\u6df7\u5408\u8a66\u9a57\uff0c\u958b\u59cb\u6642aPTT\u70ba39.2\"\uff0c1\u5c0f\u6642\u5f8c51.2\"\u3002\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Antiphospholipid antibody syndrome\nB. Acquired hemophilia\nC. von Willebrand disease\nD. Warfarin overdose\nE. Liver function impairment\n": "(B)", "100-2.\n\u4e00\u4f4d45\u6b72\u7537\u6027\uff0c\u904e\u53bb\u66fe\u56e0\u70ba\u98a8\u6fd5\u6027\u5fc3\u81df\u75c5\u63a5\u53d7\u4e8c\u5c16\u74e3\u74e3\u819c\u7f6e\u63db\u8853\uff0c\u5176\u4ed6\u7121\u7279\u6b8a\u75c5\u53f2\u3002\u6700\u8fd1\u62bd\u8840\u767c\u73fe\u8840\u7d05\u7d20 8.2 g/dL\uff0cMCV 108 fL\uff0c\u767d\u8840\u7403 9,650/\u03bcL\uff0c\u8840\u5c0f\u677f 209,000/\u03bcL\uff0cbilirubin\u5168\u91cf(total) 5.1 mg/dL\uff0c\u76f4\u63a5\u578b(direct) 0.80 mg/dL\uff0cGOT 234 IU/L\uff0cGPT 36 IU/L\uff0cLDH 4,300 IU/L\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u3002\u6b64\u75c5\u4eba\u8ca7\u8840\u6700\u53ef\u80fd\u7684\u539f\u56e0\u70ba\u4f55\uff1f\nA. Anemia related to liver disease\nB. Iron deficiency anemia\nC. Autoimmune hemolytic anemia\nD. Mechanical hemolytic anemia\nE. Thalassemia\n": "(D)", "100-3.\n\u4e00\u4f4d57\u6b72\u75c5\u4eba\u8840\u6db2\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d20 5 g/dL\uff0c\u7d05\u8840\u7403 1,655,000/\u03bcL\uff0c\u7db2\u72c0\u7d05\u8840\u7403 0.5%\uff0c\u767d\u8840\u7403 2,450/\u03bcL\uff0c\u4e2d\u6027\u9846\u7c92\u7403 20%\uff0c\u8840\u5c0f\u677f 16,000/\u03bcL\uff0c\u9aa8\u9ad3\u6aa2\u67e5\u8a3c\u5be6\u70ba\u518d\u751f\u4e0d\u826f\u6027\u8ca7\u8840\uff0c\u7d30\u80de\u7d50\u69cb\u4f54 5%\u3002\u5c0d\u6b64\u75c5\u4eba\u6700\u9069\u7576\u7684\u6cbb\u7642\u70ba\uff1f\nA. Anti-thymocyte globulin plus cyclosporine\nB. Anabolic hormone\nC. Steroids\nD. Azathioprine\nE. Allogeneic hematopoietic stem cell transplantation\n": "(A)", "100-4.\n\u4ee5\u4e0b\u5404\u75be\u75c5\u53ca\u5176\u6cbb\u7642\u85e5\u7269\u4e4b\u914d\u5c0d\u4f55\u8005\u6709\u8aa4\uff1f\nA. Acute promyeloctyic leukemia-tretinoin\nB. Chronic myeloid leukemia-imatinib\nC. Follicular lymphoma-rituximab\nD. Multiple myeloma-bortezomib\nE. Essential thrombocythemia-bevacizumab\n": "(E)", "100-5.\n\u4e0b\u5217\u4f55\u7a2e\u6210\u4eba\u8840\u6db2\u60e1\u6027\u75c5\u5728\u9054\u5230\u7de9\u89e3\u6642\u61c9\u8003\u616e\u79fb\u690d\uff0c\u4ee5\u589e\u52a0\u75c5\u4eba\u7684\u5b58\u6d3b\uff1f\nA. Acute lymphoblastic leukemia with t(9;22)\nB. Acute lymphoblastic leukemia with t(12;21)\nC. Acute lymphoblastic leukemia with t(8;21)\nD. Acute lymphoblastic leukemia with inv(16)\nE. Acute lymphoblastic leukemia with t(15;17)\n": "(A)", "100-6.\n\u4e00\u4f4d62\u6b72\u5973\u6027\uff0c\u904e\u53bb\u7121\u5168\u8eab\u6027\u75be\u75c5\u75c5\u53f2\uff0c\u56e0\u70ba\u75b2\u5026\u53ca\u80cc\u75db\u61c9\u8a3a\uff0c\u8840\u6db2\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d20 8.3 g/dL\uff0c\u767d\u8840\u7403 8,650/\u03bcL\uff0c\u5206\u985e\u6b63\u5e38\uff0c\u8840\u5c0f\u677f 165,000/\u03bcL\uff0c\u767d\u86cb\u767d 3.4 g/dL\uff0c\u7403\u86cb\u767d 2.1 g/dL\uff0cCa 2.83 mmol/L\uff0cCr 2.6 mg/dL\uff0cUA 6.6 mg/dL\uff0c\u809d\u529f\u80fd\u6b63\u5e38\uff0c\u5c3f\u86cb\u767d1+\uff0c\u7121\u8840\u5c3f\u6216\u81bf\u5c3f\uff0cX-\u5149\u6aa2\u67e5\u5982\u5716\u6240\u793a\u3002\u4e0b\u4e00\u6b65\u6700\u9069\u7576\u7684\u6aa2\u67e5\u70ba\u4f55\uff1f\nA. Renal sonogram\nB. Kidney biopsy\nC. Bone Scan\nD. Blood and urine immunoelectrophoresis\nE. Parathyroid hormone level\n": "(D)", "100-7.\n\u4e0b\u5217\u8207\u539f\u767c\u6027\u591a\u8840\u75c7(polycythemia vera)\u75c5\u4eba\u76f8\u95dc\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e\uff1f\nA. \u591a\u6709JAK2\u57fa\u56e0\u7a81\u8b8a\nB. \u8840\u4e2derythropoietin\u6fc3\u5ea6\u4e0b\u964d\nC. \u5e38\u4f34\u96a8\u767d\u8840\u7403\u53ca\u8840\u5c0f\u677f\u6578\u76ee\u589e\u52a0\nD. \u767c\u751f\u6813\u585e\u7684\u6a5f\u6703\u8f03\u4e00\u822c\u4eba\u9ad8\nE. LAP\u6578\u503c\u5e38\u4e0b\u964d\n": "(E)", "100-8.\n\u4e00\u4f4d55\u6b72\u5973\u6027\uff0c\u56e0\u76ae\u819a\u7600\u9752\u61c9\u8a3a\uff0c\u7406\u5b78\u6aa2\u67e5\u7121\u5176\u4ed6\u90e8\u4f4d\u51fa\u8840\u73fe\u8c61\u3002\u8840\u6db2\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d20 12.5 g/dL\uff0c\u767d\u8840\u7403 4,350/\u03bcL\uff0c\u5206\u985e\u6b63\u5e38\uff0c\u8840\u5c0f\u677f 15,000/\u03bcL\u3002\u9aa8\u9ad3\u6aa2\u67e5\u8a3c\u5be6\u70ba\u514d\u75ab\u6027\u8840\u5c0f\u677f\u7f3a\u4e4f\u6027\u7d2b\u6591\u75c7\u3002\u6b64\u6642\u61c9\u9078\u64c7\u4f55\u7a2e\u6cbb\u7642\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r(1)\u8f38\u6ce8\u8840\u5c0f\u677f\u6fc3\u7e2e\u6db2\r(2)\u985e\u56fa\u9187\r(3)\u514d\u75ab\u7403\u86cb\u767d\nA. 1\nB. 2\nC. 3\nD. 1+2\nE. 1+2+3\n": "(B)", "100-9.\n\u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\u4eba\u6709\u4e0b\u5217\u4f55\u7a2e\u57fa\u56e0\u7570\u5e38\u8005\u9810\u5f8c\u8f03\u597d\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r(1)NPM1mutation\r(2)FLT3-ITD\r(3)CEBPA mutation\r(4)MLL rearrangement\nA. 1\nB. 1+2\nC. 1+3\nD. 1+4\nE. 1+2+3\n": "(C)", "100-10.\n\u4e0b\u5217\u4f55\u8005\u70bahemophagocytic syndrome\u5e38\u898b\u7684\u81e8\u5e8a\u8868\u73fe?(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.fever\r2.pancytopenia\r3.hyperferritinemia\r4.high LDH level\nA. 1\nB. 1+2\nC. 1+4\nD. 1+2+3\nE. 1+2+3+4\n": "(E)", "100-1.\n\u4e0b\u5217\u4f55\u8005\u5c6c\u65bc\u764c\u75c7\u6cbb\u7642\u5f8c\u816b\u7624\u6eb6\u89e3\u75c7\u5019\u7fa4\uff08tumor lysis syndrome\uff09\u7684\u7279\u5fb5\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.hyperuricemia\r2.hyperphosphatemia\r3.hyperkalemia\r4.hypercalcemia\r5.lactic acidosis\nA. 1+2+4\nB. 1+3+4\nC. 1+4+5\nD. 1+2+3+5\nE. 2+3+4+5\n": "(D)", "100-2.\n\u4e0b\u5217\u4f55\u8005\u6703\u5f15\u8d77\u4eba\u985e\u7684\u6dcb\u5df4\u60e1\u6027\u75be\u75c5\uff08lymphoid malignancy\uff09\u7684\u767c\u751f\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.Helicobacter pylori \u611f\u67d3\r2.Hepatitis B virus\uff08HBV\uff09\u611f\u67d3\r3.Celiac sprue\r4.Human herpes virus 8\uff08HHV8\uff09\u611f\u67d3\r5.Epstein-Barr virus\uff08EBV\uff09\u611f\u67d3\nA. 1+2+3\nB. 1+2+4\nC. 1+2+4+5\nD. 1+3+4+5\nE. 1+2+3+4+5\n": "(D)", "100-3.\n\u4ee5\u4e0b\u5404\u75c7\u5019\u7fa4\uff08syndrome\uff09\u8207\u764c\u75c7\u7684\u767c\u751f\u7387\u589e\u52a0\u6709\u95dc\uff0c\u4f55\u8005\u9664\u5916\uff1f\nA. von Hippel-Lindau syndrome\nB. Fragile X syndrome\nC. Ataxia telangiectasia\nD. Neurofibromatosis, type II\nE. Bloom syndrome\n": "(B)", "100-4.\n\u4e00\u4f4d\u8eab\u9ad4\u5411\u4f86\u5065\u5eb7\u768460\u6b72\u5973\u6027\u63a5\u53d7\u4f8b\u884c\u6027\u5927\u8178\u5167\u8996\u93e1\u6aa2\u67e5\uff08colonoscopy\uff09\uff0c\u5728\u6a6b\u7d50\u8178\u767c\u73fe\u4e00\u500b1.5\u516c\u5206\u5927\u5c0f\u4e4b\u7121\u67c4\u7684\u6241\u5e73\u6027\uff08sessile, flat-based\uff09\u606f\u8089\uff0c\u9806\u5229\u9032\u884c\u606f\u8089\u5207\u9664\uff0c\u75c5\u7406\u6aa2\u67e5\u7d50\u679c\u70ba\u817a\u7624\u6027\u606f\u8089\uff08villous adenoma\uff09\uff0c\u4e26\u672a\u767c\u73fe\u60e1\u6027\u8b8a\u5316\u3002\u4f60\u5efa\u8b70\u4e0b\u4e00\u6b65\u7684\u8655\u7f6e\u65b9\u5f0f\u8f03\u9069\u7576\uff1f\nA. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\uff08CT\uff09\u6383\u63cf\u6aa2\u67e5\nB. \u90e8\u5206\u7d50\u8178\u5207\u9664\u8853\uff08partial colectomy\uff09\nC. 10\u5e74\u5f8c\uff0c\u518d\u9032\u884c\u4e00\u6b21\u5927\u8178\u5167\u8996\u93e1\u6aa2\u67e5\nD. 3\u5e74\u5f8c\uff0c\u518d\u9032\u884c\u4e00\u6b21\u5927\u8178\u5167\u8996\u93e1\u6aa2\u67e5\nE. 3\u500b\u6708\u5f8c\uff0c\u518d\u9032\u884c\u4e00\u6b21\u5927\u8178\u5167\u8996\u93e1\u6aa2\u67e5\n": "(D)", "100-5.\n\u4e0b\u5217\u54ea\u4e00\u7a2e\u6a19\u9776\u6216\u5316\u5b78\u6cbb\u7642\u8207\u76f8\u95dc\u526f\u4f5c\u7528\u7684\u914d\u5c0d\u662f\u4e0d\u6b63\u78ba\u7684\uff1f\nA. Ifosfamide \uff0d Fanconi-like syndrome\nB. Cyclophosphamide \uff0d hematuria\nC. Trastuzumab plus doxorubicin \uff0d heart failure\nD. Bevacizumab \uff0d hypertension, proteinuria\nE. Cisplatin \uff0d liver toxicity\n": "(E)", "100-6.\n\u764c\u75c7\u75c5\u4eba\u5408\u4f75\u9ad4\u6db2\u6027\u9ad8\u8840\u9223\u75c7\uff08humoral hypercalcemia of malignancy , HHM\uff09\uff0c\u6700\u5e38\u898b\u7684\u539f\u56e0\u70ba\u4f55\uff1f\nA. \u816b\u7624\u7d30\u80de\u5c0d\u9aa8\u9abc\u7684\u76f4\u63a5\u7834\u58de\nB. Parathyroid hormone\uff08PTH\uff09\u7684\u904e\u5ea6\u88fd\u9020\u5206\u6ccc\nC. 1, 25-hydroxyvitamin D\u7684\u6fc3\u5ea6\u4e0a\u5347\nD. Parathyroid hormone-related peptide\uff08PTHrP\uff09\u7684\u904e\u5ea6\u88fd\u9020\u5206\u6ccc\nE. \u9aa8\u9abc\u8f49\u79fb\u5f15\u8d77\u5c40\u90e8TNF\uff08tumor necrosis factor\uff09\u8207IL-6\u7684\u5206\u6ccc\n": "(D)", "100-7.\n\u6709\u95dc\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u7684\u4e0a\u76ae\u764c\uff08Carcinoma of unknown primary, CUP\uff09\uff0c\u6709\u6642\u9664\u4e86\u75c5\u7406\u7d44\u7e54\u7684H&E\u67d3\u8272\u578b\u614b\u4e4b\u5916\uff0c\u9700\u501f\u52a9\u65bc\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u67d3\u8272\u4f86\u5354\u52a9\u5224\u65b7CUP\u7684\u539f\u767c\u5668\u5b98\u3002\u4e0b\u5217\u54ea\u4e00\u7a2e\u6a19\u8a18\u7684\u6297\u9ad4\u6838\u67d3\u8272\u7d04\u670968%\u80ba\u817a\u764c(adenocarcinoma of the lung) \u5448\u967d\u6027\u820725%\u7684\u80ba\u9c57\u72c0\u4e0a\u76ae\u764c(squamous cell carcinoma of the lung)\u5448\u967d\u6027\uff0c\u7d93\u5e38\u505a\u70ba\u80ba\u81df\u70baCUP\u539f\u767c\u5668\u5b98\u4e4b\u9451\u5225\u8a3a\u65b7\u8f14\u52a9\u6a19\u8a18\u4e4b\u3127\uff1f\nA. Thyroglobulin\nB. Thyroid transcription factor 1 (TTF-1)\nC. CDX-2 transcription factor (CDX-2)\nD. Cytokeratin (CK)\nE. Leucocyte common antigen (LCA)\n": "(B)", "100-8.\n\u4e0b\u5217\u4f55\u7a2e\u539f\u767c\u5668\u5b98\u7522\u751f\u7684\u764c\u75c7\uff0c\u8f49\u79fb(metastasis)\u81f3\u9aa8\u9abc\u7cfb\u7d71\u76f8\u5c0d\u6a5f\u6703\u6700\u4f4e\uff1f\nA. Lung\nB. Prostate\nC. Colon\nD. Breast\nE. Kidney\n": "(C)", "100-9.\n\u4e0b\u5217\u764c\u75c7\u5747\u7d93\u5e38\u8f49\u79fb(metastasis)\u81f3\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\uff0c\u4f55\u8005\u76f8\u5c0d\u6a5f\u6703\u6700\u4f4e\uff1f\nA. Breast cancer\nB. Melanoma\nC. Acute lymphoblastic leukemia\uff08ALL\uff09\nD. Kidney cancer\nE. Hodgkin's disease\n": "(E)", "100-10.\n\u4e00\u4f4d65\u6b72\u7537\u6027\uff0c\u7121\u5176\u4ed6\u7279\u6b8a\u75be\u75c5\uff0c\u56e0\u61f7\u7591\u7f79\u60a3\u76f4\u8178\u764c(rectal cancer)\uff0c\u800c\u63a5\u53d7\u5927\u8178\u5167\u8996\u93e1\u6aa2\u67e5\uff0c\u767c\u73fe\u6709\u4e004\u00d73\u516c\u5206\u816b\u7624\uff0c\u816b\u7624\u4e0b\u7de3\u8dddanal verge\u50c53\u516c\u5206\uff0c\u75c5\u7406\u5207\u7247\u6aa2\u67e5\u767c\u73fe\u4e2d\u7b49\u5206\u5316\u4e4b\u817a\u764c\uff0c\u4e26\u7121\u5176\u4ed6\u4e4b\u5668\u5b98\u8f49\u79fb\uff0c CEA\u70ba15.0 ng/mL\u3002\u76f4\u8178\u816b\u7624\u7d93\u624b\u8853\u5207\u9664(abdomino-perineal resection)\uff0c\u75c5\u7406\u6aa2\u67e5\u816b\u7624\u5df2\u4fb5\u72af\u81f3\u6f3f\u819c\u5c64 (serosa)\u5916\uff0c15\u9846\u5c40\u90e8\u6dcb\u5df4\u7d50\u5176\u4e2d7\u9846\u6709\u764c\u7d30\u80de\u8f49\u79fb\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u8f03\u70ba\u9069\u7576\uff1f\nA. \u8f14\u52a9\u6027(adjuvant)\u5316\u5b78\u6cbb\u7642\u53ca\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u5747\u4e0d\u61c9\u8003\u616e\u7d66\u8207\nB. \u61c9\u8003\u616e\u7d66\u8207\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\uff0c\u4f46\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u4e0d\u61c9\u8003\u616e\u7d66\u8207\nC. \u61c9\u8003\u616e\u7d66\u8207\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u4f46\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\u4e0d\u61c9\u8003\u616e\u7d66\u8207\nD. \u61c9\u8003\u616e\u7d93\u809d\u52d5\u8108\u7d66\u8207\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\u4ee5\u9810\u9632\u809d\u81df\u8f49\u79fb\nE. \u61c9\u8003\u616e\u7d66\u8207\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\u53ca\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\n": "(E)", "101-1.\n\u4e00\u4f4d23\u6b72\u7537\u6027\u904e\u53bb\u7121\u7279\u6b8a\u4e0d\u9069\uff0c\u5728\u7576\u5175\u524d\u9ad4\u6aa2\u767c\u73fe\u8f15\u5fae\u8ca7\u8840\u53ca\u9ec3\u75b8\uff0cHb 11.1 gm/dL, WBC 5990/uL\uff0cplatelet 172000/uL\uff0cbilirubin\u5168\u91cf4.1 mg/dL\uff0c\u76f4\u63a5\u578b0.61 mg/dL\uff0c\u5468\u908a\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\u3002\u6b64\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Thalassemia\nB. Hereditary spherocytosis\nC. G6PD deficiency\nD. Chronic hepatitis\nE. Gilbert's disease\n": "(B)", "101-2.\n\u4e00\u4f4d\u75c5\u4eba\u56e0\u70ba\u62d4\u7259\u6d41\u8840\u4e0d\u6b62\u4f86\u5230\u6025\u8a3a\u8655\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\uff0c\u9019\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u5f97\u4e86\u4f55\u7a2e\u75c5\uff1f\nA. Lymphoma\nB. Chronic myeloid leukemia\nC. Acute lymphoblastic leukemia\nD. Acute promyelocytic leukemia\nE. Acute monocytic leukemia\n": "(D)", "101-3.\n\u4e00\u4f4d50\u6b72\u5973\u6027\u88ab\u8a3a\u65b7\u6709portal vein thrombosis\u3002\u5468\u908a\u8840\u6db2\u6aa2\u67e5\u767c\u73fe\u6709JAK2\u57fa\u56e0\u7a81\u8b8a\uff0c\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u6709\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\uff1f\nA. Myeloproliferative neoplasm\nB. Paroxysmal nocturnal hemoglobinuria\nC. Protein S deficiency\nD. Protein C deficiency\nE. Antithrombin III deficiency\n": "(A)", "101-4.\n\u4e00\u4f4d\u75c5\u4eba\u7684\u5468\u908a\u8840\u51fa\u73fe\u82bd\u7d30\u80de\uff0c\u9aa8\u9ad3\u6aa2\u67e5\u767c\u73fe\u82bd\u7d30\u80de\u70ba35%\uff0cmyeloperoxidase\u70ba\u9670\u6027\uff0c\u5176\u7d30\u80de\u8868\u9762\u6297\u539f\u8868\u73fe\u5982\u4e0bCD2(-)CD3(-)CD13(-)CD19(-)CD20(-)CD33(+)CD41(+)CD61(+)\u3002\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Early preB acute lymphoblastic leukemia\nB. T-acute lymphoblastic leukemia\nC. Acute erythroleukemia\nD. Acute monocytic leukemia\nE. Acute megakaryoblastic leukemia\n": "(E)", "101-5.\nBortezomib\u76ee\u524d\u5df2\u662f\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684\u7b2c\u4e00\u7dda\u7528\u85e5\uff0c\u5176\u4f5c\u7528\u6a5f\u8f49\u70ba\u4f55\uff1f\nA. Tyrosine kinase inhibitor\nB. Immunomodulation\nC. Proteosome inhibitor\nD. Anti-angiogenesis\nE. Anti-IL6\n": "(C)", "101-6.\n\u4e0b\u5217\u6709\u95dctransfusion related acute lung injury (TRALI)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u662f\u932f\u8aa4\u7684\uff1f\nA. \u4e00\u822c\u5728\u8f38\u5165\u5e36\u6709\u8840\u6f3f\u7684\u8840\u6db2\u6210\u5206\u5f8c\u767c\u751f\nB. \u591a\u5728\u8f38\u8840\u5f8c6\u81f312\u5c0f\u6642\u4e2d\u767c\u751f\nC. \u75c5\u4eba\u7684\u75c7\u72c0\u70ba\u7a81\u767c\u7684\u547c\u5438\u6025\u4fc3\u4e26\u6709\u80ba\u90e8\u6d78\u6f64\u7684\u73fe\u8c61\nD. \u53ef\u80fd\u7684\u6a5f\u8f49\u70ba\u8f38\u5165\u7684\u8840\u6db2\u6210\u5206\u4e2d\u6709\u5c0d\u6297\u53d7\u8840\u8005\u767d\u8840\u7403\u6297\u539f\u7684\u6297\u9ad4\nE. \u7531\u65bc\u985e\u56fa\u9187\u7684\u6cbb\u7642\u6548\u679c\u4e26\u4e0d\u78ba\u5b9a\uff0c\u4e00\u822c\u4e0d\u5efa\u8b70\u4f5c\u70ba\u4f8b\u884c\u6cbb\u7642\u4e4b\u7528\n": "(B)", "101-7.\n\u4e00\u4f4d25\u6b72\u5973\u6027\u958b\u5200\u5f8c\u51fa\u8840\u4e0d\u6b62\uff0c\u62bd\u8840\u6aa2\u67e5\u767c\u73fe Hb 10.5gm/dL\uff0cWBC 4350/uL\uff0c\u5206\u985e\u6b63\u5e38\uff0c\u8840\u5c0f\u677f 247000/uL\uff0cPT 10.1\" (\u6b63\u5e388\"~12.2\")\uff0cINR 0.96\uff0caPTT 46\" (\u6b63\u5e3826.9\"~36.3\")\u3002\u70ba\u8a3a\u65b7\u75c5\u4eba\u51fa\u8840\u50be\u5411\u7684\u539f\u56e0\uff0c\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u6700\u4e0d\u9700\u8981\uff1f\nA. Lupus anticoagulant\nB. Factor VIII\nC. vWF\nD. Platelet function test\nE. Ristocetin cofactor activity\n": "(A)", "101-8.\n\u4e00\u4f4d29\u6b72\u5973\u6027\u7121\u7279\u6b8a\u4e0d\u9069\uff0c\u4e09\u5e74\u524d\u516c\u53f8\u4f8b\u884c\u9ad4\u6aa2\u7684\u8840\u6db2\u76f8\u986f\u793aHb 11.5 gm/dL\uff0cMCV 84fL\uff0cWBC 4750/uL\uff0c\u8840\u5c0f\u677f 325000/uL\u3002\u4eca\u5e74\u7684\u9ad4\u6aa2\u986f\u793aHb 9.8 gm/dL\uff0cMCV 70fL\uff0cWBC 3350/uL\uff0c\u5206\u985e\u6b63\u5e38\uff0c\u8840\u5c0f\u677f416000/uL\u3002\u7406\u5b78\u6aa2\u67e5\u9664\u7d50\u819c\u7a0d\u5fae\u84bc\u767d\u5916\uff0c\u7121\u5176\u4ed6\u7570\u5e38\u3002\u6b64\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Thalassemia\nB. Iron deficiency\nC. Anemia of chronic disorder\nD. Essential thrombocythemia\nE. Myelodysplastic syndrome\n": "(B)", "101-9.\n\u4e0b\u5217\u6709\u95dcparoxysmal nocturnal hemoglobinuria(PNH) \u75c5\u4eba\u7684\u6558\u8ff0\u4f55\u8005\u662f\u6b63\u78ba\u7684\uff1f(\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r(1)\u5468\u908a\u8840\u5e38\u5448\u73fe\u5168\u8840\u7403\u6e1b\u5c11\r(2)\u8840\u7403\u4e0a\u7f3a\u4e4fCD53\u53caCD58\r(3)\u6613\u767c\u751f\u975c\u8108\u6813\u585e\r(4)Eculizumab\u53ef\u6539\u5584\u75c5\u4eba\u7684\u75c7\u72c0\nA. (1)+(4)\nB. (2)+(3)\nC. (1)+(3)+(4)\nD. (2)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(C)", "101-10.\n\u4e0b\u5217\u5fae\u751f\u7269\u53ca\u5176\u76f8\u95dc\u4e4b\u6dcb\u5df4\u7624\u7684\u914d\u5c0d\uff0c\u4f55\u8005\u662f\u6b63\u78ba\u7684\uff1f\r(\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r(1)Helicobacter pylori, gastric MALT lymphoma\r(2)EB virus, NK/T cell lymphoma\r(3)HTLV-I, adult T cell lymphoma/leukemia\r(4)HCV, lymphoplasmacytoid lymphoma\nA. (1)\nB. (2)+(3)\nC. (1)+(3)\nD. (1)+(2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(E)", "101-1.\n\u816b\u7624\u6a19\u8a18(tumor markers)\u7684\u61c9\u7528\uff0c\u53ef\u904b\u7528\u5728\u60e1\u6027\u816b\u7624\u7684\u6cbb\u7642\u671f\u9593\uff0c\u4f5c\u70ba\u6cbb\u7642\u6210\u6548\u7684\u8f14\u52a9\u8a55\u4f30\u3002\u4ee5\u4e0b\u5404\u7a2e\u816b\u7624\u6a19\u8a18\u8207\u816b\u7624\u7684\u914d\u5c0d\uff0c\u54ea\u4e9b\u662f\u6b63\u78ba\u7684?\r(1)catecholamines\u8207pheochromocytoma\r(2)calcitonin\u8207papillary cancer of the thyroid\r(3)human chorionic gonadotropin (hCG)\u8207gestational trophoblastic disease\r(4)\u03b1-fetoprotein\u8207gonadal germ cell tumor\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (1)+(3)+(4)\nD. (2)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(C)", "101-2.\n\u8a31\u591a\u60e1\u6027\u816b\u7624\u5e38\u6709\u81f4\u764c\u57fa\u56e0(oncogene)\u7684\u6539\u8b8a\u6216\u6d3b\u5316\u3002\u4ee5\u4e0b\u5404\u7a2e\u81f4\u764c\u57fa\u56e0\u7684\u6539\u8b8a\u8207\u764c\u75c7\u7684\u914d\u5c0d\uff0c\u54ea\u4e9b\u662f\u6b63\u78ba\u7684?\r(1)BRAF point mutation\u8207melanoma\r(2)CTNNB1 point mutation\u8207prostate cancer\r(3)FOS overexpression\u8207osteosarcomas\r(4)ERBB2 amplification\u6216point mutation\u8207colon cancer\r(5)N-MYC amplification\u8207neuroblastoma\nA. (1)+(2)+(3)+(4)\nB. (2)+(3)+(4)+(5)\nC. (1)+(2)+(4)+(5)\nD. (1)+(2)+(3)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(D)", "101-3.\n\u80c3\u8178\u9053\u6709\u5df2\u77e5\u7684\u53ef\u907a\u50b3\u6027\u7684(hereditable)\u591a\u767c\u606f\u8089\u75c7\u5019\u7fa4(polyposis syndrome)\uff0c\u751a\u81f3\u6709\u60e1\u6027\u5316\u7684\u53ef\u80fd\u6027(malignant potential)\u3002\u5176\u4e2d\u6709\u4e9b\u591a\u767c\u606f\u8089\u75c7\u5019\u7fa4\uff0c\u606f\u8089\u5207\u9664\u4e4b\u75c5\u7406\u6aa2\u67e5\u70baadenoma\uff0c\u53e6\u5916\u6709\u4e9b\u75c7\u5019\u7fa4\u606f\u8089\u5207\u9664\u606f\u8089\u4e4b\u75c5\u7406\u7d44\u7e54\u6aa2\u67e5\u5247\u70bahamartoma\u3002\u4e0b\u5217\u4f55\u7a2e \"\u53ef\u907a\u50b3\u6027\u591a\u767c\u606f\u8089\u75c7\u5019\u7fa4\" \u591a\u5728\u8178\u9053\u767c\u751f\uff0c\u4e14\u606f\u8089\u5207\u9664\u4e4b\u75c5\u7406\u6aa2\u67e5\u5c6cadenoma?\r(1)Familial adenomatous polyposis (FAP)\r(2)Gardner's syndrome\r(3)Turcot's syndrome\r(4)Peutz-Jeghers syndrome\r(5)Lynch syndrome\nA. (1)+(2)+(3)+(4)\nB. (2)+(3)+(4)+(5)\nC. (1)+(3)+(4)+(5)\nD. (1)+(2+(3)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(D)", "101-4.\n65\u6b72\u65b0\u8a3a\u65b7\u4e73\u764c\u75c5\u4eba\uff0c\u4e4b\u524d\u6574\u9ad4\u8eab\u9ad4\u72c0\u6cc1\u826f\u597d\uff0c\u7121\u986f\u8457\u5176\u4ed6\u5171\u75c5(co-morbidities)\u75c5\u53f2\uff0c\u7d93modified radical mastectomy\u624b\u8853\u5207\u9664\u53f3\u5074\u4e73\u764c\u8207\u53f3\u5074\u814b\u4e0b\u6dcb\u5df4\u7d50\u5ed3\u6e05\u8853\uff0c\u75c5\u7406\u6aa2\u67e5\u986f\u793a\u4e73\u764c\u816b\u584a\u5927\u5c0f4\u516c\u5206\uff0c\u814b\u4e0b\u6dcb\u5df4\u7d5015\u9846\u4e2d\u670910\u9846\u5df2\u6709\u4e73\u764c\u7d30\u80de\u4fb5\u72af\uff0c\u67d3\u8272ER(-)\u3001PR(-)\u3001HER2(-)\u3002\u4f60\u5efa\u8b70\u7d66\u4e88\u4f55\u7a2e\u624b\u8853\u5f8c\u8f14\u52a9\u6027(adjuvant)\u6cbb\u7642\u4f86\u964d\u4f4e\u764c\u75c7\u5fa9\u767c?\nA. tamoxifen\nB. multi-drug chemotherapy\nC. aromatase inhibitors\nD. trastuzumab\nE. no indications for adjuvant therapy\n": "(B)", "101-5.\n\u7121\u6cd5\u624b\u8853\u5207\u9664\u4e14\u7121\u6cd5\u9032\u884c\u52d5\u8108\u6813\u585e\u6cbb\u7642\u7684\u665a\u671f\u809d\u764c(HCC)\u75c5\u4eba\uff0c\u6a19\u9776\u6cbb\u7642\u85e5\u7269(targeted agents)\u8fd1\u5e74\u5df2\u6709\u91cd\u8981\u7684\u9032\u5c55\u3002\u4e0b\u5217\u4f55\u8005\u70ba\u88ab\u8b49\u5be6\u6709\u6548\u4e4b\u665a\u671f\u809d\u764c\u7684\u7b2c\u4e00\u500b\u53e3\u670d\u6a19\u9776\u85e5\u7269? \u7d93\u7531\u7b2c\u4e09\u671f(Phase III)\u81e8\u5e8a\u8a66\u9a57\u8b49\u5be6\u5c0dChild-Pugh A\u4e4b\u665a\u671f\u809d\u764c\u75c5\u4eba\u7b2c\u4e00\u7dda\u4f7f\u7528\u6642\uff0c\u6709\u6574\u9ad4\u5b58\u6d3b\u63d0\u5347\u6548\u679c\uff0c\u76ee\u524d\u5df2\u88ab\u8996\u70ba\u665a\u671f\u809d\u764cstandard of care\u4e4b\u4e00\u3002\nA. sunitinib\nB. sorafenib\nC. brivanib\nD. everolimus\nE. erlotinib\n": "(B)", "101-6.\n\u80c3\u9ecf\u819c\u76f8\u95dc\u6dcb\u5df4\u764c(MALT lymphoma)\u7684\u751f\u6210\u8207\u80c3\u5e7d\u9580\u87ba\u65cb\u687f\u83cc(H. pylori)\u5bc6\u5207\u76f8\u95dc\uff0c\u4e5f\u5df2\u77e5MALT lymphoma\u4e4b\u5e38\u898b\u67d3\u8272\u9ad4\u8b8a\u5316(cytogenetic translocation)\u6613\u9020\u6210API2/MALT\u8207Bcl-10\u7b49\u81f4\u764c\u56e0\u5b50\u4e4b\u6d3b\u5316\u3002\u80c3MALT lymphoma\u6700\u5e38\u898b\u7684\u67d3\u8272\u9ad4\u8f49\u4f4d\u8b8a\u5316\u70ba\u4f55?\nA. t(14;15) (q32;q13)\nB. t(9;22) (q34;q11)\nC. t(4;11) (q21;q23)\nD. t(11;18) (q21;q21)\nE. t(2;5) (p23;q35)\n": "(D)", "101-7.\n\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u7684\u8f49\u79fb\u6027\u4e0a\u76ae\u764c(carcinoma of unknown primary, CUP)\uff0c\u75c5\u7406\u7d44\u7e54\u5e38\u9700\u8981\u984d\u5916\u9032\u884c\u514d\u75ab\u7d44\u7e54\u67d3\u8272(immunohistochemical stains)\uff0c\u63d0\u4f9b\u81e8\u5e8a\u4e0a\u5206\u8fa8\u764c\u75c7\u5668\u5b98\u539f\u767c\u4f86\u6e90\u7684\u53c3\u8003\u4f9d\u64da\u3002cytokeratin(CK)\u662f\u7d93\u5e38\u4f7f\u7528\u7684intermediate filaments\u67d3\u8272\uff0c\u4eba\u9ad4\u670920\u591a\u7a2eCK\u4e9e\u578b\uff0c\u7576\u986f\u793a\u764c\u7d30\u80deCK20\u67d3\u8272\u967d\u6027\u4e14CK7\u67d3\u8272\u9670\u6027(CK20+/ CK7-)\u6642\uff0c\u76f8\u5c0dCUP\u6700\u53ef\u80fd\u7684\u539f\u767c\u5668\u5b98\u70ba\u4e0b\u5217\u4f55\u8005?\nA. lung\nB. breast\nC. endometrium\nD. pancreas\nE. colon\n": "(E)", "101-8.\n\u8f49\u79fb\u6027\u5927\u8178\u764c\u5728\u4f7f\u7528\u6297\u764c\u85e5\u7269\u6cbb\u7642\u6642\uff0c\u5df2\u77e5\u6709\u4e00\u91cd\u8981\u7684\u9810\u6e2c\u6027\u751f\u7269\u6a19\u8a18(predictive biomarker)\u3002\u8b6c\u5982:\u7576\u5927\u8178\u764c\u6aa2\u9ad4K-RAS\u7684codon 12\u57fa\u56e0\u578b\u5c6c\u300c\u7a81\u8b8a\u578b\u300d\u6642\uff0c\u5c0d\u4e0b\u5217\u54ea\u500b\u85e5\u5291\u660e\u986f\u300c\u7121\u6548\u300d(non-responsiveness)\uff0c\u56e0\u6b64\u4e0d\u5efa\u8b70\u9078\u7528\u8a72\u85e5\u5291\u6cbb\u7642\u3002\nA. Bevacizumab (VEGF monoclonal antibody)\nB. Cetuximab (EGFR monoclonal antibody)\nC. 5-fluorouracil (5-FU)\nD. Oxaliplatin\nE. Irinotecan (CPT-11)\n": "(B)", "101-9.\n\u95dc\u65bctesticular cancer\u5206\u70banon-seminoma\u8207seminoma\u5169\u5927\u7d44\u6210\uff0c\u4e14\u9810\u5f8c\u660e\u986f\u6709\u5dee\u5225\u3002\u4e0b\u5217\u4f55\u7a2e\u8840\u6e05\u816b\u7624\u6a19\u8a18(tumor marker)\u986f\u8457\u4e0a\u5347\u6642\uff0c\u4ee3\u8868\u8a72\u75c5\u4eba\u7684testicular cancer\u5fc5\u5b9a\u6709\u300cnon-seminoma\u300d\u6210\u5206?\nA. LDH (lactate dehydrogenase)\nB. beta-hCG (human chorionic gonadotropin)\nC. AFP (\u03b1-fetoprotein)\nD. ALP (alkaline phosphatase)\nE. ALT (alanine aminotransferase)\n": "(C)", "101-10.\n\u795e\u7d93\u5167\u5206\u6ccc\u816b\u7624(neuroendocrine tumors)\u4e2d\u4e4b\"\u985e\u764c\"(carcinoid tumor)\u6709\u6642\u4ee5\u8179\u7009(diarrhea)\u3001\u6f6e\u7d05(flushing)\uff0c\u751a\u81f3\u9663\u767c\u6027\u75bc\u75db\u3001\u6c23\u5598\u7b49\"\u985e\u764c\u75c7\u5019\u7fa4\"(carcinoid syndrome)\u4f86\u8868\u73fe\uff0c\u548c\u985e\u764c\u6240\u5206\u6ccc\u7684serotonin\u3001tachykinins\u3001motilin\u7b49\u6d3b\u6027\u7269\u8cea\u6709\u95dc\u3002\u901a\u5e38\u8868\u73fe\"\u985e\u764c\u75c7\u5019\u7fa4\"\u7684\"\u985e\u764c\"\u816b\u7624\u4f4d\u7f6e(location)\u76f8\u5c0d\u6700\u591a\u6578\u8d77\u6e90\u65bc\u80da\u80ce\u5b78\u7684\u54ea\u500b\u90e8\u4f4d?\nA. Foregut\nB. Midgut\nC. Hindgut\nD. Foregut\u3001Midgut\u3001Hindgut \u8868\u73fe\"\u985e\u764c\u75c7\u5019\u7fa4\"\u7684\u6a5f\u6703\u5747\u76f8\u8fd1\nE. Rectum\n": "(B)", "102-1.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u570b\u969b\u4e0a\u8a55\u4f30diffuse large B cell lymphoma\u75c5\u4eba\u9810\u5f8c\u7684\u6307\u6a19IPI (International Prognostic Index)\uff1f\nA. Performance status\nB. Age\nC. Hb\nD. Stage\nE. LDH\n": "(C)", "102-2.\n\u76ee\u524dAzacytidine\u4ee5\u6cbb\u7642\u9aa8\u9ad3\u5316\u751f\u4e0d\u826f\u75c7\u5019\u7fa4(MDS)\u9ad8\u5371\u96aa\u4e4b\u75c5\u60a3\uff0c\u5df2\u6709\u5065\u4fdd\u7d66\u4ed8\u3002\u6b64\u85e5\u4f5c\u7528\u7684\u6a5f\u8f49\u70ba\u4f55\uff1f\nA. Tyrosine kinase inhibitor\nB. DNA methylation inhibitor\nC. Proteosome inhibitor\nD. Immunomodulator\nE. Vascular endothelial growth factor inhibitor\n": "(B)", "102-3.\n\u4e00\u4f4d37\u6b72\u5973\u6027\u75c5\u60a3\u904e\u53bb\u7121\u7279\u6b8a\u75c5\u53f2\uff0c\u6700\u8fd1\u56e0\u70ba\u75b2\u5026\u3001\u9ec3\u75b8\u53ca\u6df1\u8272\u5c3f\u61c9\u8a3a\uff0c\u8840\u6db2\u6aa2\u67e5\u986f\u793aHb 8.7 g/dL\uff0creticulocyte 4.8%\uff0c\u767d\u8840\u74033560/uL\uff0c\u8840\u5c0f\u677f145000/uL\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\uff1bbilirubin\u5168\u91cf3.7 mg/dL\uff0c\u76f4\u63a5\u578b0.6 mg/dL\uff0cAST 75 U/L\uff0cALT 31 U/L\uff0cLDH 2350 U/L\uff0cCoombs' test\u9670\u6027\uff1b\u5c0f\u4fbf\u5982\u5716\u6240\u793a\uff0c\u6f5b\u8840\u53cd\u61c9\u5448\u967d\u6027\uff0c\u6c88\u6fb1\u7269\u4e2dRBC 0-2/HPF\uff0cWBC 1-3/HPF\u3002\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. Urine myoglobin\nB. Hb electrophoresis\nC. Bone marrow examination\nD. Hepatitis markers\nE. Flow cytometry for CD55 and CD59 expression\n": "(E)", "102-4.\n\u4e0b\u5217\u4f55\u7a2e\u72c0\u6cc1\u9020\u6210iron deficiency anemia\u7684\u6a5f\u6703\u6700\u5c0f\uff1f\nA. Gastrectomy\nB. Paroxysmal nocturnal hemoglobinuria\nC. Thalassemia\nD. Pregnancy\nE. Colon Cancer\n": "(C)", "102-5.\n\u4e0b\u5217\u5316\u5b78\u6cbb\u7642\u6216\u6a19\u9776\u6cbb\u7642\u85e5\u7269\u4e2d\uff0c\u4f55\u8005\u9020\u6210\u795e\u7d93\u5b78\u6bd2\u6027\u7684\u53ef\u80fd\u6027\u6700\u5c0f\uff1f\nA. Vincristine\nB. Cisplatin\nC. Thalidomide\nD. Etoposide\nE. Bortezomib\n": "(D)", "102-6.\n\u4e0b\u5217\u6aa2\u67e5\u70ba\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u8a3a\u65b7\u6216\u5206\u671f\u6240\u5fc5\u9700\uff0c\u4f55\u8005\u70ba\u4f8b\u5916\uff1f\nA. Bone scan\nB. \u03b22-microglobulin\nC. Albumin\nD. Daily urine light chain quantification\nE. Blood M-protein level\n": "(A)", "102-7.\n\u4e00\u4f4d25\u6b72\u6025\u6027\u767d\u8840\u75c5\u4eba\u5468\u908a\u8840\u4e2d\u8840\u7d05\u7d207.5 g/dL\uff0c\u767d\u8840\u7403165000/uL\uff0c\u8840\u5c0f\u677f13000/uL\uff1b\u5c3f\u917810.5 mg/dL\uff0cCr 1.7 mg/dL\uff1b\u70ba\u53ca\u65e9\u964d\u4f4e\u767d\u8840\u7403\u7684\u6578\u76ee\uff0c\u5316\u5b78\u6cbb\u7642\u5fc5\u9808\u5118\u5feb\u958b\u59cb\u3002\u5728\u5316\u5b78\u6cbb\u7642\u524d\uff0c\u70ba\u5feb\u901f\u9054\u5230\u9810\u9632\u53ca\u6cbb\u7642tumor lysis syndrome\u7684\u76ee\u7684\uff0c\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u6700\u9069\u7576\uff1f\nA. Allopurinol\nB. Rasburicase\nC. Benzbromarone\nD. Furosemide\nE. Magnexium oxide\n": "(B)", "102-8.\n\u4e00\u4f4d31\u6b72\u5973\u6027\u8eab\u9ad4\u6aa2\u67e5\u986f\u793a\u6709\u8f15\u5fae\u9ec3\u75b8\uff0c\u76ae\u819a\u5c11\u8a31\u6de4\u9752\uff0c\u7121\u5176\u4ed6\u51fa\u8840\u73fe\u8c61\u3002\u8840\u7d05\u7d209.2 g/dL\uff0c\u7db2\u72c0\u7d05\u8840\u7403(reticulocyte) 4.1%\uff0c\u767d\u8840\u74034750/uL\uff0c\u8840\u5c0f\u677f23000/uL\uff1bPT\u53caPTT\u6b63\u5e38\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\uff0c\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Thrombotic thrombocytopenic purpura\nB. Disseminated intravascular coagulation\nC. G-6PD deficiency\nD. Evan syndrome\nE. Hypersplenism\n": "(A)", "102-9.\n\u4e00\u4f4d35\u6b72\u75c5\u60a3\uff0c\u88ab\u8a3a\u65b7\u5f97\u4e86\u8cbb\u57ce\u67d3\u8272\u9ad4(Ph)\u967d\u6027\u4e4bacute lymphoblastic leukemia\u3002\u9664\u4e86\u5316\u5b78\u6cbb\u7642\u5916\uff0c\u4e0b\u5217\u4f55\u7a2e\u6cbb\u7642\u53ef\u9032\u4e00\u6b65\u6539\u5584\u75c5\u4eba\u7684\u9810\u5f8c\uff1f(1)all-trans retinoic acid (2)dasatinib (3)allogeneic hematopoietic stem cell transplantation(\u5fc5\u9808\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)\nB. (3)\nC. (2)+(3)\nD. (1)+(3)\nE. (1)+(2)+(3)\n": "(C)", "102-10.\n\u4e00\u4f4d72\u6b72\u7537\u6027\uff0c\u6709\u9577\u671f\u80ba\u75c5\u75c5\u53f2\uff0c\u6700\u8fd1\u62bd\u8840\u6aa2\u9a57\u767c\u73feHb 18.6 g/dL\uff0cHct 55%\uff0c\u88ab\u8f49\u8a3a\u5230\u8840\u6db2\u79d1\u9580\u8a3a\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u5176\u9762\u8272\u6f6e\u7d05\uff0c\u5634\u5507\u7a0d\u6709\u767c\u9257\u73fe\u8c61\uff0c\u4e26\u6709\u6775\u72c0\u6307\u3002\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u5340\u5206\u6b64\u75c5\u4eba\u662fpolycythemia vera\u6216secondary erythrocytosis\u6709\u5e6b\u52a9\uff1f(\u5fc5\u9808\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r(1)arterial blood gas (2)JAK2 mutation (3)erythropoietin level\nA. (1)\nB. (2)\nC. (1)+(2)\nD. (2)+(3)\nE. (1)+(2)+(3)\n": "(E)", "102-1.\n\u4e0b\u5217\u6709\u95dc\u5c0f\u7d30\u80de\u80ba\u764c(small-cell-lung cancer\uff0cSCLC)\uff0c\u76f8\u8f03\u65bc\u975e\u5c0f\u7d30\u80de\u80ba\u764c(non-small-cell lung cancer\uff0cNSCLC)\uff0c\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\nA. \u5c0f\u7d30\u80de\u80ba\u764c\u6bd4\u8f03\u5e38\u898b\u65bc\u80ba\u90e8\u5468\u570d(periphery)\nB. \u5c0f\u7d30\u80de\u80ba\u764c\u6e90\u8d77\u65bc\u80ba\u7d44\u7e54\u7684alveolar\u7d30\u80de\nC. \u5c0f\u7d30\u80de\u80ba\u764c\u5c0d\u5316\u5b78\u6cbb\u7642\u8f03\u4e0d\u654f\u611f (less chemosensitive)\nD. \u5c0f\u7d30\u80de\u80ba\u764c\u5c0d\u653e\u5c04\u7dda\u6cbb\u7642\u8f03\u70ba\u654f\u611f(more radiosensitive)\nE. \u975e\u5c0f\u7d30\u80de\u80ba\u764c\u8f03\u5e38\u898b\u9aa8\u9ad3\u8f49\u79fb\n": "(D)", "102-2.\n\u6709\u4e0028\u6b72\u7537\u6027\uff0c\u8eab\u9ad4\u72c0\u6cc1\u5927\u81f4\u826f\u597d\uff0c\u7121\u767c\u71d2\u3001\u7121\u9ad4\u91cd\u6e1b\u8f15\u7b49\u75c7\u72c0\u3002\u6700\u8fd1\u56e0\u6b32\u52a0\u5165\u4fdd\u96aa\u800c\u63a5\u53d7\u4f8b\u884c\u6027\u80f8\u90e8X\u5149\u651d\u5f71\u6aa2\u67e5\uff0c\u767c\u73fe\u7e31\u8188\u8154\u6dcb\u5df4\u7d50\u816b\u5927(mediastinal lymphadenopathy)\u3002\u7576\u7136\uff0c\u6dcb\u5df4\u7d50\u7a7f\u523a\u5207\u7247\u6709\u52a9\u65bc\u78ba\u5b9a\u8a3a\u65b7\uff0c\u9664\u6dcb\u5df4\u7d50\u7a7f\u523a\u5207\u7247\u4e4b\u5916\uff0c\u4e5f\u9700\u8981(indicated)\u4e0b\u5217\u4f55\u7a2e\u62bd\u8840\u6aa2\u9a57\u76f8\u5c0d\u6700\u6709\u52a9\u65bc\u8a3a\u65b7\uff1f\nA. C-reactive protein (CRP)\nB. Prostate-specific antigen (PSA)\nC. Alpha-fetoprotein (AFP)\nD. Thyroid stimulating hormone (TSH)\nE. Angiotensin-converting enzyme (ACE) level\n": "(C)", "102-3.\n\u975e\u5c0f\u7d30\u80de\u80ba\u764c(NSCLC)\u75c5\u4eba\u63a5\u53d7\"\u4e0a\u76ae\u751f\u9577\u56e0\u5b50\u63a5\u53d7\u9ad4(EGFR)\u5c0f\u5206\u5b50\u6291\u5236\u5291(EGFR-TKI)\"\u4e4b\u6a19\u9776\u6cbb\u7642\u85e5\u7269(gefitinib\u3001erlotinib\u7b49)\uff0c\u5df2\u77e5\u8a72\u985eEGFR-TKI\u6a19\u9776\u6cbb\u7642\u85e5\u7269\u6709\u6cbb\u7642\u816b\u7624\u7de9\u89e3\u7387\u4e4b\u9810\u6e2c\u56e0\u5b50\uff0c\u4ee5\u4e0b\u4f55\u7a2eEGFR\u57fa\u56e0\u7a81\u8b8a\u53ef\u9810\u6e2c\u4f7f\u7528EGFR-TKI\u6cbb\u7642\u6642\u816b\u7624\u7de9\u89e3\u7387\u6700\u9ad8?\nA. EGFR exon 20 duplication (exon 20 dup)\nB. EGFR exon 19 deletion (exon 19 del)\nC. EGFR T790M mutation\nD. EGFR L747S mutation\nE. EGFR T854A mutation\n": "(B)", "102-4.\n\u6bd4\u8f03\u4e0b\u5217\u5404\u7a2e\u6dcb\u5df4\u764c\uff0c\u4f55\u8005\u76f8\u5c0d\u6709\u6700\u4f73\u7684\u9810\u5f8c(prognosis)\uff1f\nA. Burkitt's lymphoma\nB. Lymphoblastic lymphoma\nC. Mantle cell lymphoma\nD. Hodgkin's disease, nodular sclerosis\nE. Diffuse large B cell lymphoma (DLBCL)\n": "(D)", "102-5.\n\u8f49\u79fb\u6027\u5927\u8178\u764c\u5728\u4f7f\u7528\u6297\u764c\u85e5\u7269\u6cbb\u7642\u6642\uff0c\u5df2\u77e5\u6709\u4e00\u91cd\u8981\u7684\u9810\u6e2c\u6027\u751f\u7269\u6a19\u8a18(predictive biomarker)\u3002\u8b6c\u5982:\u7576\u5927\u8178\u764c\u6aa2\u9ad4K-RAS\u7684codon 12\u57fa\u56e0\u578b\u5c6c\u300c\u91ce\u751f\u578b\u300d(wild-type)\u6642\uff0c\u662f\u5c0d\u4e0b\u5217\u54ea\u500b\u85e5\u5291\u6709\u6548 (responsiveness)\u7684\u9810\u6e2c\u56e0\u5b50\uff0c\u56e0\u6b64\u5efa\u8b70\u53ef\u9078\u7528\u8a72\u85e5\u5291\u6cbb\u7642\u3002\nA. 5-Fluorouracil (5-FU)\nB. Oxaliplatin\nC. Irinotecan (CPT-11)\nD. Cetuximab (EGFR monoclonal antibody)\nE. Bevacizumab (VEGF monoclonal antibody)\n": "(D)", "102-6.\n\u4e73\u764c\u7684\u75c5\u7406\u6aa2\u67e5\u7279\u5fb5\uff0c\u4e0b\u5217\u4f55\u8005\u986f\u793a\"\u4e0d\u826f\u7684\u9810\u5f8c\"(poor prognosis)\uff1f\nA. Ki-67 index < 2%\nB. Estrogen receptor (ER)\u967d\u6027 (>95%)\nC. p53\u91ce\u751f\u578b\nD. \u6838\u7684\u60e1\u6027\u5ea6\uff0cgrade I\nE. erbB2 (HER-2/neu)\u904e\u5ea6\u8868\u73fe(3+)\n": "(E)", "102-7.\n\"\u764c\u75c7\u95dc\u806f\u75c7\u5019\u7fa4\"(Paraneoplastic syndrome)\u5e38\u898b\"\u9ad8\u8840\u9223\u8840\u75c7\" (hypercalcemia)\uff0c\u5176\u4e2d\u6709\u4e9b\u60c5\u5f62\u4fc2\u7531\u65bc\u764c\u75c7\u5206\u6ccc\u904e\u591a\u76841,25-dihydroxy-vitamin D\uff0c\u6700\u5178\u578b\u7684\u764c\u75c7\u985e\u5225\u70ba\u4f55\uff1f\nA. \u982d\u9838\u90e8\u9e9f\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\nB. \u4e73\u764c\nC. \u6ccc\u5c3f\u4e0a\u76ae\u764c\nD. \u60e1\u6027\u6dcb\u5df4\u764c\nE. \u76ae\u819a\u764c\n": "(D)", "102-8.\n\u6839\u64da\u7f8e\u570b\u7684\u570b\u5bb6\u80ba\u764c\u7be9\u6aa2\u8a08\u756b(National Lung Cancer Screening Trial)\u7d50\u679c\uff0c\u4f4e\u5291\u91cf\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u6383\u63cf(low-dose chest CT scan)\u7be9\u6aa2\uff0c\u53ef\u6709\u6548\u964d\u4f4e\u80ba\u764c\u6b7b\u4ea1\u738720%\u3002\u6b64\u8a08\u756b\u91dd\u5c0d\u7684\u7be9\u6aa2\u5c0d\u8c61\uff1f\nA. \u226715 pack-years of smoking\uff0c\u4e14\u6212\u83f8\u672a\u6eff15\u5e74\u8005\nB. \u226720 pack-years of smoking\uff0c\u4e14\u6212\u83f8\u672a\u6eff15\u5e74\u8005\nC. \u226730 pack-years of smoking\uff0c\u4e14\u6212\u83f8\u672a\u6eff15\u5e74\u8005\nD. \u226740 pack-years of smoking\uff0c\u4e14\u6212\u83f8\u672a\u6eff15\u5e74\u8005\nE. \u6240\u6709smoking\u7684\u6210\u5e74\u4eba\n": "(C)", "102-9.\n\u4e0b\u5217\u816b\u7624\u8207\u75c5\u56e0\u7684\u914d\u5c0d\u4f55\u8005\u4e0d\u6b63\u78ba ?\nA. Burkitt's lymphoma\u8207Epstein-Barr virus (EBV) infection\nB. \u9f3b\u54bd\u764c (Nasopharyngeal carcinoma)\u8207 cytomegalovirus (CMV)infection\nC. \u53e3\u8154\u9e9f\u72c0\u4e0a\u76ae\u7d30\u80de\u764c(oral cavity squamous cell carcinoma)\u8207human papillomavirus(HPV)\nD. \u80c3\u7684mucosa-associated lymphoid tissue (MALT)lymphoma \u8207Helicobactor pylori infection\nE. Adult T-cell leukemia/lymphoma\u8207HTLV-1\n": "(B)", "102-10.\n\u4e0b\u5217\u54ea\u4e9b\u7279\u5fb5\u662f\u5178\u578b\"\u764c\u7d30\u80de\"\u7684phenotypes\u7279\u5fb5\uff1f(1)Success to differentiate (2)Loss of normal apoptosis pathways (3)Genetic stability (4)Loss of replicative senescence (5)Increased angiogenesis  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (2)+(4)+(5)\nD. (2)+(3)+(4)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(C)", "103-1.\n\u904e\u53bb\u672a\u66fe\u63a5\u53d7heparin\u6ce8\u5c04\u904e\u4e4b\u75c5\u4eba\uff0c\u6ce8\u5c04heparin\u5f8c\u5f15\u767c\u8840\u5c0f\u677f\u4f4e\u4e0b(Heparin induced thrombocytopenia)\u6700\u5e38\u51fa\u73fe\u7684\u6642\u9593\u70baheparin\u6ce8\u5c04\u5f8c\nA. 1\u5929\u5167\nB. 1\u81f33\u5929\nC. 5\u81f310\u5929\nD. 14\u81f328\u5929\nE. 1\u500b\u6708\u5f8c\n": "(C)", "103-2.\n\u4e0b\u5217\u6709\u95dcTRALI(transfusion-related acute lung injury)\u7684\u6558\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f\nA. \u8f38\u6ce8\u4efb\u4f55\u8840\u6db2\u6210\u5206\u90fd\u6709\u53ef\u80fd\u767c\u751f\nB. \u4e00\u822c\u5728\u8f38\u8840\u4e2d\u6216\u8f38\u8840\u5f8c6\u5c0f\u6642\u5167\u767c\u751f\nC. \u767c\u751f\u7684\u539f\u56e0\u53ef\u80fd\u8207\u53d7\u8840\u8005\u9ad4\u5167\u6709\u6297\u6350\u8840\u8005\u767d\u8840\u7403\u7684\u6297\u9ad4\u6709\u95dc\nD. \u75c5\u4eba\u7684\u80f8\u90e8X\u5149\u6703\u51fa\u73fe\u5169\u908a\u80ba\u8449\u7684\u6d78\u6f64\nE. \u76ee\u524d\u4e26\u7121\u660e\u78ba\u8b49\u64da\u986f\u793a\u985e\u56fa\u9187\u6cbb\u7642\u6709\u6548\n": "(C)", "103-3.\n\u4e00\u4f4d63\u6b72\u7537\u6027\u5728\u5065\u5eb7\u6aa2\u67e5\u6642\u5076\u7136\u767c\u73fe\u8840\u5c0f\u677f\u6578\u70ba732,000/uL\uff0c\u8840\u7d05\u7d20\u53ca\u767d\u8840\u7403\u7121\u7570\u5e38\uff1b\u8eab\u9ad4\u6aa2\u67e5(physical examination)\u4e26\u7121\u7279\u6b8a\u767c\u73fe\uff0c\u57fa\u56e0\u6aa2\u6e2c\u672a\u767c\u73fe\u6709JAK2\u7a81\u8b8a\u3002\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u7d50\u679c\u5c0d\u539f\u767c\u6027\u8840\u5c0f\u677f\u589e\u751f\u75c7\u7684\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. \u9aa8\u9ad3\u9435\u67d3\u8272\u53ef\u770b\u5230ring sideroblasts\nB. \u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\nC. PDGFRA\u57fa\u56e0\u7a81\u8b8a\nD. EGFR\u57fa\u56e0\u7a81\u8b8a\nE. CALR\u57fa\u56e0\u7a81\u8b8a\n": "(E)", "103-4.\n\u4e00\u4f4d\u75c5\u4eba\u5728\u62bd\u8840\u6aa2\u67e5\u4e2d\u767c\u73fePT\u70ba16.3\"(\u6b63\u5e389.8~11.5\")\uff0cINR 1.52\uff0cPTT\u70ba54.3\"(\u6b63\u5e3825.6~32.6\")\u3002\u75c5\u4eba\u6700\u4e0d\u53ef\u80fd\u6709\u4ee5\u4e0b\u4f55\u7a2e\u72c0\u6cc1\uff1f\nA. Warfarin treatment\nB. Rivaroxaban treatment\nC. Aspirin treatment\nD. Factor XII deficiency\nE. Liver disease\n": "(D)", "103-5.\n\u4e00\u4f4d52\u6b72\u75c5\u4eba\u62bd\u8840\u6aa2\u67e5\u767c\u73fe\u767d\u8840\u7403\u6578\u70ba25,500/uL\uff0c\u6dcb\u5df4\u7d30\u80de\u4f5478%\uff0c\u5468\u908a\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\uff0c\u6d41\u6c0f\u7d30\u80de\u5100\u986f\u793a\u9019\u4e9b\u6dcb\u5df4\u7d30\u80de\u8868\u73feCD19\uff0cCD20\uff0cCD5\uff0cCD23\uff0c\u53ca\u03ba-\u8f15\u93c8\uff0c\u4f46\u7121CD3\uff0cCD10\u53ca\u03bb-\u8f15\u93c8\u8868\u73fe\uff0c\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u5f97\u4e86\u4ec0\u9ebc\u75c5\uff1f\nA. Chronic lymphocytic leukemia\nB. Large granular lymphocyte leukemia\nC. Reactive lymphocytosis\nD. Acute lymphoblastic leukemia\nE. Follicular lymphoma\n": "(A)", "103-6.\n\u4e00\u4f4d17\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u767c\u71d2\u4f4f\u9662\uff0c\u8840\u6db2\u6aa2\u67e5\u986f\u793a\u7d05\u8840\u74032,350,000/uL\uff0c\u767d\u8840\u74031,050/uL\uff0c\u5176\u4e2dsegmented forms 10%\uff0cbands 2%\uff0clymphocytes 82%\uff0cmonocytes 6%\uff0c\u8840\u5c0f\u677f16,400/uL\uff0c\u7db2\u72c0\u7d05\u8840\u74031%\uff1b\u4f7f\u7528\u6297\u751f\u7d20\u5f8c\uff0c\u9ad4\u6eab\u56de\u5fa9\u6b63\u5e38\u3002\u9aa8\u9ad3\u6aa2\u67e5\u986f\u793a\u70ba\u518d\u751f\u4e0d\u826f\u6027\u8ca7\u8840\uff0c\u4e0b\u4e00\u6b65\u6700\u9069\u7576\u7684\u6cbb\u7642\u70ba\u4f55\uff1f\nA. Antithymocyte globulin\nB. Cyclosporine\nC. Antithymocyte globulin\u53cacyclosporine\nD. Anabolic hormone\nE. Allogeneic hematopoietic stem cell transplantation from a HLA-matched sibling donor\n": "(E)", "103-7.\n\u4e00\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u60a3\u8005\uff0c\u8840\u6db2\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d2010.5 gm/dL\uff0c\u767d\u86cb\u767d3.6 gm/dL\uff0c\u7403\u86cb\u767d5.1 gm/dL\uff0cCr 1.1 mg/dL\uff0c\u03b22-microglobulin 4.1 mg/L\uff0c\u6b64\u75c5\u4eba\u5728\u570b\u969b\u5206\u671f\u7cfb\u7d71(International Staging System)\u4e4b\u671f\u5225\u70ba\uff1f\nA. 0\nB. I\nC. II\nD. III\nE. IV\n": "(C)", "103-8.\n\u4e00\u4f4d47\u6b72\u7537\u6027\u65b0\u8a3a\u65b7\u51fa\u6709\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\uff0c\u4e0b\u5217\u6709\u95dc\u6b64\u75c5\u4eba\u7684\u6558\u8ff0\u4f55\u8005\u662f\u6b63\u78ba\u7684\uff1f(\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r(1)\u6709\u67d3\u8272\u9ad4\u7570\u5e38t(9;22)\r(2)\u6709\u7570\u5e38\u4e4b\u878d\u5408\u57fa\u56e0BCR-ABL\r(3)\u6700\u9069\u7576\u7684\u6cbb\u7642\u70ba\u916a\u80fa\u9178\u6fc0\ufffdC\u6291\u5236\u5291(tyrosine kinase inhibitor)\nA. (1)\nB. (2)\nC. (1)+(2)\nD. (1)+(3)\nE. (1)+(2)+(3)\n": "(E)", "103-9.\n\u4e00\u4f4d58\u6b72\u5973\u6027\uff0c\u56e0\u9838\u90e8\u6dcb\u5df4\u7d50\u816b\u5927\u63a5\u53d7\u5207\u7247\u6aa2\u67e5\uff0c\u75c5\u7406\u521d\u6b65\u5831\u544a\u70ba\u7591\u4f3c\u6ffe\u6ce1\u578b\u6dcb\u5df4\u7624(follicular lymphoma)\u3002\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u7d50\u679c\u53ef\u4ee5\u5e6b\u5fd9\u8a3a\u65b7\u6ffe\u6ce1\u578b\u6dcb\u5df4\u7624\uff1f(\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r(1) t(14;18)\r(2) BCL-2\u7570\u5e38\u8868\u73fe\r(3) CD5\u7d30\u80de\u8868\u9762\u6297\u539f\u967d\u6027\nA. (1)\nB. (1)+(2)\nC. (1)+(3)\nD. (2)+(3)\nE. (1)+(2)+(3)\n": "(B)", "103-10.\n\u4e0b\u5217\u4f55\u7a2e\u72c0\u6cc1\u6709\u53ef\u80fd\u9020\u6210\u5168\u8840\u7403\u6e1b\u5c11\uff1f(\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r(1) Vit B12 deficiency\r(2) Myelodysplastic syndrome\r(3) Liver cirrhosis\r(4) Autoimmune disease\nA. (4)\nB. (2)+(4)\nC. (2)+(3)\nD. (2)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(E)", "103-1.\n\u95dc\u65bc\u80f8\u817a\u7624(thymoma)\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e?\nA. \u7d0490%\u7684thymoma\u767c\u751f\u65bc\u524d\u7e31\u8188\u8154(anterior mediastinum)\nB. \u7d0440%\u7684thymoma\u75c5\u4eba\u53e6\u5408\u4f75\u4e00\u500b\u5168\u8eab\u6027\u7684\u81ea\u9ad4\u514d\u75ab\u75be\u75c5(systemic autoimmune illness)\nC. \u7d0430%\u7684thymoma\u75c5\u4eba\u5408\u4f75\u91cd\u75c7\u808c\u7121\u529b\u75c7(myasthenia gravis)\nD. \u7d045-8%\u7684thymoma\u75c5\u4eba\u5408\u4f75pure red cell aplasia\nE. \u7d045%\u7684thymoma\u75c5\u4eba\u5408\u4f75hypergammaglobulinemia\n": "(E)", "103-2.\n\u4ee5\u4eba\u985e\u4e73\u7a81\u75c5\u6bd2(human papilloma virus, HPV)\u75ab\u82d7\u6ce8\u5c04\uff0c\u53ef\u4ee5\u9810\u9632\u81f3\u5c11\u7d0470%\u7684\u4eba\u985e\u5b50\u5bae\u9838\u764c(cervical cancer)\u3002\u6240\u8b02HPV bivalent\u75ab\u82d7\uff0c\u4e3b\u8981cover HPV\u7684\u82e5\u5e72strains\u4ee5\u9810\u9632\u5b50\u5bae\u9838\u764c?\nA. HPV strains 6, 11\nB. HPV strains 11, 16\nC. HPV strains 16, 18\nD. HPV strains 6, 18\nE. HPV strains 6, 11, 16, 18\n": "(C)", "103-3.\n\u6839\u64da\u4e73\u764c\u7684\u57fa\u56e0\u8868\u73fe\u5716\u8b5c(gene expression profiling)\u70ba\u4e94\u500b\u6b21\u7fa4\u7d44(subclassification)\uff0c\u5206\u5225\u6709\u4e0d\u540c\u7684\u81e8\u5e8a\u9810\u5f8c\u8207\u6cbb\u7642\u9078\u9805\u3002\u4e0b\u5217\u6b21\u7fa4\u7d44\u4f55\u8005\u5c6c\u65bc\u6240\u8b02\u300c\u4e09\u9670\u6027\u300d(triple negative)\u4e73\u764c?\nA. Luminal A\nB. Luminal B\nC. HER2 amplified\nD. Basal\nE. Normal breast-like\n": "(D)", "103-4.\n\u4e0b\u5217\u80c3\u7684\u60e1\u6027\u816b\u7624\u4e2d\uff0c\u4f55\u8005\u8207\u5e7d\u9580\u87ba\u65cb\u687f\u83cc(H. pylori, HP)\u5bc6\u5207\u76f8\u95dc\uff0c\u800c\u4e14\u4f7f\u7528\u5e7d\u9580\u87ba\u65cb\u687f\u83cc(HP)\u5ed3\u6e05\u7642\u6cd5\u5f8c\u81f3\u5c11\u8d85\u904e\u534a\u6578(\u7d0450%\u81f375%)\u7684\u764c\u75c7\u53ef\u9054\u5230\u6301\u7e8c\u6027\u7de9\u89e3(durable remission)?\nA. Gastric adenocarcinomas\nB. Gastric MALT (mucosa-associated lymphoid tissue) lymphomas\nC. Gastric leiomyosarcomas\nD. Gastric GISTs (gastrointestinal stromal tumors)\nE. Gastric NETs (neuroendocrine tumors)\n": "(B)", "103-5.\n\u80c3\u8178\u9053\u6709\u591a\u985e\u5177\u907a\u50b3\u6027\u7684\u591a\u767c\u761c\u8089\u75c7\u5019\u7fa4(hereditable polyposis syndrome)\u3002\u5176\u4e2d\u6709\u4e00\u985esyndrome\uff0c\u75c5\u4eba\u5e38\u5408\u4f75\u9ecf\u819c\u76ae\u819a\u4e4b\u8272\u7d20\u6c88\u8457\u75c7(mucocutaneous pigmentation)\uff0c\u5176\u761c\u8089\u7684\u7d44\u7e54\u75c5\u7406\u5b78\u986f\u793a\u70bahamartoma\uff0c\u800c\u975e\u8f03\u5e38\u898b\u7684\u817a\u7624(adenoma)\uff0c\u761c\u8089\u53ef\u5206\u5e03\u65bc\u5c0f\u8178\u3001\u5927\u8178\u6216\u80c3\u3002\u4ee5\u4e0b\u4f55\u985esyndrome\u7b26\u5408?\nA. Lynch syndrome\nB. Gardner's syndrome\nC. Turcot's syndrome\nD. Peutz-Jeghers syndrome\nE. Familial adenomatous polyposis (FAP)\n": "(D)", "103-6.\n\u651d\u8b77\u817a\u764c(prostate cancer)\u5316\u5b78\u9810\u9632(chemoprevention)\u7684\u5927\u578b\u7b2c\u4e09\u671f\u81e8\u5e8a\u8a66\u9a57\u7684\u7d50\u679c\uff0c\u4e0b\u5217\u4f55\u8005\u5df2\u986f\u793a\u6700\u53ef\u4ee5\u964d\u4f4e\u651d\u8b77\u817a\u764c\u7684\u76db\u884c\u7387(prevalence)?\nA. \u7852 (selenium)\nB. \u776a\u56fa\u916e\u4e4b5\u03b1-\u9084\u539f\u9175\u7d20\u6291\u5236\u5291 (5\u03b1-reductase inhibitor, 5ARI, of testosterone)\nC. \u7dad\u751f\u7d20 E\nD. \u7dad\u751f\u7d20 A\nE. \u7dad\u751f\u7d20 C\n": "(B)", "103-7.\n\u751f\u6b96\u7d30\u80de\u7624(germ cell tumor)\u5206\u70ba\u7cbe\u539f\u7d30\u80de\u7624(seminoma)\u8207\u975e\u7cbe\u539f\u7d30\u80de\u7624(nonseminoma)\u5169\u5927\u985e\u7d44\u6210\u5206\u3002\u4e0b\u5217\u4f55\u7a2e\u816b\u7624\u6a19\u8a18\u4e4b\u4e0a\u5347\uff0c\u50c5\u6703\u767c\u751f\u65bc\u5177\u6709\u975e\u7cbe\u539f\u7d30\u80de\u7624(nonseminoma)\u7d44\u6210\u4e4b\u751f\u6b96\u7d30\u80de\u7624?\nA. AFP (\u03b1-fetoprotein)\nB. hCG (human chorionic gonadotropin)\nC. LDH (lactate dehydrogenase)\nD. ALP (alkaline phosphatase)\nE. ALT (alanine transaminase)\n": "(A)", "103-8.\n\u91dd\u5c0d\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u4e4b\u8f49\u79fb\u764c(carcinoma of unknown primary\uff0cCUP)\uff0c\u4e3b\u8981\u75c5\u7406\u7d44\u7e54\u578b\u614b\u5340\u5206\u70ba\u4e94\u5927\u985e\uff0c\u54ea\u4e00\u5927\u985e\u6700\u70ba\u5e38\u898b?\nA. squamous cell cancer\nB. neuroendocrine\nC. poorly differentiated adenocarcinoma\uff0cpoorly differentiated carcinoma\nD. well to moderately differentiated adenocarcinoma\nE. undifferentiated malignancy\n": "(D)", "103-9.\n\u809d\u7d30\u80de\u764c(\u809d\u764c)\u7684\u816b\u7624\u95dc\u806f\u75c7\u5019\u7fa4(paraneoplastic syndrome)\uff0c\u53ef\u80fd\u5305\u62ec\u4e0b\u5217\u54ea\u4e9b\u75c7\u5019? (1)\u7d05\u8840\u7403\u7d30\u80de\u6578\u76ee\u589e\u591a\u75c7(erythrocytosis) (2)\u9ad8\u8840\u9223\u75c7(hypercalcemia) (3)\u9ad8\u8840\u7cd6\u75c7(hyperglycemia) (4)\u9ad8\u81bd\u56fa\u9187\u8840\u75c7(hypercholesterolemia) (5)\u7537\u6027\u5973\u4e73\u75c7(gynecomastia)\uff0c\u776a\u4e38\u840e\u7e2e\u75c7(testicular atrophy) (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(2)+(4)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(D)", "103-10.\n\u60e1\u6027\u9aa8\u8089\u7624(osteosarcoma)\u4f54\u4e86\u8fd1\u534a\u6578(\u7d0445%)\u7684\u9aa8\u9abc\u8089\u7624(sarcoma)\uff0c\u96a8\u8457\u6cbb\u7642\u5b78\u7684\u9032\u6b65\uff0c\u5df2\u6709\u8d85\u904e\u7d0480%\u75c5\u4eba\u53ef\u4ee5\u9054\u6210\u80a2\u9ad4\u4fdd\u5168\u624b\u8853(limb-sparing surgery)\u7684\u76ee\u7684\uff0c\u4f7f\u7528\u8853\u524d/\u8853\u5f8c\u7684\u5316\u5b78\u6cbb\u7642\u6642\uff0c\u5c0d\u60e1\u6027\u9aa8\u8089\u7624\u654f\u611f(chemosensitive)\u7684\u5316\u7642\u85e5\u7269\uff0c\u5305\u62ec\u4e0b\u5217\u4f55\u8005?(\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848) (1)doxorubicin (2)cisplatin (3)ifosfamide (4)\u9ad8\u5291\u91cfmethotrexate (5)\u4ee5\u4e0a\u7686\u975e\nA. (1)+(2)\nB. (3)+(4)\nC. (1)+(3)+(4)\nD. (1)+(2)+(3)+(4)\nE. (5)\n": "(D)", "104-1.\n\u4e00\u4f4d35\u6b72\u5973\u6027\uff0c\u7121\u7279\u6b8a\u75c5\u53f2\uff0c\u4e94\u5e74\u524d\u7684\u9ad4\u6aa2\u986f\u793a\u8840\u6db2\u76f8\u70ba\u6b63\u5e38\u3002\u6700\u8fd1\u611f\u89ba\u722c\u5761\u6642\u6703\u6709\u547c\u5438\u6025\u4fc3\u7684\u73fe\u8c61\uff1b\u8eab\u9ad4\u6aa2\u67e5\u986f\u793a\u8840\u58d3\u70ba126/82 mmHg\uff0c\u8108\u640f\u898f\u5247\uff0c\u6bcf\u5206\u941892\u4e0b\uff0c\u81c9\u8272\u84bc\u767d\uff0c\u7121\u5176\u4ed6\u7570\u5e38\uff1b\u8840\u6db2\u6aa2\u67e5\u986f\u793aHb 8.4 g/dL\uff0cMCV 69fL\uff0c\u767d\u8840\u7403\u53ca\u8840\u5c0f\u677f\u7121\u7570\u5e38\u3002\u6b64\u75c5\u4eba\u8ca7\u8840\u6700\u53ef\u80fd\u7684\u539f\u56e0\u70ba\nA. \u6d77\u6d0b\u6027\u8ca7\u8840 (Thalassemia)\nB. \u7f3a\u9435\u6027\u8ca7\u8840 (Iron deficiency anemia)\nC. \u6162\u6027\u708e\u6027\u53cd\u61c9\u5f15\u767c\u4e4b\u8ca7\u8840 (Anemia of chronic inflammation)\nD. \u7532\u72c0\u817a\u75be\u75c5\nE. \u814e\u81df\u75c5\n": "(B)", "104-2.\n\u4e00\u4f4d27\u6b72\u7537\u6027\u60a3\u6709\u514d\u75ab\u6027\u8840\u5c0f\u677f\u4f4e\u4e0b\u6027\u7d2b\u6591\u75c7(ITP)\uff0c\u5c0d\u65bc\u50b3\u7d71\u6cbb\u7642\u5982prednisolone, azathioprine\u7b49\u7684\u6548\u679c\u4e0d\u4f73\uff0c\u91ab\u5e2b\u5efa\u8b70\u4ed6\u5207\u9664\u813e\u81df\u3002\u5728\u624b\u8853\u524d\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u6cbb\u7642\u662f\u6700\u9069\u7576\u7684\u9078\u64c7\uff1f\nA. Eltrombopag\nB. GM-CSF\nC. Desmopressin\nD. High dose dexamethasone\nE. Tranexamic acid\n": "(A)", "104-3.\n\u4e0b\u5217\u75be\u75c5\u4f55\u8005\u5f15\u767c\u8840\u6813(thromboembolism)\u7684\u53ef\u80fd\u6027\u6700\u5c0f\uff1f\nA. Antiphospholipid antibody syndorme\nB. Paroxysmal nocturnal hemoglobinuria\nC. Hereditary spherocytosis\nD. Myeloproliferative neoplasm\nE. Ovarian cancer\n": "(C)", "104-4.\n\u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\u7684\u75c5\u4eba\uff0c\u5e36\u6709\u4e0b\u5217\u4f55\u7a2e\u67d3\u8272\u9ad4\u6216\u57fa\u56e0\u8b8a\u7570\u9810\u5f8c\u6700\u5dee\uff1f\nA. -7\nB. t(8;21)\nC. inv(16)\nD. CEBPA mutation\nE. NPM1 mutation\n": "(A)", "104-5.\n\u4e0b\u5217\u5404\u60e1\u6027\u8840\u6db2\u75be\u75c5\u8207\u6a19\u9776\u6cbb\u7642\u7684\u914d\u5c0d\uff0c\u4f55\u8005\u6709\u8aa4\uff1f\nA. Diffuse large B-cell lymphoma : rituximab\nB. Acute promyelocytic leukemia : arsenic trioxide\nC. Multiple myeloma : bortezomib\nD. Myelofibrosis : azacitidine\nE. Acute lymphoblastic leukemia with t(9;22) : imatinib\n": "(D)", "104-6.\n\u4e00\u4f4d19\u6b72\u75c5\u60a3\uff0c\u56e0\u767c\u71d2\u4e0d\u9000\u4f86\u5230\u6025\u8a3a\u8655\u3002\u8eab\u9ad4\u6aa2\u67e5\u986f\u793a\u5589\u56a8\u767c\u7d05\uff0c\u7121\u51fa\u8840\u50be\u5411\uff0c\u7121\u547c\u5438\u6025\u4fc3\uff1b\u62bd\u8840\u6aa2\u67e5\u767c\u73fe\u8840\u7d05\u7d20 8.1 g/dL\uff0c\u7d05\u8840\u7403 2,710,000/uL\uff0c\u7db2\u72c0\u7d05\u8840\u7403 0.5%\uff1b\u767d\u8840\u7403 1,200/uL\uff0c\u5176\u4e2dneutrophils 15%\uff0clymphocytes 80%\uff0cmonocytes 4.5%\uff0ceosinophils 0.5%\uff1b\u8840\u5c0f\u677f 18,000/uL\uff1b\u9aa8\u9ad3\u6aa2\u67e5\u8a3c\u5be6\u70ba\u518d\u751f\u4e0d\u826f\u6027\u8ca7\u8840\u3002\u4ee5\u4e0b\u8655\u7f6e\uff0c\u4f55\u8005\u6700\u4e0d\u9700\u8981\uff1f\nA. Search for HLA-matched sibling donor\nB. Blood culture\nC. Chest X-ray\nD. Platelet concentrate transfusion\nE. Antibiotics treatment\n": "(D)", "104-7.\n\u4e00\u4f4d38\u6b72\u75c5\u60a3\uff0c\u5065\u5eb7\u6aa2\u67e5\u6642\u767c\u73fe\u767d\u8840\u7403\u6578\u76ee\u589e\u9ad8\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\uff0c\u6b64\u75c5\u4eba\u767d\u8840\u7403\u589e\u9ad8\u6700\u53ef\u80fd\u7684\u539f\u56e0\u70ba\u4f55\uff1f\nA. \u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\nB. \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\nC. \u6025\u6027\u6dcb\u5df4\u82bd\u7d30\u80de\u767d\u8840\u75c5\nD. \u6162\u6027\u6dcb\u5df4\u82bd\u7d30\u80de\u767d\u8840\u75c5\nE. \u53cd\u61c9\u6027\u767d\u8840\u7403\u589e\u751f\n": "(B)", "104-8.\n\u985e\u8840\u53cb\u75c5(von Willebrand disease)\u7684\u767c\u751f\u7387\u8f03\u8840\u53cb\u75c5\u9ad8\uff0c\u9019\u7a2e\u75c5\u4eba\u5927\u591a\u6703\u51fa\u73fe\u4e0b\u5217\u4f55\u7a2e\u6aa2\u9a57\u7570\u5e38\uff1f\r(1) \u8840\u5c0f\u677f\u529f\u80fd\u7570\u5e38\r(2) PT\u5ef6\u5e38\r(3) aPTT\u5ef6\u5e38\r(4) Factor VIII\u6fc3\u5ea6\u4e0b\u964d\nA. (3)\nB. (2)+(3)\nC. (1)+(3)\nD. (3)+(4)\nE. (1)+(3)+(4)\n": "(E)", "104-9.\n\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684\u570b\u969b\u5206\u671f\u7cfb\u7d71(International staging system)\uff0c\u662f\u6839\u64da\u4e0b\u5217\u90a3\u4e9b\u6307\u6a19\uff1f\r(1) \u767d\u86cb\u767d\u7684\u6fc3\u5ea6\r(2) \u514d\u75ab\u7403\u86cb\u767d\u7684\u6fc3\u5ea6\r(3) \u03b22-microglobulin\r(4) \u8840\u7d05\u7d20\nA. (1)+(2)\nB. (2)+(3)\nC. (1)+(3)\nD. (1)+(3)+(4)\nE. (2)+(3)+(4)\n": "(C)", "104-10.\n\u816b\u7624\u6eb6\u89e3\u75c7\u5019\u7fa4(Tumor lysis syndorme)\u5e38\u767c\u751f\u5728\u751f\u9577\u5feb\u901f\u7684\u816b\u7624\uff0c\u5c24\u5176\u662f\u5c0d\u5316\u5b78\u6cbb\u7642\u5f88\u654f\u611f\u7684\u60e1\u6027\u75c5\uff0c\u4ee5\u4e0b\u4f55\u8005\u70ba\u5e38\u898b\u7684\u6aa2\u9a57\u7570\u5e38\uff1f\r(1) Hyperkalemia\r(2) Hyperphosphatemia\r(3) Hyperuricemia\r(4) Hypercalcemia\nA. (1)+(3)\nB. (2)+(3)\nC. (1)+(2)+(3)\nD. (1)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(C)", "104-1.\n\u4e0b\u5217\u4f55\u7d44\u816b\u7624\u6a19\u8a18(tumor markers)\u8207\u7279\u5b9a\u764c\u75c7\u7684\u914d\u5c0d\u6700\u70ba\u5408\u5b9c? \u7576\u8a72\u764c\u75c7\u6cbb\u7642\u671f\u9593\uff0c\u53ef\u6aa2\u6e2c\u8a72\u816b\u7624\u6a19\u8a18\uff0c\u505a\u70ba\u8a55\u4f30\u816b\u7624\u7e3d\u91cf(tumor burden)\u7684\u8f14\u52a9\u5224\u65b7\u53c3\u8003\u3002\nA. CA-125\u8207Colon cancer\nB. CD30\u8207Hairy cell leukemia\nC. CA-153\u8207Gestational trophoblastic disease\nD. Calcitonin\u8207Medullary cancer of the thyroid\nE. Neuron-specific enolase (NSE)\u8207Non-small cell carcinoma of the lung\n": "(D)", "104-2.\n\u4e00\u4f4d63\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u56e0\u8072\u97f3\u6c99\u555e(hoarseness)\u7d043\u500b\u6708\u800c\u5c31\u91ab\uff0c\u4ed6\u904e\u53bb25\u5e74\u5e73\u5747\u6bcf\u5929\u62bd\u83f8\u4e00\u5305\uff0c\u521d\u6b65\u7406\u5b78\u6aa2\u67e5\u982d\u9838\u90e8\u5927\u81f4\u6b63\u5e38\uff0c\u6c92\u6709\u9838\u90e8\u6dcb\u5df4\u7d50\u816b\u5927\uff0c\u8033\u9f3b\u5589\u93e1\u6aa2\u767c\u73fe\u4e00\u5589\u90e8(laryngeal)\u75c5\u7076\uff0c\u5207\u7247\u6aa2\u67e5\u8b49\u5be6\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c(squamous cell carcinoma)\uff0cCT\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u986f\u793a\u4e3b\u8981\u75c5\u7076\u6700\u9577\u5f91\u7d042.2\u516c\u5206\uff0c\u6b63\u5b50\u6383\u63cf(FDG-PET)\u4e26\u6c92\u6709\u767c\u73fe\u61f7\u7591\u7684\u6dcb\u5df4\u7d50\u8f49\u79fb\u3002 \u5efa\u8b70\u6b64\u75c5\u4eba\u6700\u5408\u9069\u7684\u6cbb\u7642\u65b9\u5f0f\u70ba\u4f55?\nA. \u5316\u5b78\u6cbb\u7642\nB. \u624b\u8853\u5207\u9664\u4f75\u7528\u6839\u6cbb\u6027\u9838\u90e8\u6dcb\u5df4\u7d50\u5ed3\u6e05\u8853\nC. \u624b\u8853\u5207\u9664\u4f75\u7528\u6839\u6cbb\u6027\u9838\u90e8\u6dcb\u5df4\u7d50\u5ed3\u6e05\u8853\uff0c\u8853\u5f8c\u518d\u7528\u540c\u6b65\u5316\u7642\u653e\u5c04\u6cbb\u7642\nD. \u653e\u5c04\u7dda\u6cbb\u7642\nE. \u7de9\u548c\u5b89\u5be7(Hospice)\u6cbb\u7642\n": "(D)", "104-3.\n\u4e00\u4f4d58\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u4ee5\u4e0a\u8154\u975c\u8108\u75c7\u5019\u7fa4(SVC syndrome)\u70ba\u6700\u521d\u8868\u73fe\u800c\u81f3\u6025\u8a3a\u5c31\u91ab\uff0c\u88ab\u8a3a\u65b7\u7f79\u60a3\u5c0f\u7d30\u80de\u80ba\u764c(small cell lung cancer\uff0cSCLC)\u3002\u70ba\u9032\u4e00\u6b65\u5b8c\u6574\u7684\u764c\u75c7\u5206\u671f\uff0c\u9700\u518d\u5b89\u6392\u54ea\u4e9b\u6aa2\u67e5?\nA. \u80f8\u8154\u8207\u8179\u8154CT\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u6aa2\u67e5\nB. \u8166\u90e8\u96fb\u8166\u65b7\u5c64\u6383\u63cfCT\uff0c\u6216\u8166\u90e8\u78c1\u632f\u9020\u5f71\u6383\u63cfMRI\u6aa2\u67e5(\u52a0\u4e0a\u975c\u8108\u986f\u5f71\u5291\u6ce8\u5c04)\nC. \u9aa8\u9ad3\u5207\u7247(Bone marrow biopsy)\u6aa2\u67e5\nD. A + B\nE. A + B + C\n": "(D)", "104-4.\n\u4e00\u4f4d41\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u7d93\u75c5\u7406\u5207\u7247\u78ba\u8a3a\u7f79\u60a3\u4e86\u7b2c\u4e8c\u671f\u7684\u5b50\u5bae\u9838\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c(squamous cell carcinoma)\uff0c\u5979\u5148\u63a5\u53d7\u4e86\u8179\u5f0f\u5168\u5b50\u5bae\u5207\u9664\u8853\uff0c\u52a0\u4e0a\u96d9\u5074\u8f38\u5375\u7ba1\u8207\u5375\u5de2\u6458\u9664\u8853\uff0c\u8207\u9aa8\u76c6\u8154\u6dcb\u5df4\u7d50\u63a1\u6a23\u3002\u624b\u8853\u5f8c\u75c5\u7406\u6aa2\u67e5\u5831\u544a\u986f\u793a\u816b\u7624\u6700\u9577\u5f913.3\u516c\u5206\uff0c\u4e26\u5408\u4f75\u591a\u500b\u9ad8\u5371\u96aa\u75c5\u7406\u7d50\u679c\u967d\u6027 (\u5305\u62ecdeep stromal invasion\uff0clymphovascular invasion\uff0c4\u500b\u6dcb\u5df4\u7d50\u816b\u7624\u967d\u6027)\u3002\r\u5efa\u8b70\u4e0b\u4e00\u6b65\u6700\u9069\u5b9c\u7684\u6cbb\u7642\u8a08\u756b\u70ba\u4f55 ?\nA. \u5df2\u5145\u5206\u624b\u8853\uff0c\u50c5\u9700\u5b9a\u671f\u8ffd\u8e64\u89c0\u5bdf\u5373\u53ef\u3002\u81f3\u5c11\u6bcf3-4\u500b\u6708\u8ffd\u8e64\u9aa8\u76c6\u8154\u7406\u5b78\u6aa2\u67e5\uff0c\u8207\u7cfb\u5217CT\u96fb\u8166\u65b7\u5c64\u6383\u63cf\nB. \u8840\u6e05Human papilloma virus (HPV) \u6aa2\u67e5\nC. \u624b\u8853\u5f8c\u9aa8\u76c6\u8154\u653e\u5c04\u7dda\u6cbb\u7642\nD. \u624b\u8853\u5f8c\u5316\u5b78\u6cbb\u7642\nE. \u624b\u8853\u5f8c\u9aa8\u76c6\u8154\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5408\u4f75\u540c\u6b65\u5316\u5b78\u6cbb\u7642\n": "(E)", "104-5.\n\u4e0b\u5217\u5973\u6027\uff0c\u4f55\u8005\u53ef\u80fd\u6709\u300c\u6700\u4f4e\u300d\u7684\u4e73\u764c\u7f79\u60a3\u98a8\u96aa?\nA. \u4e00\u5973\u6027\u521d\u7d93(menarche)\u572816\u6b72\uff0c\u7b2c\u4e00\u80ce\u61f7\u5b55\u751f\u7522\u572818\u6b72\uff0c\u4e4b\u5f8c\u505c\u7d93(menopause)\u572844\u6b72\nB. \u4e00\u5973\u6027\u521d\u7d93(menarche)\u572814\u6b72\uff0c\u7b2c\u4e00\u80ce\u61f7\u5b55\u751f\u7522\u572818\u6b72\uff0c\u4e4b\u5f8c\u505c\u7d93(menopause)\u572852\u6b72\nC. \u4e00\u5973\u6027\u521d\u7d93(menarche)\u572812\u6b72\uff0c\u7b2c\u4e00\u80ce\u61f7\u5b55\u751f\u7522\u572824\u6b72\uff0c\u4e4b\u5f8c\u505c\u7d93(menopause)\u572848\u6b72\nD. \u4e00\u5973\u6027\u521d\u7d93(menarche)\u572816\u6b72\uff0c\u7b2c\u4e00\u80ce\u61f7\u5b55\u751f\u7522\u572832\u6b72\uff0c\u4e4b\u5f8c\u505c\u7d93(menopause)\u572852\u6b72\nE. \u4ee5\u4e0a\u5973\u6027\uff0c\u7f79\u60a3\u4e73\u764c\u7684\u98a8\u96aa\u5747\u76f8\u540c\n": "(A)", "104-6.\n\u4e00\u4f4d68\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u56e0\u7d04\u4e00\u500b\u6708\u7684\u7121\u75db\u6027\u9ec3\u75b8(painless jaundice)\u9010\u6f38\u60e1\u5316\u800c\u5c31\u91ab\uff0c\u5408\u4f75\u6709\u7d043\u516c\u65a4\u9ad4\u91cd\u6e1b\u8f15\uff0c\u7406\u5b78\u6aa2\u67e5\u7121\u660e\u986f\u5176\u4ed6\u7570\u5e38\u3002\u9032\u884cdual-phase\u986f\u5f71CT\u96fb\u8166\u65b7\u5c64\u6383\u63cf\uff0c\u767c\u73fe\u80f0\u81df\u982d\u90e8\u6709\u4e00\u7591\u4f3c\u816b\u584a\uff0c\u5408\u4f75\u81bd\u7ba1\u64f4\u5f35\u3002 \u8981\u9032\u4e00\u6b65\u8b49\u5be6\u78ba\u8a3a\u300c\u80f0\u81df\u764c\u300d\uff0c\u5efa\u8b70\u6700\u9069\u5b9c\u7684\u6aa2\u67e5\u8a3a\u65b7\u65b9\u5f0f\u70ba\u4f55?\nA. \u5167\u8996\u93e1\u9006\u884c\u81bd\u80f0\u7ba1\u651d\u5f71(ERCP)\u5408\u4f75\u80f0\u6db2\u63a1\u6a23\uff0c\u4ee5\u9032\u884c\u7d30\u80de\u5b78\u6aa2\u67e5(cytology)\nB. CT\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5c0e\u5f15\u4e0b\uff0c\u7d93\u76ae\u819a(percutaneous)\u9032\u884cneedle biopsy\u5207\u7247\u75c5\u7406\u6aa2\u67e5\nC. \u5167\u8996\u93e1\u8d85\u97f3\u6ce2(endoscopic ultrasound, EUS)\u5c0e\u5f15\u4e0b\uff0c\u9032\u884cneedle biopsy\u5207\u7247\u75c5\u7406\u6aa2\u67e5\nD. FDG-PET \u6b63\u5b50\u6383\u63cf\u651d\u5f71\nE. \u62bd\u8840\u6aa2\u67e5\u8840\u6e05CA19-9\u6578\u503c\n": "(C)", "104-7.\n\u6709\u4e0021\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u7d04\u4e00\u500b\u6708\u524d\u56e0\u53f3\u5c0f\u817f\u811b\u9aa8\u524d\u5074\u816b\u75db\u800c\u5c31\u91ab\uff0c\u5148\u524d\u4e26\u7121\u78b0\u649e\u53d7\u50b7\u7684\u75c5\u53f2\u3002\u53f3\u4e0b\u80a2X\u5149\u986f\u793a\u9aa8\u9abc\u4f3c\u87f2\u86c0\u6a23(moth-eaten)\u7834\u58de\uff0c\u4e14\u5ef6\u4f38\u81f3\u9aa8\u5468\u570d\u7684\u8edf\u7d44\u7e54\uff0c\u4e26\u6709\u91dd\u6a23\u7684\u9aa8\u5468\u570d\u53cd\u61c9(periosteal reaction)\uff0c\u8edf\u7d44\u7e54\u816b\u584a\u548c\u9aa8\u5468\u570d\u53cd\u61c9\uff0c\u7d50\u5408\u5f62\u6210Codman\u6c0f\u4e09\u89d2(Codman's triangle)\u5fb5\u8c61\u3002\r\u91ab\u5e2b\u5224\u65b7\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff0c\u8207\u5efa\u8b70\u4f55\u7a2e\u6700\u5408\u9069\u7684\u6cbb\u7642\u8a08\u756b?\nA. \u6f3f\u7d30\u80de\u816b\u7624(plasma cell tumor\uff0cplasmacytoma)\uff1b\u5316\u5b78\u6cbb\u7642\nB. \u60e1\u6027\u8edf\u9aa8\u8089\u7624(chondrosarcoma)\uff1b\u5316\u5b78\u6cbb\u7642\nC. \u60e1\u6027\u8edf\u9aa8\u8089\u7624(chondrosarcoma)\uff1b\u653e\u5c04\u7dda\u6cbb\u7642\u5408\u4f75\u5c40\u90e8\u5207\u9664\u624b\u8853\nD. \u60e1\u6027\u9aa8\u8089\u7624(osteosarcoma)\uff1b\u624b\u8853\u524d\u5316\u5b78\u6cbb\u7642\uff0c\u4e4b\u5f8c\u9032\u884c\u80a2\u9ad4\u4fdd\u5168(limb-sparing)\u624b\u8853\nE. \u60e1\u6027\u9aa8\u8089\u7624(osteosarcoma)\uff1b\u653e\u5c04\u7dda\u7642\u6cd5\n": "(D)", "104-8.\n\u4ee5\u4e0b\u54ea\u4e9b\u75c5\u75c7\u6216\u75c7\u5019\u7fa4\uff0c\u6703\u589e\u52a0\u60a3\u8005\u7f79\u60a3\u764c\u75c7\u7684\u98a8\u96aa?\r(1) Fanconi's anemia\r(2) Down syndrome\r(3) Von Hippel-Lindau syndrome\r(4) Fragile X syndrome\r(5) Neurofibromatosis\nA. (1+)(2)+(4)\nB. (2)+(3)+(4)\nC. (1)+(3)+(4)+(5)\nD. (1)+(2)+(3)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(D)", "104-9.\n\u764c\u75c7\u7684\u6a19\u9776\u6cbb\u7642(targeted therapy)\u85e5\u5291\uff0c\u901a\u5e38\u91dd\u5c0d\u7279\u5b9a\u7684\u8a0a\u606f\u50b3\u905e\u8def\u5f91\u6216\u5206\u5b50\u6a19\u9776\u9032\u884c\u6291\u5236\uff0c\u4ee5\u9054\u5230\u6cbb\u7642\u764c\u75c7\u7684\u76ee\u7684\u3002 \u4e0b\u5217\u6cbb\u7642\u85e5\u5291\u8207\u5206\u5b50\u6a19\u9776(molecular target) \u7684\u914d\u5c0d\uff0c\u54ea\u4e9b\u6b63\u78ba?\r(1) Erlotinib \u8207 EGFR\r(2) Ipilimumab \u8207 CTLA-4\r(3) Imatinib \u8207 Bcr-Abl\r(4) Vemurafenib \u8207 B-Raf\r(5) Rituximab \u8207 CD30\nA. (1)+(2)+(3)+(5)\nB. (1)+(2)+(3)+(4)\nC. (2)+(3)+(4)+(5)\nD. (3)+(4)+(5)\nE. (2)+(4)+(5)\n": "(B)", "104-10.\n\u4e00\u4f4d70\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u56e0\u8fd12\u500b\u6708\u53f3\u5074\u8170\u75db\uff0c\u5408\u4f75\u8fd11\u500b\u6708\u8840\u5c3f(hematuria)\u9010\u6f38\u52a0\u91cd\u800c\u5c31\u91ab\u3002\u4e09\u661f\u671f\u524d\uff0c\u5728\u9580\u8a3a\u521d\u8a3a\u65b7\u70ba\u8180\u80f1\u708e\u5148\u9032\u884c\u6cbb\u7642\uff0c\u4f46\u75c7\u72c0\u4e26\u672a\u6539\u5584\uff0c\u4e14\u75c5\u4eba\u5408\u4f75\u98df\u617e\u4e0d\u632f\u8207\u9ad4\u91cd\u6e1b\u8f15\u7d044\u516c\u65a4\u3002\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u53f3\u5074\u8170\u90e8\u6709\u4e00\u53ef\u89f8\u8a3a\u7684\u816b\u584a\u7d0410\u516c\u5206\uff0c\u814e\u529f\u80fd\u6aa2\u67e5\u76ee\u524d\u4ecd\u5c6c\u6b63\u5e38\u3002 \u4ee5\u4e0b\u6709\u95dc\u6b64\u75c5\u4eba\u7684\u53ef\u80fd\u8a3a\u65b7\uff0c\u90a3\u4e9b\u6b63\u78ba?\r(1) \u8d85\u904e\u534a\u6578\u7684\u75c5\u7406\u8a3a\u65b7\uff0c\u591a\u5c6c\u4eae\u7d30\u80de\u4e0a\u76ae\u764c(clear cell carcinoma)\r(2) \u62bd\u83f8\u70ba\u5df2\u77e5\u7684\u76f8\u95dc\u5371\u96aa\u56e0\u5b50\u4e4b\u4e00\r(3) \u8ca7\u8840(anemia)\u8f03\u7d05\u8840\u7403\u589e\u591a\u75c7(erythrocytosis)\u5e38\u898b\r(4) \u7b2c\u4e00\u671f\u6216\u7b2c\u4e8c\u671f\u7684\u6b64\u7a2e\u764c\u75c7\uff0c\u7d93\u6839\u6cbb\u6027\u624b\u8853\u5207\u9664\u5f8c\uff0c5\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u8d85\u904e80%\r(5) \u7b2c\u56db\u671f\u8f49\u79fb\u6027\u7684\u6b64\u7a2e\u764c\u75c7\uff0c\u7d93\u7531\u5404\u7a2e\u6a19\u9776\u6cbb\u7642(targeted therapy)\u85e5\u5291\u7684\u9032\u5c55\uff0c5\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u5df2\u53ef\u8d85\u904e50%\nA. (1)+(3)+(5)\nB. (3)+(4)+(5)\nC. (1)+(2)+(3)+(5)\nD. (1)+(2)+(3)+(4)\nE. (1)+(2)+(3)+(4)+(5)\n": "(D)", "105-1.\n\u4e00\u4f4d\u75c5\u4eba\u88ab\u767c\u73fe\u6709\u7d05\u8840\u7403\u904e\u591a\u75c7\uff0c\u4e0b\u5217\u8b8a\u5316\u5728\u539f\u767c\u6027\u591a\u8840\u75c7\u75c5\u60a3\u8f03\u6b21\u767c\u6027\u591a\u8840\u75c7\u75c5\u60a3\u70ba\u5e38\u898b\uff0c\u4f55\u8005\u4f8b\u5916\uff1f\nA. Leukocytosis\nB. Thrombocytosis\nC. Basophilia\nD. High erythropoietin level\nE. Splenomegaly\n": "(D)", "105-2.\n\u4e00\u4f4d63\u6b72\u7537\u6027\u5728\u5065\u6aa2\u6642\u88ab\u767c\u73fe\u767d\u8840\u7403\u6578\u76ee\u589e\u9ad8\uff0c\u5176\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\u3002\u9019\u4e9b\u7d30\u80de\u8868\u73feCD5/CD19/CD20/CD23\uff0c\u4f46CD2/CD3/CD10\u70ba\u9670\u6027\u3002\u9019\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\uff1f\nA. Chronic myeloid leukemia\nB. B cell chronic lymphocytic leukemia\nC. Follicular lymphoma\nD. Mantle cell lymphoma\nE. Adult T cell lymphoma/leukemia\n": "(B)", "105-3.\n\u4e0b\u5217\u85e5\u7269\u8207\u5176\u4f5c\u7528\u6a5f\u8f49\u7684\u914d\u5c0d\uff0c\u4f55\u8005\u6709\u8aa4\uff1f\nA. Bortezomib : proteosome inhibitor\nB. Imatinib : tyrosine kinase inhibitor\nC. Ruxolitinib : JAK inhibitor\nD. Azacitidine : demethylation agent\nE. Ibrutinib : anti-CD30 antibody\n": "(E)", "105-4.\n\u4e00\u4f4d\u75c5\u4eba\u4e3b\u8a34\u547c\u5438\u6025\u4fc3\uff0c\u8840\u6db2\u6aa2\u67e5\u986f\u793aHb 9.6 gm/dL\uff0c\u767d\u8840\u7403\u53ca\u8840\u5c0f\u677f\u6578\u76ee\u6b63\u5e38\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\u3002\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\uff1f\nA. Aplastic anemia\nB. Iron deficiency anemia\nC. Hemolytic anemia\nD. Vit B12 deficiency anemia\nE. Thalassemia\n": "(C)", "105-5.\n\u4e0b\u5217\u6709\u95dcheparin\u5f15\u767c\u8840\u5c0f\u677f\u4f4e\u4e0b\u75c7\u7684\u6558\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f\nA. \u7b2c\u4e00\u6b21\u4f7f\u7528\u7684\u75c5\u4eba\uff0c\u4e00\u822c\u5728\u4f7f\u7528\u5f8c2\u81f33\u661f\u671f\u767c\u751f\nB. Low-molecular-weight heparin\u767c\u751f\u6a5f\u6703\u8f03unfractionated heparin\u5c0f\nC. \u5bb9\u6613\u4f75\u767c\u6813\u585e\nD. \u8840\u5c0f\u677f\u5f88\u5c11\u6389\u523020000/uL\u4ee5\u4e0b\nE. \u75c5\u4eba\u8840\u4e2d\u53ef\u5075\u6e2c\u5230\u6297heparin/platelet factor 4\u7684\u6297\u9ad4\n": "(A)", "105-6.\n\u5927\u90e8\u5206\u9aa8\u9ad3\u589e\u751f\u4e0d\u826f\u75c7\u5019\u7fa4(Myelodysplastic syndrome, MDS)\u7684\u75c5\u4eba\u90fd\u88ab\u767c\u73fe\u6709\u57fa\u56e0\u7a81\u8b8a\u3002\u5176\u4e2drefractory anemia with ring sideroblasts\u8207\u90a3\u4e00\u7a2e\u7a81\u8b8a\u7279\u5225\u6709\u95dc\uff1f\nA. KIT\nB. JAK2\nC. SFS3B1\nD. DNMT3A\nE. MYC\n": "(C)", "105-7.\n\u6025\u6027\u524d\u9aa8\u9ad3\u82bd\u7d30\u80de\u767d\u8840\u75c5(Acute promyelocytic leukemia, APL)\u5728\u6cbb\u7642\u5f8c\u53ef\u4ee5\u7528\u4f55\u7a2e\u751f\u7269\u6a19\u8a18\u8ffd\u8e64\u5176\u5fae\u91cf\u6b98\u5b58\u75be\u75c5(minimal residual disease)\nA. NPM1 mutant\nB. BCR-ABL\nC. RUNX1-RUNX1T1\nD. PML-RARA\nE. CBFB-MYH11\n": "(D)", "105-8.\n\u4e00\u4f4d55\u6b72\u75c5\u4eba\u6700\u8fd1\u4e00\u661f\u671f\u51fa\u73fe\u5169\u8173\u591a\u8655\u7600\u9752\uff0c\u5176\u4ed6\u7121\u7279\u6b8a\u7570\u5e38\u3002\u8edf\u7d44\u7e54\u8d85\u97f3\u6ce2\u6aa2\u67e5\u986f\u793a\u6709\u8840\u816b\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73fePT\u70ba12\u79d2(\u53c3\u8003\u503c9.8~11.5)\uff0cINR 0.95\uff0cPTT 58\u79d2(\u53c3\u8003\u503c25.6~32.6)\u3002mixing test\u986f\u793a\uff0c0\u5c0f\u6642PTT\u70ba37\u79d2\uff0c2\u5c0f\u6642\u70ba54\u79d2\u3002\u9019\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\uff1a\nA. Acquired hemophilia\nB. Antiphospholipid syndrome\nC. von Willebrand disease\nD. Factor XII deficiency\nE. Disseminated intravascular coagulation\n": "(A)", "105-9.\n\u4e00\u4f4d45\u6b72\u75c5\u4eba\u56e0\u80c3\u75db\u5c31\u8a3a\uff0c\u80c3\u93e1\u6aa2\u67e5\u986f\u793a\u67092\u516c\u5206\u5927\u816b\u7624\uff0c\u5207\u7247\u53ca\u75c5\u7406\u6aa2\u67e5\u8b49\u5be6\u70bamarginal zone B-cell lymphoma, H. pylori\u967d\u6027\uff1b\u5206\u671f\u6aa2\u67e5\u672a\u767c\u73fe\u5176\u4ed6\u5730\u65b9\u6709\u88ab\u4fb5\u72af\u3002\u5c0d\u6b64\u75c5\u4eba\u6700\u9069\u7576\u7684\u6cbb\u7642\u70ba\u4f55\uff1f\nA. Surgery\nB. Anti-H. pylori treatment\nC. Rituximab\nD. Rituximab plus oral chemotherapeutic drug\nE. Rituximab plus CHOP(Cyclophosphamide, Adriamycin, Vincristine and Prednisolone)\n": "(B)", "105-10.\n\u4e0b\u5217\u4f55\u8005\u70baTumor lysis\u5e38\u898b\u7684\u8b8a\u5316\uff1f(\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r1. Hyperuricemia\r2. Hyperkalemia\r3. Hypercalcemia\r4. Renal failure\nA. 1+3\nB. 1+3+4\nC. 1+2+3\nD. 1+2+4\nE. 1+2+3+4\n": "(D)", "105-1.\n\u4e0055\u6b72\u7537\u6027\u75c5\u4eba\u8a3a\u65b7\u6709\u60e1\u6027\u9ed1\u8272\u7d20\u7d30\u80de\u7624(melanoma)\u5408\u4f75\u80ba\u81df\u8207\u9aa8\u9abc\u8f49\u79fb\uff0c\u76ee\u524d\u4e00\u822c\u9ad4\u80fd\u72c0\u6cc1\u826f\u597d\u3002\u4ed6\u7684\u816b\u7624\u57fa\u56e0\u6aa2\u6e2c\u8b49\u5be6BRAF V600E\u7a81\u8b8a\u967d\u6027\u3002\u5efa\u8b70\u6b64\u75c5\u4eba\u63a5\u53d7\u4f55\u7a2e\u6cbb\u7642\u53ef\u4ee5\u6709\u6700\u4f73\u7684\u816b\u7624\u7de9\u89e3\u7387(response rates)?\nA. Cisplatin\nB. Dacarbazine\nC. Vemurafenib\nD. Interleukin-2\nE. Hospice care\n": "(C)", "105-2.\n\u4e0065\u6b72\u7537\u6027\uff0c\u5f9e16\u6b72\u958b\u59cb\u62bd\u83f8\uff0c\u5230\u76ee\u524d\u4ecd\u5e73\u5747\u4e00\u5929\u7d04\u62bd1\u5305\u9999\u83f8\u3002\u4ed6\u5728\u6700\u8fd1\u4e00\u6b21\u5065\u5eb7\u6aa2\u67e5\u4e2d\uff0cCT\u6383\u63cf\u767c\u73fe\u5de6\u4e0b\u80ba\u8449\u5916\u570d(periphery)\u6709\u55ae\u4e00\u500b10mm\u76f4\u5f91\u5927\u5c0f\u7684\u80ba\u7d50\u7bc0(nodule)\uff0c\u4e26\u6c92\u6709\u767c\u73fe\u660e\u986f\u7684\u7e31\u8188\u8154\u6dcb\u5df4\u7d50\u816b\u5927\uff0c\u4ed6\u57282\u5e74\u524d\u6709\u6aa2\u67e5\u904eCXR\uff0c\u4e26\u6c92\u6709\u767c\u73fe\u9019\u4e00\u500b\u7d50\u7bc0\u3002\u76ee\u524d\u4ed6\u4e26\u7121\u4efb\u4f55\u986f\u8457\u7684\u547c\u5438\u7cfb\u7d71\u75c7\u72c0\uff0c\u80ba\u529f\u80fd\u6aa2\u67e5FEV1\u70ba87% predicted\uff0cFVC\u70ba91% predicted\uff0cdiffusion capacity\u70ba81% predicted\u3002\u5efa\u8b70\u4e0b\u5217\u4e0b\u4e00\u6b65\u8655\u7f6e\u4f55\u8005\u6700\u70ba\u9069\u7576?\nA. \u9032\u884cFDG-PET-CT\u6b63\u5b50\u65b7\u5c64\u6383\u63cf\u651d\u5f71\u6aa2\u67e5\nB. \u9032\u884cBronchoscope with biopsy\u4ee5\u78ba\u8a3a\nC. 3\u500b\u6708\u5f8c\u9032\u884cChest MRI\u6383\u63cf\u4ee5\u8a55\u4f30interval growth\nD. \u8f49\u4ecb\u80f8\u8154\u5916\u79d1\u9032\u884cVideo-assisted thoracoscopic (VATS) biopsy\uff0c\u82e5\u8b49\u5be6\u70ba\u60e1\u6027\uff0c\u5247\u5408\u4f75\u75c5\u7076\u5207\u9664\nE. \u8f49\u4ecb\u653e\u5c04\u816b\u7624\u79d1\u9032\u884cStereotactic radiation\n": "(D)", "105-3.\n\u4e00\u4f4d66\u6b72\u7537\u6027\u56e0\u7a81\u7136\u767c\u89ba\u53f3\u5074\u773c\u77bc\u4e0b\u5782\u8207\u8996\u529b\u6a21\u7cca\u800c\u5230\u6025\u8a3a\u5c31\u91ab\uff0c\u75c5\u4eba\u4e3b\u8a34\u904e\u53bb\u90fd\u6c92\u6709\u985e\u4f3c\u7684\u75c7\u72c0\u767c\u751f\uff0c\u53ea\u662f\u904e\u53bb\u7d043\u500b\u6708\u4ee5\u4f86\uff0c\u4ed6\u81ea\u89ba\u53f3\u80a9\u8207\u53f3\u4e0a\u81c2\u75bc\u75db\u7684\u554f\u984c\uff0c\u4ed6\u7684\u5bb6\u5ead\u91ab\u5e2b\u5148\u8a3a\u65b7\u70ba\u767c\u708e\u6027\u75bc\u75db(shoulder bursitis)\u4e26\u7d66\u4e88\u85e5\u7269\uff0c\u4f46\u75bc\u75db\u4e26\u672a\u80fd\u5b8c\u5168\u63a7\u5236\u3002\u4ed6\u5e73\u5747\u6bcf\u5929\u62bd\u83f8\u7d04\u4e00\u5305\uff0c\u5df2\u6709\u8d85\u904e30\u5e74\u4e4b\u4e45\uff0c\u9577\u671f\u6709COPD\u8207\u6162\u6027\u54b3\u75f0\u7684\u554f\u984c\u3002\u6025\u8a3a\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u53f3\u773c\u77bcptosis\u4e14\u5169\u5074pupils\u5927\u5c0f\u4e0d\u7b49\uff0c\u53f3\u5074pupil 2 mm\u4e14not reactive\uff0c\u5de6\u5074pupil 4 mm\u4e14reactive\uff0c\u5169\u773c\u7403\u7684\u5404\u773c\u5916\u808c\u6d3b\u52d5\u7684\u5404\u65b9\u5411\u5747\u6b63\u5e38(full and\rfree)\u3002\u80ba\u90e8\u807d\u8a3a\u5927\u81f4\u6b63\u5e38\u3002\u80a2\u9ad4\u6aa2\u67e5\u767c\u73fe\u53f3\u624b\u638c\u7684intrinsic\u808c\u8089\u5df2\u6709wasting\u73fe\u8c61\u3002\r\u4f60\u63a8\u6e2c\u4ed6\u6700\u53ef\u80fd\u7684\u81e8\u5e8a\u8a3a\u65b7\u70ba\u4f55?\nA. CXR\u53ef\u898b\u5230\u4e00cervical rib\u7684\u5b58\u5728\nB. Eaton-Lambert myasthenic syndrome (Eaton-Lambert\u91cd\u75c7\u808c\u7121\u529b\u75c7\u5019\u7fa4)\nC. \u5c0f\u7d30\u80de\u80ba\u764c(Small cell lung cancer)\u5df2\u6709midbrain\u8f49\u79fb\nD. CXR\u53ef\u898b\u5230\u53f3\u4e0a\u80ba\u5c16(apical)\u808b\u819c\u589e\u539a\u4e14\u5408\u4f75\u6709\u4e00\u500b\u7d042\u516c\u5206\u539a\u5ea6\u7684\u816b\u584a\u9670\u5f71\nE. \u7e31\u8188\u8154\u6dcb\u5df4\u7d50\u816b\u5927\uff0c\u58d3\u8feb\u4e0a\u8154\u975c\u8108(SVC)\uff0c\u9020\u6210SVC\u75c7\u5019\u7fa4\n": "(D)", "105-4.\n\u4e0033\u6b72\u5973\u6027\u56e0\u53f3\u5074\u4e73\u623f\u816b\u584a\u4f86\u5c31\u91ab\u3002\u7d04\u4e00\u9031\u524d\u5979\u5728\u6dcb\u6d74\u6642\u767c\u73fe\u9019\u4e00\u816b\u584a\uff0c\u4e26\u6c92\u6709nipple\u7684\u7570\u5e38\u5206\u6ccc\u7269\uff0c\u4e5f\u6c92\u6709\u4efb\u4f55\u7d05\u816b\u6216\u4e0d\u9069\uff0c\u5979\u904e\u53bb\u4e5f\u6c92\u6709\u7279\u5b9a\u91ab\u7642\u75c5\u53f2\u3002\u7406\u5b78\u6aa2\u67e5\u89f8\u8a3a\u767c\u73fe\u53f3\u5074\u4e73\u623f\u7684\u300c\u53f3\u4e0a\u5916\u5074\u56db\u5206\u4e4b\u4e00\u300d\u90e8\u4f4d\u6709\u4e00\u500b\u7d041.5 x 2.0\u516c\u5206\u7684\u816b\u584a\uff0c\u5de6\u5074\u4e73\u623f\u6b63\u5e38\uff0c\u5169\u5074\u814b\u4e0b\u6dcb\u5df4\u7d50\u5747\u7121\u816b\u5927\u30024\u9031\u5f8c\u518d\u6b21\u7406\u5b78\u6aa2\u67e5\u4f9d\u7136\u4e00\u6a23\u3002\u65bc\u662f\u9032\u884c\u7d30\u91dd\u62bd\u5438\u8853\uff0c\u62bd\u51fa\u7d042.5\u6beb\u5347\u6e05\u6f88\u7684\u6db2\u9ad4\uff0c\u4e4b\u5f8c\u816b\u584a\u5c31\u89f8\u8a3a\u4e0d\u5230\u4e86\u3002\u4e0b\u5217\u5efa\u8b70\u4f55\u8005\u6700\u70ba\u9069\u5b9c?\nA. \u7acb\u5373\u9032\u884cMammography\u9032\u4e00\u6b65\u8a55\u4f30\nB. \u7acb\u5373\u9032\u884cBreast MRI\u5075\u6e2c\u8207\u5206\u8fa8\u6b98\u9918\u6db2\u9ad4\u7684\u5206\u5e03\nC. \u7acb\u5373\u8f49\u4ecbBreast surgeon\u9032\u884c\u5207\u9664\u624b\u8853\nD. \u65e5\u5f8c\u6b64\u75c5\u4eba\u4e0d\u61c9\u9935\u5979\u7684\u5c0f\u5b69\u6bcd\u4e73\nE. \u5b89\u6392\u6b64\u75c5\u4eba1\u500b\u6708\u5f8c\u518d\u56de\u8a3a\u8ffd\u8e64\uff0c\u4ee5\u6c7a\u5b9a\u5f8c\u7e8c\u7684\u6aa2\u67e5\u6216\u6cbb\u7642\u9700\u8981\u8207\u5426\n": "(E)", "105-5.\n\u4e00\u500b\u8eab\u9ad4\u72c0\u6cc1\u5927\u81f4\u6b63\u5e38\u768465\u6b72\u5973\u6027\u9032\u884c\u5065\u5eb7\u6aa2\u67e5\uff0ccolonoscope\u5728\u5347\u7d50\u8178\u90e8\u4f4d\u767c\u73fe2\u500b\u5927\u5c0f\u5206\u5225\u70ba1.2\u516c\u5206\u30011.4\u516c\u5206\u7684\u6241\u5e73\u6a23sessile (flat-based)\u606f\u8089\uff0c\u5167\u8996\u93e1\u6aa2\u540c\u6642\u9032\u884c\u5167\u8996\u93e1\u606f\u8089\u5207\u9664\uff0c\u75c5\u7406\u5831\u544a\u5747\u70ba\u7d68\u6bdb\u6a23\u817a\u7624(villous adenoma)\uff0c\u4e26\u7121\u7d50\u8178\u764c\u3002\u4ee5\u4e0b\u5efa\u8b70\u4f55\u7a2e\u6700\u9069\u7576?\nA. Abdominal and Pelvic CT scan\nB. Partial colectomy\nC. Reassurance only\nD. Follow-up colonoscopy in 3 years\nE. Follow-up colonoscopy in 10 years\n": "(D)", "105-6.\n\u4f4e\u5291\u91cf\u80f8\u8154CT\u6383\u63cf\u767c\u73fe\u55ae\u4e00\u80ba\u7d50\u7bc0(solitary pulmonary nodule)\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u771f?\nA. About 70% of incidentally found pulmonary nodules are benign.\nB. A lobulated and irregular contour is more indicative of malignancy than a smooth one.\nC. Ground-glass nodules should be benign.\nD. Multiple nodules indicate malignant disease.\nE. Absence of growth over a period of 6-12 months is sufficient to determine whether it is benign.\n": "(B)", "105-7.\n\u4e0055\u6b72\u7537\u6027\u63a5\u53d7\u5065\u5eb7\u6aa2\u67e5\uff0c\u809b\u9580\u6307\u6aa2(digital rectal examination\uff0cDRE)\u767c\u73fe\u660e\u986f\u7684\u651d\u8b77\u817a\u816b\u5927\uff0c\u4e14\u89f8\u8a3a\u5df2\u767c\u73fe\u651d\u8b77\u817a\u53f3\u8449\u660e\u986f\u7d50\u7bc0\uff0c\u4ed6\u5df2\u4e0d\u8a18\u5f97\u524d\u4e00\u6b21\u7684DRE\u6642\u9593\uff0c\u4e5f\u5f9e\u672a\u62bd\u8840\u6e2c\u904e\u651d\u8b77\u817a\u7279\u7570\u6027\u6297\u539f(prostate-specific antigen\uff0cPSA)\u6578\u503c\u3002\u6839\u64da\u5065\u5eb7\u6aa2\u67e5\u7684\u7d50\u679c\u8207\u81e8\u5e8a\u6307\u5f15\uff0c\u5efa\u8b70\u4e0b\u4e00\u6b65\u6700\u9069\u5b9c\u7684\u8655\u7f6e\u70ba\u4f55?\nA. \u53ea\u6e2c\u91cf\u4e00\u6b21PSA\u5373\u53ef\nB. \u73fe\u5728\u82076\u500b\u6708\u5f8c\u5404\u6e2c\u91cf\u4e00\u6b21PSA, \u4ee5\u8a08\u7b97PSA velocity\nC. \u5b89\u6392\u5168\u8eab\u6027\u9aa8\u9abc\u540c\u4f4d\u7d20\u6383\u63cf\u4ee5\u8a55\u4f30\u53ef\u80fd\u7684\u8f49\u79fb\nD. \u5b89\u6392\u5728\u300c\u7d93\u76f4\u8178\u8d85\u97f3\u6ce2\u6aa2\u67e5\u300d\u7684\u5c0e\u5f15\u4e0b\uff0c\u9032\u884c\u651d\u8b77\u817a\u5207\u7247\u6aa2\u67e5\nE. \u7b493\u500b\u6708\u5f8c\u518d\u91cd\u8907\u4e00\u6b21DRE\u6aa2\u67e5\n": "(D)", "105-8.\n\u4e0080\u6b72\u7537\u6027\u8f49\u79fb\u6027\u651d\u8b77\u817a\u764c\u75c5\u4eba\uff0c\u56e0\u610f\u8b58\u72c0\u614b\u6539\u8b8a(altered mental status)\u800c\u88ab\u5bb6\u4eba\u9001\u81f3\u6025\u8a3a\u3002\u4ed6\u56e0\u651d\u8b77\u817a\u764c\u5b9a\u6642\u63a5\u53d7goserelin\u808c\u8089\u6ce8\u5c04\u6297\u8377\u723e\u8499\u6cbb\u7642\u3002\u6025\u8a3a\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\uff0c\u8840\u58d3106/52 mmHg\uff0c\u8108\u640f112/min\uff0c\u770b\u4f86\u5341\u5206\u75b2\u5026\u55dc\u7761\u4e14\u5c0d\u80f8\u9aa8\u58d3\u75db\u53cd\u61c9\u6975\u5fae\u5f31\uff0c\u773c\u7aa9\u51f9\u9677\u4e14\u9ecf\u819c\u4e7e\u71e5\uff0cgag reflex\u4ecdintact\uff0c\u56db\u80a2\u5c0d\u5287\u75db\u523a\u6fc0\u7684withdrawal\u5747\u4ecd\u5c0d\u7a31\uff0c\u4e14rectal tone\u4ecd\u6b63\u5e38\u3002\u7570\u5e38\u5be6\u9a57\u5ba4\u6578\u64dacreatinine 4.2 mg/dL\uff0ccalcium 3.25 mmol/L (13.0 mg/dL)\uff0calbumin 2.6 g/dL\u3002\u4e0b\u5217\u5408\u9069\u7684\u8655\u7f6e\uff0c\u4f55\u8005\u70ba\u975e?\nA. Dexamethasone\nB. Normal saline\nC. \u7576\u75c5\u4eba\u6062\u5fa9euvolemic\u72c0\u614b\u6642\uff0c\u7d66\u4e88Furosemide\nD. Calcitonin\nE. Palmidronate\n": "(A)", "105-9.\n\u6709\u4e9b\u764c\u75c7\u75c5\u4eba\u96d6\u7136\u5df2\u7d93\u662f\u8f49\u79fb\u6027\u7684\u764c\u75c7\u671f\u5225(metastatic disease)\uff0c\u4ee5\u624b\u8853\u5207\u9664\u65b9\u5f0f\u6cbb\u7642\uff0c\u4ecd\u6709\"\u5c11\u6578\"\u75c5\u4eba\u6709\u9577\u671f\u5b58\u6d3b\u6216\u751a\u81f3\u300c\u6cbb\u7652\u7684\u53ef\u80fd\u6027\u300d(potentially curable)\u3002 \u4e0b\u5217\u72c0\u6cc1\u4f55\u8005\u70ba\u771f? (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r1. \u4e00\u4f4d58\u6b72\u5973\u6027\u7d50\u8178\u764c\u75c5\u4eba\u624b\u8853\u6cbb\u7642\u5f8c\uff0c2\u5e74\u5f8c\u67093\u9846\u809d\u81df\u8f49\u79fb\u7684\u7d50\u8178\u764c\uff0c\u5747\u4f4d\u65bc\u809d\u81df\u5de6\u8449\uff0c\u8f49\u4ecb\u81f3\u5916\u79d1\u9032\u884cleft hepatic lobectomy\u624b\u8853\u5207\u9664\r2. \u4e00\u4f4d25\u6b72\u7537\u6027\u75c5\u4eba\u6709\u5de6\u80a1\u9aa8(femur)\u60e1\u6027\u9aa8\u8089\u7624(osteosarcoma)\u75c5\u53f2\uff0c\u5982\u4eca\u767c\u73fe\u53f3\u4e0b\u80ba\u8449\u67091.2\u516c\u5206\u5927\u5c0f\u8f49\u79fb\u75c5\u7076\uff0c\u8f49\u4ecb\u81f3\u5916\u79d1\u9032\u884cright lower lobectomy of lung\u624b\u8853\u5207\u9664\r3. \u4e00\u4f4d75\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u651d\u8b77\u817a\u764c\u8f49\u79fb\u81f3\u591a\u8655\u810a\u67f1\u9aa8\u9abc(vertebrae)\uff0c\u8f49\u4ecb\u81f3\u6ccc\u5c3f\u816b\u7624\u79d1\u5148\u9032\u884corchiectomy\u624b\u8853\u5207\u9664\nA. 1\nB. 1+2\nC. 2+3\nD. 1+2+3\nE. \u4ee5\u4e0a\u7686\u975e\n": "(D)", "105-10.\n\u4e00\u4f4d52\u6b72\u5973\u6027\u7b2c\u4e09\u671f\u4e73\u764c\u75c5\u4eba\uff0c\u6ce8\u5c04\u5305\u542bdoxorubicin\u70ba\u4e3b\u7684CAF\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\u8655\u65b9\uff0c\u6ce8\u5c04\u5316\u7642\u5f8c\u7b2c8\u5929\u75c5\u4eba\u56e0\u9ad8\u71d239.2\u2103\u4f86\u5230\u6025\u8a3a\uff0c\u5408\u4f75\u5bd2\u986b\u8207\u982d\u75db\u3002\u6025\u8a3a\u521d\u6b65\u6aa2\u67e5\u767d\u8840\u7403\u7e3d\u6578490/\u03bcL (\u5206\u985e10% neutrophils\uff0c20% monocytes\uff0c70% lymphocytes)\uff0c\u80f8\u90e8X\u5149(CXR)\u6aa2\u67e5\uff0c\u5c3f\u6db2\u6aa2\u67e5\uff0c\u8207\u4e2d\u5fc3\u975c\u8108\u5c0e\u7ba1\u5747\u6c92\u6709\u660e\u986f\u611f\u67d3\u7684\u8b49\u64da\uff0c\u5df2\u7531\u5468\u908a\u8207\u4e2d\u5fc3\u975c\u8108\u62bd\u8840\u9032\u884c\u8840\u6db2\u57f9\u990a\u6aa2\u67e5\u3002 \u4f60\u5efa\u8b70\u4e0b\u4e00\u6b65\u5982\u4f55\u8655\u7f6e\u6700\u9069\u5b9c?\nA. \u7d66\u4e88\u5ee3\u6548\u6027\u6297\u751f\u7d20ceftazidime\u3001vancomycin\u8207voriconazole\nB. \u7d66\u4e88\u5ee3\u6548\u6027\u6297\u751f\u7d20ceftazidime\u8207vancomycin\nC. \u4e0b\u4e00\u500b\u6216\u5f80\u5f8c\u7684\u76f8\u540c\u8655\u65b9\u5316\u5b78\u6cbb\u7642\u7642\u7a0b\uff0c\u53ef\u9810\u9632\u6027\u7d66\u4e88G-CSF (granulocyte colony-stimulating factor)\nD. (A)+(C)\nE. (B)+(C)\n": "(E)", "106-1.\n\u4e0b\u5217\u75be\u75c5\u8207\u76ee\u524d\u5df2\u77e5\u6709\u6548\u4e4b\u6cbb\u7642\u85e5\u7269\u7684\u914d\u5c0d\uff0c\u4f55\u8005\u662f\u932f\u8aa4\u7684\uff1f\nA. Multiple myeloma: Lenalidomide\nB. Chronic myeloid leukemia: Dasatinib\nC. Diffuse large B-cell lymphoma: Rituximab\nD. Paroxysmal nocturnal hemoglobinuria: Eculizumab\nE. Polycythemia vera: Prednisolone\n": "(E)", "106-2.\n\u4e00\u4f4d72\u6b72\u75c5\u4eba\u56e0\u70ba\u51fa\u8840\u50be\u5411\u53ca\u75b2\u5026\u61c9\u8a3a\uff0c\u62bd\u8840\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d20\u70ba8.2 g/dL\uff0c\u767d\u8840\u740324000/uL\uff0c\u8840\u5c0f\u677f12000/uL\uff1b\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\u3002\u9019\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u5f97\u4e86\u4f55\u7a2e\u75c5\uff1f\nA. Chronic myeloid leukemia\nB. Chronic myelomonocytic leukemia\nC. Chronic lymphocytic leukemia\nD. Acute myeloid leukemia\nE. Acute lymphoblastic leukemia (ALL)\n": "(B)", "106-3.\n\u4e00\u4f4d23\u6b72\u75c5\u4eba\u56e0\u547c\u5438\u6025\u4fc3\u61c9\u8a3a\uff0c\u8840\u6db2\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d20\u70ba6.3 g/dL\uff0c\u8840\u5c0f\u677f\u3001\u767d\u8840\u7403\u53ca\u5206\u985e\u6b63\u5e38\uff0c\u7db2\u72c0\u7d05\u8840\u7403(reticulocyte) 3.5%\uff0c\u5168\u81bd\u7d05\u7d20 (total bilirubin) 3.4 mg/dL\uff0c\u76f4\u63a5\u81bd\u7d05\u7d20 (direct bilirubim) 0.7 mg/dL\uff1b\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\u3002\u6b64\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u5f97\u4e86\u4ec0\u9ebc\u75c5\uff1f\nA. Iron deficiency anemia\nB. Autoimmune hemolytic anemia\nC. Vit B12 deficiency anemia\nD. Thalassemia\nE. G6PD deficiency\n": "(D)", "106-4.\n\u6a19\u9776\u6cbb\u7642\u85e5\u7269Tyrosine kinase inhibitor, Imatinib, \u5c0d\u4e0b\u5217\u4f55\u7a2e\u6025\u6027\u6dcb\u5df4\u82bd\u7d30\u80de\u767d\u8840\u75c5(ALL)\u6709\u6548\uff1f\nA. B-lineage ALL with t(9;22)\nB. B-lineage ALL with t(4;11)\nC. CD19 positive B-lineage ALL\nD. CD20 positive B-lineage ALL\nE. CD3 positive T-lineage ALL\n": "(A)", "106-5.\nEltrombopag\u76ee\u524d\u70ba\u5065\u4fdd\u7d66\u4ed8\u6cbb\u7642\u514d\u75ab\u6027\u8840\u5c0f\u677f\u4f4e\u4e0b\u6027\u7d2b\u6591\u75c7(immune thrombocytopenic purpura)\u7684\u7b2c\u4e8c\u7dda\u7528\u85e5\uff0c\u5b83\u7684\u4f5c\u7528\u6a5f\u8f49\u70ba\u4f55\uff1f\nA. Anabolic hormone\nB. Corticosteroid\nC. Immunosuppressive agent\nD. Thrombopoietin receptor agonist\nE. JAK inhibitor\n": "(D)", "106-6.\n\u4e00\u4f4d\u75c5\u4eba\u56e0\u8840\u5c0f\u677f\u4f4e\u4e0b\u61c9\u8a3a\uff0c\u4e0b\u5217\u5404\u9805\u6aa2\u9a57\u4e2d\u4f55\u8005\u70ba\u9451\u5225\u8840\u5c0f\u677f\u4f4e\u4e0b\u539f\u56e0\u5e6b\u5fd9\u6700\u5c0f\u8005\uff1f\nA. H. pylori infection\nB. Serology tests for SLE\nC. Hepatitis C infection\nD. HIV infection\nE. Platelet antibodies\n": "(E)", "106-7.\n\u5c0d\u65bc\u591a\u767c\u6027\u9aa8\u9ad3\u7624(multipel myeloma)\u7684\u8a3a\u65b7\u53ca\u5206\u671f\uff0c\u4e0b\u5217\u4f55\u9805\u6aa2\u67e5\u662f\u6700\u4e0d\u9700\u8981\u8005\uff1f\nA. Immunoelectrophoresis\nB. Albumin level\nC. Beta 2-microglobulin level\nD. Bone scan\nE. Plain bone radiography\n": "(D)", "106-8.\n\u4e00\u4f4d40\u6b72\u75c5\u4eba\u62b1\u6028\u80c3\u75db\uff0c\u5167\u8996\u93e1\u6aa2\u67e5\u767c\u73fe\u80c3\u7ac7(gastric antrum)\u6709\u4e00\u816b\u7624\uff0c\u75c5\u7406\u5207\u7247\u6aa2\u67e5\u986f\u793a\u70bamucosa-associated lymphoid tissue lymphoma\uff0cCD20\u967d\u6027\u53caH. pylori\u967d\u6027\uff0c\u5206\u671f\u6aa2\u67e5\u672a\u767c\u73fe\u5176\u4ed6\u7570\u5e38\u3002\u4e0b\u5217\u4f55\u8005\u70ba\u6b64\u75c5\u4eba\u6700\u9069\u7576\u7684\u7b2c\u4e00\u7dda\u6cbb\u7642\uff1f\nA. Eradication of H. pylori\nB. Rituximab\nC. Chemotherapy\nD. Rituximab + Chemotherapy\nE. Local irradiation\n": "(A)", "106-9.\n\u4e0b\u5217\u4f55\u7a2e\u72c0\u6cc1\u5e38\u6703\u51fa\u73feprothrombin time (PT)\u6b63\u5e38\u4f46activated partial thromoplostim time (aPTT)\u5ef6\u5e38\u7684\u73fe\u8c61\uff1f(1) Hepatic failure\uff1b(2) Antiphospholipid syndrome\uff1b(3) von Willebrand disease\uff1b(4) Disseminated intravascular coagulation\nA. (1)+(4)\nB. (2)+(4)\nC. (1)+(2)\nD. (2)+(3)\nE. (1)+(2)+(4)\n": "(D)", "106-10.\n\u4e0b\u5217\u4f55\u8005\u662fB\u7d30\u80de\u6162\u6027\u6dcb\u5df4\u6027\u767d\u8840\u75c5(chronic lymphocytic leukemia)\u7d30\u80de\u7684\u7279\u5fb5\uff0c\u53ef\u8207\u53cd\u61c9\u6027\u6dcb\u5df4\u7d30\u80de\u904e\u591a\u75c7\u505a\u9451\u5225\u8a3a\u65b7\uff1f(1) Monoclonal light chain restriction\uff1b(2) CD5 expression\uff1b(3) CD10 expression\nA. (1)\nB. (1)+(2)\nC. (1)+(3)\nD. (2)+(3)\nE. (1)+(2)+(3)\n": "(B)", "106-1.\n\u6709\u4e0058\u6b72\u5973\u6027\uff0c\u5728\u4f8b\u884c\u6027\u4e73\u623fX\u5149\u651d\u5f71\u6aa2\u67e5\u767c\u73fe\u53f3\u5074\u4e73\u623f\u7684\u4e0a\u5916\u5074\u56db\u5206\u4e4b\u4e00\u8c61\u9650\u6709\u4e00\u65b0\u7684\u9223\u5316\u816b\u584a\u3002\u5c40\u90e8\u4e73\u623f\u816b\u584a\u5207\u9664(lumpectomy)\u5f8c\uff0c\u8b49\u5be6\u70ba\u4e73\u817a\u764c\uff0c\u6700\u9577\u76f4\u5f91\u70ba2.2\u516c\u5206\uff0c\u4e14Estrogen\u63a5\u53d7\u9ad4(ER)\uff0cProgesterone\u63a5\u53d7\u9ad4(PR)\uff0cHER2\u63a5\u53d7\u9ad4\uff0c\u4e09\u8005\u7686\u70ba\u9670\u6027\u3002\u524d\u54e8(sentinel)\u6dcb\u5df4\u7d50\u5207\u7247\u986f\u793a\u67092\u9846\u6dcb\u5df4\u7d50\u6709\u764c\u7d30\u80de\u4fb5\u72af\u967d\u6027\u3002\u5979\u4e00\u822c\u8eab\u9ad4\u72c0\u6cc1\u5927\u81f4\u826f\u597d\uff0c\u7121\u5df2\u77e5\u5171\u75c5(comorbidities)\u3002\u5b8c\u6574\u7684\u764c\u75c7\u5206\u671f\u5f71\u50cf\u6aa2\u67e5\u4e26\u7121\u5df2\u77e5\u8f49\u79fb\u75c5\u7076\u3002\u653e\u5c04\u816b\u7624\u91ab\u5e2b\u5efa\u8b70\u5b89\u6392\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u4f60\u5efa\u8b70\u75c5\u4eba\u7684\u6cbb\u7642\u8a08\u756b\uff0c\u4e0b\u5217\u9078\u9805\u4f55\u8005\u8f03\u70ba\u5408\u5b9c?\nA. Lumpectomy\u52a0\u4e0aradiation therapy\u5df2\u8db3\u5920\nB. \u9700\u52a0\u4e0acomplete mastectomy\nC. \u9700\u52a0\u4e0aaxillary lymph node dissection, followed by tamoxifen for 5 years\nD. \u9700\u52a0\u4e0a6 cycles of capecitabine chemotherapy\nE. \u9700\u52a0\u4e0a4 cycles of doxorubicin + cyclophosphamide (AC), followed by paclitaxel chemotherapy\n": "(E)", "106-2.\n\u4e00\u4f4d66\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u6700\u8fd1\u88ab\u8a3a\u65b7\u7f79\u60a3\u7b2c\u56db\u671f\u60e1\u6027\u9ed1\u8272\u7d20\u7d30\u80de\u764c\uff0c\u764c\u75c7\u5206\u671f\u6aa2\u67e5\u986f\u793a\u5df2\u6709\u591a\u8655\u809d\u81df\u3001\u80ba\u81df\u8207\u9aa8\u9abc\u8f49\u79fb\u3002\u4ed6\u7684\u81e8\u5e8a\u75c7\u72c0\u5305\u62ec\u547c\u5438\u6025\u4fc3\u3001\u54b3\u55fd\u3001\u9aa8\u9abc\u75bc\u75db\u8207\u9ad4\u91cd\u6e1b\u8f15\u7d045\u516c\u65a4\u3002\u816b\u7624\u6aa2\u9ad4\u4e4b\u57fa\u56e0\u6aa2\u6e2c\u986f\u793aBRAF\u57fa\u56e0\u4e4bV600E\u7a81\u8b8a\u967d\u6027\u3002\u4f60\u5efa\u8b70\u9078\u64c7\u7d66\u4e88\u4f55\u7a2e\u85e5\u5291\u6cbb\u7642\u8f03\u70ba\u9069\u5b9c?\nA. Gefitinib\nB. Vemurafenib\nC. Trametinib\nD. Imatinib\nE. Sorafenib\n": "(B)", "106-3.\n\u4e0084\u6b72\u5973\u6027\u75c5\u4eba\u5728\u904e\u53bb3\u9031\u5167\u7a81\u7136\u6709\u4e00\u9838\u90e8\u5feb\u901f\u9577\u5927\u7684\u816b\u584a\uff0c\u5979\u547c\u5438\u6025\u4fc3\u3001\u8072\u97f3\u6c99\u555e\u3001\u5589\u56a8\u75bc\u75db\u3002\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u5979\u7532\u72c0\u817a\u5de6\u8449\u6709\u4e0010\u516c\u5206\u5927\u5c0f\u7684\u786c\u816b\u584a\uff0c\u5589\u93e1\u6aa2\u67e5\u5df2\u767c\u73fe\u816b\u7624\u76f4\u63a5\u64f4\u5c55\u4fb5\u72af\u6c23\u7ba1\uff0c\u80f8\u90e8X\u5149\u7247\u986f\u793a\u5169\u5074\u80ba\u91ce\u5df2\u6709\u8a31\u8a31\u591a\u591a\u5c0f\u65bc1\u516c\u5206\u7684\u80ba\u7d50\u7bc0\u3002\u7d30\u91dd\u62bd\u5438\u7d30\u80de\u5b78\u6aa2\u67e5\u78ba\u8a3a\u70ba\u300c\u5206\u5316\u4e0d\u826f\u7684\u7532\u72c0\u817a\u764c\u300d(anaplastic thyroid cancer)\u3002\u56de\u9867\u4e00\u500b\u6708\u524d\uff0c\u5979\u4ecd\u80fd\u5927\u81f4\u7368\u7acb\u65e5\u5e38\u751f\u6d3b\uff0c\u4f46\u8fd13\u9031\u4f86\u6025\u901f\u60e1\u5316\uff0c\u5df2\u5411\u75c5\u4eba\u53ca\u5bb6\u5c6c\u8aaa\u660e\u6b64\u764c\u75c7\u4e4b\u81e8\u5e8a\u9810\u5f8c\u5341\u5206\u4e0d\u826f\u3002\u4f60\u5efa\u8b70\u4e0b\u5217\u4f55\u7a2e\u6cbb\u7642\uff0c\u76f8\u5c0d\u8f03\u70ba\u9069\u5b9c?\nA. Bortezomib\u6a19\u9776\u6cbb\u7642\nB. Vandetanib\u6a19\u9776\u6cbb\u7642\nC. Brentuximab vedotin\u55ae\u682a\u6297\u9ad4\u6cbb\u7642\nD. Palliative external beam radiation therapy to the neck\nE. Surgical en bloc resection of the thyroid, anterior tracheal wall with reconstruction, followed by chemotherapy\n": "(D)", "106-4.\n\u6709\u4e0065\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u670970-pack-years\u7684\u62bd\u83f8\u53f2\uff0c\u8207\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(COPD)\uff0c\u6aa2\u67e5\u767c\u73fe\u5728ambient air\u4e4b\u4e0b\uff0c\u6c27\u6c23\u98fd\u548c\u5ea6\u4ecd\u670997%\uff0c\u4f46\u5410\u6c23expiratory phase\u5247\u5df2\u660e\u986f\u5ef6\u9577\u3002\u5176\u4ed6\u7406\u5b78\u6aa2\u67e5\u5927\u81f4\u826f\u597d(unremarkable)\u3002\u5979\u5e0c\u671b\u5b89\u6392\u80ba\u764c\u7be9\u6aa2(screening)\u6aa2\u67e5\u3002\u4f60\u5efa\u8b70\u4f55\u7a2e\u7be9\u6aa2\u6aa2\u67e5\u8f03\u70ba\u9069\u5b9c?\nA. Chest X-ray\nB. 18-FDG-PET-CT scan\nC. Serum CEA (carcinoembryonic antigen)\nD. Low-dose non-contrast CT scan of the chest\nE. Routine screening for lung cancer should NOT be offered to her\n": "(D)", "106-5.\n\u4e0066\u6b72\u7537\u6027\u7cd6\u5c3f\u75c5\u75c5\u4eba\uff0c\u904e\u53bb\u75c5\u53f2\u4e3b\u8981\u6709\u6162\u6027\u75b2\u5026\u75c7\u5019\u7fa4(chronic fatigue syndrome)\u3002\u6700\u8fd1\uff0c\u4ed6\u7d93\u8a3a\u65b7\u7f79\u60a3\u7b2c\u56db\u671f\u8f49\u79fb\u6027\u814e\u7d30\u80de\u764c(renal cell carcinoma, RCC)\uff0c\u5408\u4f75\u80ba\u81df\u8207\u9aa8\u9abc\u8f49\u79fb\u3002\u4ed6\u4e3b\u8a34\u8f15\u5ea6\u9aa8\u9abc\u75bc\u75db\uff0c\u672a\u958b\u59cb\u6cbb\u7642\u524d\u5df2\u6709\u4e2d\u5ea6\u75b2\u5026(baseline moderate fatigue)\u75c7\u72c0\u3002\u4f60\u70ba\u4ed6\u9078\u64c7\u7b2c\u4e00\u7dda\u6cbb\u7642\u85e5\u5291\uff0c\u5efa\u8b70\u4ee5\u4e0b\u4f55\u8005\u6700\u70ba\u9069\u5b9c?\nA. Erlotinib\nB. Sunitinib\nC. Pazopanib\nD. Everolimus\nE. Axitinib\n": "(C)", "106-6.\n\u4e0029\u6b72\u5e74\u8f15\u5973\u6027\uff0c\u8fd13\u500b\u6708\u4f86\u53f3\u524d\u81c2\u8207\u53f3\u624b\u6f38\u6f38\u611f\u89ba\u9ebb\u6728\u8207\u77e5\u89ba\u7570\u5e38(paresthesia)\u3002\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u53f3\u524d\u81c2\u8207\u53f3\u624b\u8155\u4f38\u5c55(extension)\u660e\u986f\u7121\u529b\uff0c\u5979\u8eab\u4e0a\u6709\u591a\u767c\u7684\u5c0f\u5c0f\u795e\u7d93\u7e96\u7dad\u7624(neurofibromas)\u7d50\u7bc0\uff0c\u8a31\u591a\u7684\u5496\u5561\u725b\u5976\u50cf(cafe-au-lait)\u7684\u76ae\u819a\u6591\u584a\uff0c\u814b\u4e0b\u8207\u80a1\u6e9d\u6709\u591a\u767c\u6591\u9ede(freckles)\uff0c\u53f3\u814b\u4e0b\u6709\u4e00\u500b\u5805\u786c\u7684(firm)\u816b\u584a\u3002\u5169\u5074\u4e73\u623f\u6aa2\u67e5\u4e26\u7121\u7570\u5e38\u7684\u767c\u73fe\u3002\u96fb\u8166\u65b7\u5c64(CT)\u6383\u63cf\u986f\u793a\u53f3\u814b\u4e0b\u6709\u4e00\u500b5\u516c\u5206\u76f4\u5f91\u5927\u5c0f\u7684\u816b\u584a\u3002\u5979\u63a5\u53d7\u53f3\u814b\u4e0b\u816b\u584a\u5207\u7247\uff0c\u63a8\u6e2c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55?\nA. Adenocarcinoma\nB. Squamous cell carcinoma\nC. Malignant peripheral nerve sheath tumor\nD. Leiomyosarcoma\nE. Lymphoma\n": "(C)", "106-7.\n\u4e00\u4f4d31\u6b72\u5e74\u8f15\u7537\u6027\u75c5\u4eba\uff0c\u8a3a\u65b7\u7f79\u60a3\u7d50\u8178\u764c(colon cancer)\u3002\u4ed6\u6709\u5df2\u77e5\u7684\u7d50\u8178\u764c\u5bb6\u65cf\u75c5\u53f2\uff0c\u5305\u62ec\uff1a\u4ed6\u6bcd\u89aa\u572823\u6b72\u6642\u66fe\u88ab\u8a3a\u65b7\u7f79\u60a3\u7b2c\u4e00\u671f\u5b50\u5bae\u5167\u819c\u764c(endometrial cancer)\uff0c\u7d93\u6cbb\u7642\u5f8c\u75ca\u7652\uff0c\u4e4b\u5f8c\u53c8\u572846\u6b72\u6642\u8a3a\u65b7\u6709\u7d50\u8178\u764c\u3002\u4ed6\u7684\u5916\u7956\u723655\u6b72\u6642\u56e0\u7d50\u8178\u764c\u53bb\u4e16\u3002\u4ed6\u768436\u6b72\u59ca\u59ca\u6700\u8fd1\u5728\u5927\u8178\u5167\u8996\u93e1\u6aa2\u6642\u4e5f\u767c\u73fe\u7b2c\u4e00\u671f\u7d50\u8178\u764c\uff0c\u4f46\u4e26\u7121\u984d\u5916\u7684\u606f\u8089(polyps)\u88ab\u767c\u73fe\u3002\u9019\u4f4d31\u6b72\u7537\u6027\u7d50\u8178\u764c\u75c5\u4eba\uff0c\u6700\u53ef\u80fd\u6709\u4ee5\u4e0b\u7684\u57fa\u56e0\u8b8a\u7570?\nA. ATM\u57fa\u56e0\u7684loss of heterozygosity\nB. p53\u6291\u764c\u57fa\u56e0\u7684germline mutation\nC. Rb\u6291\u764c\u57fa\u56e0\u7684germline mutation\nD. MSH2\u57fa\u56e0\u7684germline mutation\nE. Nucleotide excision repair\u76f8\u95dc\u57fa\u56e0\u7684somatic mutation\n": "(D)", "106-8.\n\u4e0065\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u9ad4\u80fdperformance status (PS)\u826f\u597d\uff0c\u4e14\u6c92\u6709\u660e\u986f\u5df2\u77e5\u5171\u75c5(comorbidities)\uff0c\u88ab\u78ba\u8a3a\u8f49\u79fb\u6027\u80c3\u817a\u764c\uff0cHER2\u9670\u6027\uff0c\u75c5\u4eba\u5df2\u6709\u809d\u81df\u8207\u8179\u819c\u8f49\u79fb\u3002\u4ed6\u63a5\u53d7\u7b2c\u4e00\u7dda\u5316\u5b78\u6cbb\u7642\u6ce8\u5c04Cisplatin\u4f75\u7528\u6bcf\u903124\u5c0f\u6642\u9ad8\u5291\u91cf5-FU\u52a0\u4e0a\u6d3b\u6027\u8449\u9178(Cisplatin-HDFL\u8655\u65b9)\uff0c\u4e8c\u500b\u6708\u5f8c\u816b\u7624\u9806\u5229\u9054\u5230\u90e8\u5206\u7de9\u89e3(partial response)\uff0c\u4e14\u526f\u4f5c\u7528\u8f15\u5fae\uff0c\u75c5\u4eba\u8010\u53d7\u6027\u826f\u597d\u3002\u75c5\u4eba\u6301\u7e8c\u7b2c\u4e00\u7dda\u5316\u7642\u51718\u500b\u6708\u5f8c\uff0c\u96fb\u8166\u65b7\u5c64(CT)\u6383\u63cf\u986f\u793a\u809d\u81df\u8f49\u79fb\u75c5\u7076\u958b\u59cb\u589e\u5927\u60e1\u5316\uff0c\u7b26\u5408progressive disease (PD)\u3002\u6b64\u6642\u75c5\u4eba\u9ad4\u80fd\u72c0\u6cc1performance status (PS)\u4ecd\u826f\u597d(WHO/ECOG\r0-1)\uff0c\u4e14\u6709\u9ad8\u5ea6\u610f\u9858\u63a5\u53d7\u7b2c\u4e8c\u7dda\u6cbb\u7642\u3002\u4f60\u5efa\u8b70\u4e0b\u4e00\u6b65\u7684\u6cbb\u7642\uff0c\u4f55\u8005\u53ef\u70ba\u5408\u9069\u7684\u9078\u9805?\r(1)\tSecond-line chemotherapy with irinotecan\r(2)\tSecond-line chemotherapy with paclitaxel or docetaxel\r(3)\tSecond-line therapy with ramucirumab (VEGFR2\u55ae\u682a\u6297\u9ad4)\r(4)\tSecond-line therapy with ramucirumab plus paclitaxel\r(5)\tBest supportive care alone\nA. \u50c5(5)\u9069\u5408\nB. \u50c5(1)\u3001(2)\u9069\u5408\nC. \u50c5(1)\u3001(2)\u3001(3)\u9069\u5408\nD. (1)\u3001(2)\u3001(3)\u3001(5)\u5747\u9069\u5408\nE. (1)\u3001(2)\u3001(3)\u3001(4)\u5747\u9069\u5408\n": "(E)", "106-9.\n\u4e0056\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u904e\u53bb15\u5e74\u9678\u7e8c\u6709intermittent diarrhea\u8179\u7009\u7684\u75c7\u72c0\uff0c\u5747\u88ab\u8a3a\u65b7\u70ba\u8178\u8e81\u75c7irritable bowel syndrome\u7d66\u4e88\u75c7\u72c0\u6cbb\u7642\u3002\u6700\u8fd1\u4e00\u5e74\u4f86\uff0c\u5979\u958b\u59cb\u6709\u8173\u8e1d\u6c34\u816bankle edema\uff0c\u4e14\u6f38\u6709\u60e1\u5316\u8da8\u52e2\uff0c\u6f38\u6f38\u9700\u53e3\u670d\u5229\u5c3f\u5291\u624d\u80fd\u7de9\u89e3\u3002\u4ed4\u7d30\u8a62\u554f\u75c5\u53f2\uff0c\u5979\u9593\u65b7\u6709\u71b1\u6f6e\u7d05(hot flashes)\u7684\u60c5\u5f62\u5df2\u6709\u591a\u5e74\uff0c\u4f46\u4e00\u76f4\u7576\u4f5c\u662f\u505c\u7d93\u75c7\u5019\u7fa4\u7684\u4e00\u90e8\u5206\u75c7\u72c0\u3002\u7406\u5b78\u6aa2\u67e5\u6240\u898b\u75c5\u4eba\u767c\u80b2\u8207\u71df\u990a\u72c0\u614b\u826f\u597d\uff0c\u7121\u9ec3\u75b8\uff0c\u7121\u5468\u908a\u6dcb\u5df4\u7d50\u816b\u5927\uff0chepatojugular reflux\u967d\u6027\uff0c\u5fc3\u81df\u807d\u8a3a\u6709\u660e\u986fS3\u5fc3\u97f3\uff0c\u809d\u816b\u5927\u81f3\u53f3\u808b\u7de3\u4e0b\u7d043\u6307\u5e45\uff0c\u4e14\u660e\u986f\u5169\u5074\u8db3\u8e1d\u6c34\u816b\u3002\u4f60\u5efa\u8b70\u9032\u4e00\u6b65\u70ba\u6b64\u75c5\u4eba\u5b89\u6392\u4ee5\u4e0b\u7684\u6aa2\u67e5\uff0c\u4f55\u8005\u9069\u5b9c?\r(1)\t24-hour urine for 5-HIAA (5-hydroxyindoleacetic acid)\r(2)\tCT scan of the abdomen and pelvis\r(3)\tOctreoscan\r(4)\tEchocardiogram\r(5)\t18-FDG-PET scan\nA. \u50c5(1)\u9069\u5408\nB. \u50c5(1)+(2)\u9069\u5408\nC. \u50c5(1)+(2)+(3)\u9069\u5408\nD. (1)+(2)+(3)+(4)\u5747\u9069\u5408\nE. (1)+(2)+(3)+(5)\u5747\u9069\u5408\n": "(D)", "106-10.\n\u764c\u75c7\u7684\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291(immune checkpoint inhibitors)\u6216\u6a19\u9776\u6cbb\u7642\u85e5\u5291(molecular targeted agents)\u901a\u5e38\u91dd\u5c0d\u7279\u5b9a\u7684\u8a0a\u606f\u50b3\u905e\u8def\u5f91\u6216\u5206\u5b50\u6a19\u9776\u9032\u884c\u6291\u5236\uff0c\u4ee5\u9054\u5230\u6cbb\u7642\u764c\u75c7\u7684\u76ee\u7684\u3002\u6cbb\u7642\u85e5\u5291\u8207\u514d\u75ab\u6216\u5206\u5b50\u6a19\u9776\u7684\u914d\u5c0d\uff0c\u4e0b\u5217\u90a3\u4e9b\u70ba\u6b63\u78ba?(1)Afatinib\u8207EGFR\uff1b(2)Ipilimumab\u8207CTLA-4\uff1b(3)Trastuzumab\u8207HER-2\uff1b(4)Rituximab\u8207CD30\uff1b(5)Nivolumab\u8207PD-1\nA. (1)+(2)+(3)+(5)\nB. (1)+(2)+(3)+(4)\nC. (2)+(3)+(4)+(5)\nD. (3)+(4)+(5)\nE. (2)+(4)+(5)\n": "(A)", "107-1.\n\u4e00\u4f4d35\u6b72\u75c5\u4eba\u9664\u4e0a\u4e0b\u80a2\u5076\u6709\u6de4\u9752\u5916\u7121\u5176\u4ed6\u4e0d\u9069\u3002\u5728\u5065\u5eb7\u6aa2\u67e5\u6642\u767c\u73fe\u5c0f\u817f\u6709\u4e00\u8655\u6de4\u9752\uff0c\u5176\u4ed6\u7121\u7570\u5e38\u3002\u62bd\u8840\u6aa2\u67e5\u986f\u793a\u8840\u5c0f\u677f\u6578\u70ba47000/\u03bcL\uff0c\u8840\u7d05\u7d20\u3001\u767d\u8840\u7403\u6578\u53ca\u5206\u985e\u6b63\u5e38\uff0c\u5176\u4ed6\u809d\u3001\u814e\u529f\u80fd\u7121\u7570\u5e38\uff0cHBsAg(-)\uff0cAnti-HBs(+)\uff0cAnti-HCV(-)\uff1bHIV(-)\uff1bC3\uff0cC4\uff0c\u53caANA\u5728\u6b63\u5e38\u7bc4\u570d\uff0c\u80c3\u93e1\u6aa2\u67e5\u7121\u7279\u6b8a\u767c\u73fe\u3002\u5c0d\u6b64\u75c5\u4eba\u6700\u9069\u7576\u7684\u6cbb\u7642\u70ba\u4f55\uff1f\nA. \u8f38\u6ce8\u8840\u5c0f\u677f\u6fc3\u7e2e\u6db2\nB. \u53e3\u670d\u985e\u56fa\u9187\nC. \u975c\u8108\u6ce8\u5c04\u514d\u75ab\u7403\u86cb\u767d\nD. \u975c\u8108\u6ce8\u5c04Rituximab\nE. \u89c0\u5bdf\u53ca\u8ffd\u8e64\uff0c\u4e0d\u9700\u6cbb\u7642\n": "(E)", "107-2.\n\u4e00\u4f4d68\u6b72\u5a66\u5973\u56e0\u70ba\u8179\u75db\u4f86\u5230\u6025\u8a3a\u8655\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u4e0b\u8179\u90e8\u6709\u4e00\u816b\u584a\uff0c\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u986f\u793a\u8179\u5167\u6709\u4e005\u516c\u5206\u5927\u4e4b\u8840\u816b\u3002\u75c5\u4eba\u904e\u53bb\u7121\u51fa\u8840\u50be\u5411\u3002\u62bd\u8840\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d2010.5 gm/dL\uff0c\u767d\u8840\u74039650/\u03bcL\uff0c\u5206\u985e\u6b63\u5e38\uff0c\u8840\u5c0f\u677f175000/\u03bcL\uff1bPT 12\u79d2\uff0caPPT 55\u79d2\uff1b\u75c5\u4eba\u8207\u6b63\u5e38\u4eba\u4e4b\u8840\u6f3f\u6df7\u5408\u8a66\u9a57(mixing test)\uff0caPTT\u70ba48\u79d2\u3002\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. \u6297\u78f7\u8102\u75c7\u5019\u7fa4(anti-phospholipid antibody syndrome)\nB. \u809d\u81df\u8870\u7aed\nC. \u5f8c\u5929\u8840\u53cb\u75c5\nD. von Willebrand\u75be\u75c5\nE. \u5f4c\u6f2b\u6027\u8840\u7ba1\u5167\u51dd\u8840(DIC)\n": "(C)", "107-3.\n\u4e00\u4f4d28\u6b72\u5973\u6027\u56e0\u904b\u52d5\u5f8c\u547c\u5438\u6025\u4fc3\u6c42\u8a3a\u3002\u8eab\u9ad4\u6aa2\u67e5\u9664\u81c9\u8272\u84bc\u767d\u5916\u7121\u5176\u4ed6\u7570\u5e38\uff1b\u62bd\u8840\u6aa2\u67e5\u986f\u793a\uff0c\u8840\u7d05\u7d207.2 gm/dL\uff0cMCV 69 fL\uff0c\u767d\u8840\u74034350/\u03bcL\uff0c\u8840\u5c0f\u677f395000/\u03bcL\uff1b\u56de\u9867\u5979\u5728\u5927\u5b78\u5165\u5b78\u6642\u7684\u62bd\u8840\u7d50\u679c\uff0c\u8840\u7d05\u7d20\u70ba11.5 gm/dL\uff0cMCV 88 fL\u3002\u5c0d\u5176\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\u7684\u6aa2\u67e5\u70ba\u4f55\uff1f\nA. \u8840\u7d05\u7d20\u96fb\u6cf3\u5206\u6790(Hb electrophoresis)\nB. \u8840\u6e05\u9435\u6fc3\u5ea6\nC. \u81ea\u9ad4\u514d\u75ab\u6297\u9ad4\u6aa2\u6e2c\nD. \u7532\u72c0\u817a\u529f\u80fd\u6aa2\u6e2c\nE. \u814e\u529f\u80fd\u6aa2\u6e2c\n": "(B)", "107-4.\n\u4e00\u4f4d43\u6b72\u7537\u6027\u62b1\u6028\u9019\u5e7e\u500b\u6708\u4f86\u5c0f\u4fbf\u4e0d\u6642\u6703\u5448\u73fe\u6df1\u7d05\u8272\u3002\u8eab\u9ad4\u6aa2\u67e5\u986f\u793a\u81c9\u8272\u84bc\u767d\uff0c\u8f15\u5fae\u9ec3\u75b8\uff1b\u8840\u6db2\u6aa2\u67e5\u8840\u7d05\u7d20\u70ba8.2 gm/dL\uff0cMCV 101 fL\uff0c\u7db2\u72c0\u7d05\u8840\u74034.5%\uff0c\u767d\u8840\u74033150/\u03bcL\uff0c\u5206\u985e\u6b63\u5e38\uff0c\u8840\u5c0f\u677f78000/\u03bcL\uff1b\u81bd\u7d05\u7d20(bilirubin)\u5168\u91cf3.5 mg/dL\uff0c\u76f4\u63a5\u578b0.5 mg/dL\uff0cALT 30 U/L\uff0cAST 85 U/L\uff0cLDH 2100 U/L\uff0cCoombs test\u9670\u6027\uff1b\u5c0f\u4fbf\u6f5b\u8840\u967d\u6027(+++)\uff0c\u86cb\u767d(+/-)\uff0c\u5c3f\u6db2\u6c88\u6fb1\u5f8c\u9ad8\u500d\u986f\u5fae\u93e1\u4e0b\u89c0\u5bdf\u7d05\u8840\u74032-3\u500b\uff0c\u767d\u8840\u74030-2\u500b\u3002\u4e0b\u9762\u4f55\u9805\u6aa2\u67e5\u5c0d\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. \u6d41\u5f0f\u7d30\u80de\u5100(flow cytometry)\u6aa2\u6e2c\u8840\u7403\u4e0aCD55\u53caCD59\u7684\u8868\u73fe\nB. B\u578b\u53caC\u578b\u809d\u708e\u6aa2\u6e2c\nC. \u8840\u6e05\u7dad\u751f\u7d20B12\u6e2c\u5b9a\nD. \u9aa8\u9ad3\u6aa2\u67e5\nE. \u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\n": "(A)", "107-5.\n\u4e00\u4f4d78\u6b72\u75c5\u4eba\u56e0\u5bb9\u6613\u75b2\u5026\u4f86\u8a3a\uff0c\u7121\u5176\u4ed6\u4e0d\u9069\u3002\u62bd\u8840\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d209.1 gm/dL\uff0c\u767d\u8840\u74033250/\u03bcL\uff0c\u5206\u985e\u67092% blasts\uff0c\u8840\u5c0f\u677f32000/\u03bcL\uff1b\u9aa8\u9ad3\u6aa2\u67e5\u986f\u793a\u9020\u8840\u7d30\u80de\u6709\u5316\u751f\u4e0d\u826f(dysplasia)\uff0c\u82bd\u7d30\u80de\u4f54\u6240\u6709\u6709\u6838\u7d30\u80de\u76849%\uff0c\u67d3\u8272\u9ad4\u7570\u5e38\u8d85\u904e3\u500b\u3002\u5c0d\u6b64\u75c5\u4eba\u76ee\u524d\u6700\u9069\u7576\u7684\u6cbb\u7642\u70ba\u4f55\uff1f\nA. Antithymocyte globulin\nB. Azacitidine\nC. Danazol\nD. Allogeneic hematopoietic stem cell transplantation\nE. Platelet concentrate transfusion\n": "(B)", "107-6.\n\u4e00\u4f4d42\u6b72\u7537\u6027\u75c5\u4eba\u904e\u53bb\u7121\u7279\u6b8a\u75c5\u53f2\uff0c\u8eab\u9ad4\u4ea6\u7121\u4e0d\u9069\uff0c\u5728\u4e00\u6b21\u5065\u5eb7\u6aa2\u67e5\u767c\u73fe\u8840\u5c0f\u677f\u6578\u70ba896000/\u03bcL\uff0c\u8840\u7d05\u7d2013.5 gm/dL\uff0c\u767d\u8840\u740310500/\u03bcL\uff0c\u5206\u985e\u6b63\u5e38\uff1b\u5206\u5b50\u6aa2\u9a57\u767c\u73fe\u6709JAK2V617F\u7a81\u8b8a\u3002\u4ee5\u4e0b\u4f55\u8005\u70ba\u76ee\u524d\u6700\u9069\u7576\u7684\u6cbb\u7642\uff1f\nA. Hydroxyurea\nB. Anagrelide\nC. Ruxolitinib\nD. Busulfan\nE. Observation\n": "(E)", "107-7.\n\u4e00\u4f4d65\u6b72\u7537\u6027\u5728\u9ad4\u9a57\u6642\u7121\u610f\u767c\u73fe\u8840\u7d05\u7d2010.5 gm/dL\uff0c\u767d\u8840\u7403130810/\u03bcL\uff0c\u8840\u5c0f\u677f47000/\u03bcL\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\u3002\u9019\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Acute myeloid leukemia\nB. Chronic myeloid leukemia\nC. Leukemoid reaction\nD. Hemolytic anemia\nE. Myelodysplastic syndrome\n": "(B)", "107-8.\n\u4e00\u4f4d57\u6b72\u5973\u6027\u56e0\u70ba\u865b\u5f31\uff0c\u610f\u8b58\u6df7\u4e82\u88ab\u5bb6\u4eba\u9001\u5230\u6025\u8a3a\u8655\uff0c\u8eab\u9ad4\u6aa2\u67e5\u986f\u793a\u9ad4\u6eab37.9\u00b0C\uff0c\u8f15\u5fae\u9ec3\u75b8\uff0c\u624b\u8173\u6709\u6de4\u9752\uff0c\u7121\u9ecf\u819c\u51fa\u8840\uff1b\u5c0d\u6642\u3001\u5730\u6709\u4e9b\u6df7\u6dc6\uff0c\u4f46\u53ef\u4ee5\u56de\u7b54\u554f\u984c\uff0c\u4ea6\u7121\u5c40\u90e8\u611f\u89ba\u53ca\u795e\u7d93\u5b78\u5fb5\u72c0\u3002\u8840\u6db2\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d207.5 gm/dL\uff0c\u7db2\u72c0\u7d05\u8840\u74035.4 %\uff0c\u8840\u5c0f\u677f11000/\u03bcL\uff0c\u767d\u8840\u74038500/\u03bcL\uff0c\u5206\u985e\u6709normoblast\uff0c\u5168\u81bd\u7d05\u7d20(bilirubin) 3.1 mg/dL\uff0c\u76f4\u63a5\u578b0.7 mg/dL\uff0cALT 23 U/L\uff0cAST 55 U/L\uff0cLDH 1350 U/L\uff0cCr 1.1 mg/dL\uff0cPT\u53caaPTT\u6b63\u5e38\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u3002\u4e0b\u5217\u90a3\u4e9b\u8655\u7f6e\u5c0d\u75c5\u4eba\u662f\u6709\u5e6b\u52a9\u7684\uff1f (1). platelet concentrate transfusion (2). plasma exchange (3). immunomodulatory therapy\nA. (2)\nB. (3)\nC. (1)+(2)\nD. (2)+(3)\nE. (1)+(2)+(3)\n": "(D)", "107-9.\n\u4e0b\u5217\u5fae\u751f\u7269\u611f\u67d3\u8207\u5176\u53ef\u80fd\u9020\u6210\u4e4b\u8840\u6db2\u60e1\u6027\u75c5\u7684\u914d\u5c0d\uff0c\u4f55\u8005\u662f\u6b63\u78ba\u7684\uff1f (1). Ebstein-Barr virus: Nasal type NK/T cell lymphoma (2). Hepatitis C virus: Lymphoplasmacytoid lymphoma (3). Helicobacter pylori: Gastric mucosa associated lymphoid tissue lymphoma (4). HTLV-1: Adult T-cell lymphoma/leukemia\nA. (1)+(2)\nB. (1)+(3)\nC. (3)+(4)\nD. (1)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(E)", "107-10.\n\u4e0b\u5217\u4f55\u8005\u70baInternational Staging System(ISS)\u5c0d\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u5206\u671f\u6240\u6839\u64da\u7684\u9810\u5f8c\u56e0\u5b50\uff1f (1). Serum albumin level (2). Serum monoclonal globulin level (3). Serum beta2-microglobulin (4). Serum lactate dehydrogenase level\nA. (1)+(2)\nB. (1)+(3)\nC. (1)+(4)\nD. (1)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(B)", "107-1.\n49\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u7f79\u60a3\u8f49\u79fb\u6027\u80ba\u817a\u764c(NSCLC, adenocarcinoma)\uff0c\u5df2\u63a5\u53d7\u7b2c\u4e00\u7ddacarboplatin\u3001paclitaxel\uff0c\u5408\u4f75bevacizumab\u6cbb\u7642\uff0c\u6709\u6548\"\u7de9\u89e3\"(partial response)\u4e00\u6bb5\u671f\u9593\u4e4b\u5f8c\"\u60e1\u5316\"(progressive disease)\u3002\u4ed6\u7684\u9ad4\u80fd\u72c0\u614bperformance status (PS)\u70ba1\uff0c\u91ab\u5e2b\u91dd\u5c0d\u4ed6\u5468\u908a\u80ba\u91ce\u8f03\u5927\u7684\u75c5\u7076\u5b89\u6392\u91cd\u65b0\u5207\u7247\uff0c\u5206\u5b50\u6aa2\u6e2c\u767c\u73feALK\u57fa\u56e0rearrangement\u967d\u6027\u3002\u4f60\u5efa\u8b70\u4e0b\u4e00\u6b65\u7684\u6cbb\u7642\uff0c\u4f55\u8005\u6700\u70ba\u9069\u5b9c?\nA. Pemetrexed\nB. Gemcitabine\nC. Docetaxel\nD. Erlotinib\nE. Crizotinib\n": "(E)", "107-2.\n68\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u6709\u9ad8\u8840\u58d3\u75c5\u53f2\u820750 pack-years\u7684\u5438\u83f8\u53f2\uff0c\u56e0\u7121\u75db\u6027\u5de8\u89c0\u8840\u5c3f\u75c7(painless gross hematuria)\u6c42\u8a3a\uff0c\u521d\u6b21\u4ee5\u670d\u7528\u4e00\u500b\u7642\u7a0b\u5ee3\u6548\u6027\u6297\u751f\u7d20\u6cbb\u7642\uff0c\u4f46\u8840\u5c3f\u4f9d\u7136\u6301\u7e8c\u5b58\u5728\u3002\u6ccc\u5c3f\u79d1\u91ab\u5e2b\u70ba\u4ed6\u5b89\u6392cystoscopy\u6aa2\u67e5\uff0c\u767c\u73fe\u8180\u80f1\u5f8c\u58c1\u6709\u4e003\u516c\u5206\u7684\u816b\u7624\u3002\u5207\u7247\u75c5\u7406\u6aa2\u67e5\u8b49\u5be6\u70ba\u4e00\u300c\u808c\u8089\u4fb5\u5165\u578b\u6ccc\u5c3f\u4e0a\u76ae\u8180\u80f1\u764c\u300d(muscle-invasive urothelial carcinoma)\u3002\u96fb\u8166\u65b7\u5c64(CT)\u6383\u63cf\u986f\u793a\u5ee3\u6cdb\u7684\u8180\u80f1\u58c1\u6d78\u6f64\u589e\u539a\uff0c\u76ee\u524d\u7121\u5468\u570d\u6dcb\u5df4\u7d50\u589e\u5927\u7684\u8de1\u8c61\u3002\u5efa\u8b70\u4e0b\u4e00\u6b65\u7684\u6cbb\u7642\u8a08\u756b\uff0c\u4f55\u8005\u70ba\u6700\u9069\u5b9c\u7684\u9078\u9805?\nA. Repeat transurethral biopsy\nB. Intravesical BCG (Bacille Calmette-Guerin)\nC. Neoadjuvant cisplatin-based combination chemotherapy, followed by radical cystectomy\nD. Capecitabine-based chemotherapy\nE. Radiation therapy alone\n": "(C)", "107-3.\n30\u6b72\u5e74\u8f15\u7537\u6027\u75c5\u4eba\uff0c\u8a3a\u65b7\u7f79\u60a3\u7d50\u8178\u764c(colon cancer)\u3002\u4ed6\u6709\u5df2\u77e5\u7684\u7d50\u8178\u764c\u5bb6\u65cf\u75c5\u53f2\uff0c\u5305\u62ec\uff1a\u4ed6\u6bcd\u89aa\u572825\u6b72\u6642\u66fe\u88ab\u8a3a\u65b7\u7f79\u60a3\u7b2c\u4e00\u671f\u5b50\u5bae\u5167\u819c\u764c(endometrial cancer)\uff0c\u7d93\u6cbb\u7642\u5f8c\u75ca\u7652\uff0c\u4e4b\u5f8c\u53c8\u572845\u6b72\u6642\u8a3a\u65b7\u6709\u7d50\u8178\u764c\u3002\u4ed6\u7684\u5916\u7956\u723653\u6b72\u6642\u56e0\u7d50\u8178\u764c\u53bb\u4e16\u3002\u4ed6\u768435\u6b72\u59ca\u59ca\u6700\u8fd1\u5728\u5927\u8178\u5167\u8996\u93e1\u6aa2\u6642\u4e5f\u767c\u73fe\u7b2c\u4e00\u671f\u7d50\u8178\u764c\uff0c\u4f46\u4e26\u6c92\u6709\u984d\u5916\u7684\u606f\u8089(polyps)\u88ab\u767c\u73fe\u3002\u9019\u4f4d30\u6b72\u7537\u6027\u7d50\u8178\u764c\u75c5\u4eba\uff0c\u6700\u53ef\u80fd\u6709\u4ee5\u4e0b\u7684\u57fa\u56e0\u8b8a\u7570?\nA. MSH2\u57fa\u56e0\u7684germline mutation\nB. p53\u6291\u764c\u57fa\u56e0\u7684germline mutation\nC. Rb\u6291\u764c\u57fa\u56e0\u7684germline mutation\nD. Nucleotide excision repair (NER)\u76f8\u95dc\u57fa\u56e0\u7684somatic mutation\nE. ATM\u57fa\u56e0\u7684loss of heterozygosity\n": "(A)", "107-4.\n67\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u4e3b\u8a34\u4e8c\u500b\u6708\u9010\u6f38\u52a0\u91cd\u7684\u53f3\u8170\u75db\uff0c\u5408\u4f75\u4e00\u500b\u6708\u9010\u6f38\u52a0\u91cd\u7684\u8840\u5c3f(hematuria)\u3002\u56e0\u8840\u5c3f\u5230\u4e00\u822c\u8a3a\u6240\u8a3a\u7642\uff0c\u8a3a\u6240\u91ab\u5e2b\u5148\u4ee5\u8180\u80f1\u708e\u6cbb\u7642\u4e09\u9031\uff0c\u4f46\u672a\u898b\u6539\u5584\u3002\u4e14\u81ea\u89ba\u6c92\u6709\u80c3\u53e3\u5728\u4e8c\u500b\u6708\u5167\u9ad4\u91cd\u6e1b\u8f15\u7d04\u4e09\u516c\u65a4\u3002\u75c5\u4eba\u8f49\u81f3\u5927\u91ab\u9662\u6c42\u8a3a\uff0c\u7406\u5b78\u6aa2\u67e5\u89f8\u8a3a\u5df2\u767c\u73fe\u53f3\u8170\u90e8\u6709\u81f3\u5c115\u516c\u5206\u5927\u5c0f\u816b\u584a\uff0c\u814e\u529f\u80fd\u5927\u81f4\u6b63\u5e38\u3002\u5f71\u50cf\u6aa2\u67e5\u767c\u73fe\u53f3\u814e\u6709\u4e009.6\u516c\u5206\u5be6\u9ad4\u816b\u584a\uff0c\u5169\u5074\u80ba\u91ce\u6709\u591a\u767c\u7684\u80ba\u7d50\u7bc0\uff0c\u986f\u793a\u5df2\u6709\u591a\u767c\u80ba\u81df\u8f49\u79fb\u3002\u7d30\u91dd\u7a7f\u523a\u5207\u7247\u75c5\u7406\u8b49\u5be6\u70ba\u814e\u7d30\u80de\u764c(renal cell carcinoma)\u4e4b\u4eae\u7d30\u80de(clear cell)\u4e9e\u578b\u3002 \u5efa\u8b70\u4e0b\u4e00\u6b65\u5982\u4f55\u8655\u7f6e\u6700\u70ba\u5408\u9069?\nA. Radical nephrectomy\nB. Gemcitabine\nC. Sunitinib\nD. Interleukin-2\nE. Interferon-\u03b3\n": "(C)", "107-5.\n55\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u8a3a\u65b7\u7f79\u60a3\u7b2c\u4e8c\u671f\u4e73\u764c\uff0c\u63a5\u53d7\u4e73\u623f\u5207\u9664\u624b\u8853(mastectomy)\u5f8c\uff0c\u75c5\u7406\u6aa2\u67e5\u767c\u73fe\u6709\u5169\u9846\"\u814b\u4e0b\u6dcb\u5df4\u7d50\"\u816b\u7624\u4fb5\u72af\u967d\u6027\uff0c\u816b\u7624\u7d44\u7e54\u514d\u75ab\u67d3\u8272\u986f\u793aestrogen\u63a5\u53d7\u9ad4\u967d\u6027(ER+)\uff0cprogesterone\u63a5\u53d7\u9ad4\u967d\u6027(PR+)\uff0cHER2/Neu\u9ad8\u5ea6\u8868\u73fe(3+)\u3002\u624b\u8853\u5f8c\u63a5\u53d7\"\u8f14\u52a9\u6027\"(adjuvant)\u8907\u65b9\u6cbb\u7642(doxorubicin\u3001cisplatin\u3001trastuzumab)\u3002\u4e0b\u5217\u4f55\u7a2e\u53ef\u80fd\u6bd2\u6027\u548cdoxorubicin\u8f03\u5bc6\u5207\u76f8\u95dc?\nA. Cardiomyopathy\uff0creversible\nB. Cardiomyopathy\uff0cirreversible\nC. Sensorimotor neuropathy\uff0creversible\nD. Sensorimotor neuropathy\uff0cirreversible\nE. Hearing loss\uff0cirreversible\n": "(B)", "107-6.\n40\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u7f79\u60a3\u7b2c\u56db\u671f\u5375\u5de2\u764c(ovarian cancer)\uff0c\u63a5\u53d7carboplatin\u5408\u4f75paclitaxel\u5316\u5b78\u6cbb\u7642\u3002\u7d93\u904e6\u500b\u7642\u7a0bcarboplatin\u5408\u4f75paclitaxel\u8907\u65b9\u5316\u5b78\u6cbb\u7642\u4e4b\u5f8c\uff0c\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u524d\u5f8c\u6bd4\u8f03\u7684\u7d50\u679c\uff0c\u816b\u7624\u7e3d\u91cf(tumor burden)\u5171\u6e1b\u5c11\u4e8625%\u3002\u53ef\u4ee5\u8a55\u4f30\u5979\u7684\u5375\u5de2\u764c\u5c0d\u5316\u5b78\u6cbb\u7642\u7684\"\u53cd\u61c9\"(response)\u70ba\u4f55?\nA. Complete response (CR)\nB. Partial response (PR)\nC. Stable disease (SD)\nD. Progressive disease (PD)\nE. \u4ee5\u4e0a\u7686\u975e\n": "(C)", "107-7.\n48\u6b72\u5973\u6027\u75c5\u4eba\uff0c3\u5e74\u524d\u56e0\u5f8c\u4e0a\u80cc\u90e8\u9ed1\u8272\u7d20\u7624(melanoma)\u624b\u8853\u5207\u9664\uff0c\u764c\u75c7\u5206\u671f\u7b2cIIB\u671f\u3002\u5979\u56e0\u547c\u5438\u6025\u4fc3\u81f3\u6025\u8a3a\u5c31\u91ab\uff0c\u767c\u73fe\u5169\u5074\u80ba\u91ce\u591a\u767c\u75c5\u7076\uff0c\u5f8c\u7e8c\u6aa2\u67e5\u8b49\u5be6\u60e1\u6027\u9ed1\u8272\u7d20\u7624\u5169\u5074\u80ba\u8f49\u79fb\u3002\u5728\u6c7a\u5b9a\u9078\u64c7\u6a19\u9776\u6cbb\u7642\u3001\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291\u3001\u6216\u5316\u5b78\u6cbb\u7642\u4e4b\u524d\uff0c\u61c9\u6aa2\u9a57\u4f55\u7a2e\u57fa\u56e0\u7a81\u8b8a(genetic mutation)\uff0c\u53ef\u4f5c\u70ba\u9078\u64c7\u6cbb\u7642\u4e4b\u53c3\u8003?\nA. C-KIT\nB. N-RAS\nC. MEK\nD. BRAF\nE. ERK\n": "(D)", "107-8.\n\u6709\u95dc\u80f0\u81df\u764c(pancreatic cancer)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u771f?\nA. \u7531\u65bc\u8d85\u904e85%\u7684\u80f0\u81df\u764c\u8a3a\u65b7\u8f03\u665a\uff0c\u5df2\u5c6c\u7121\u6cd5\u624b\u8853\u5207\u9664(inoperable)\u6216\u5df2\u8f49\u79fb\uff0c\u6240\u4ee5\u5404\u671f\u5225\u5408\u4f75\u8a08\u7b97\u7684\u80f0\u81df\u764c5\u5e74\u5b58\u6d3b\u7387\u6574\u9ad4\u5c0f\u65bc10%\nB. \u80f0\u81df\u764c\u82e5\u80fd\u65e9\u671f\u8a3a\u65b7\uff0c5\u5e74\u5b58\u6d3b\u7387\u53ef\u80fd\u63d0\u5347\u81f3\u7d0420%\uff0c\u751a\u81f3\u66f4\u9ad8\u4e9b\nC. \u904e\u53bb\u5341\u5e74\u4f86\uff0c\u7b2c\u56db\u671f\u8f49\u79fb\u6027\u80f0\u81df\u764c\u76845\u5e74\u5b58\u6d3b\u7387\u6709\u9577\u8db3(3\u500d\u5de6\u53f3)\u7684\u5927\u5e45\u63d0\u5347\nD. \u62bd\u83f8\u662f\u80f0\u81df\u764c\u7684\u5371\u96aa\u56e0\u5b50(risk factor)\u4e4b\u4e00\nE. \u559d\u9152\u672c\u8eab\u4e0d\u662f\u80f0\u81df\u764c\u7684\u91cd\u8981\u5371\u96aa\u56e0\u5b50(risk factor)\n": "(C)", "107-9.\n\u4ee5\u4e0b\u90a3\u4e9b\u75c5\u75c7\u6216\u75c7\u5019\u7fa4(syndrome)\u6703\u589e\u52a0\u60a3\u8005\u7f79\u60a3\u764c\u75c7\u7684\u98a8\u96aa\uff1f(1).\tFanconi's anemia (2). Down syndrome (3). Von Hippel-Lindau syndrome (4). Fragile X syndrome (5). Neurofibromatosis\nA. (1)+(2)+(4)\nB. (2)+(3)+(4)\nC. (1)+(2)+(3)+(5)\nD. (1)+(3)+(4)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(C)", "107-10.\n\u764c\u75c7\u7684\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291(immune checkpoint inhibitors)\u6216\u6a19\u9776\u6cbb\u7642\u85e5\u5291(molecular targeted agents)\u901a\u5e38\u91dd\u5c0d\u7279\u5b9a\u7684\u8a0a\u606f\u50b3\u905e\u8def\u5f91\u6216\u5206\u5b50\u6a19\u9776\u9032\u884c\u6291\u5236\uff0c\u4ee5\u9054\u5230\u6cbb\u7642\u764c\u75c7\u7684\u76ee\u7684\u3002\u6cbb\u7642\"\u85e5\u5291\"\u8207\u514d\u75ab\u6216\u5206\u5b50\"\u6a19\u9776\"\u7684\u914d\u5c0d\uff0c\u4e0b\u5217\u90a3\u4e9b\u70ba\u771f\uff1f(1). Afatinib\u8207EGFR (2).\tIpilimumab\u8207PD-L1 (3).\tTrastuzumab\u8207HER-2 (4). Rituximab\u8207CD20 (5). Pembrolizumab\u8207PD-1\nA. (1)+(2)+(3)+(4)\nB. (1)+(3)+(4)+(5)\nC. (2)+(3)+(4)+(5)\nD. (2)+(4)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(B)", "108-1.\n\u4e00\u4f4d\u75c5\u4eba\u62bd\u8840\u6aa2\u67e5\u986f\u793aHb\u70ba10.2 gm/dL\uff0cMCV 75 fL\uff0creticulocyte 0.8%\uff0cferritin 78 ng/mL(\u53c3\u8003\u503c5-200)\uff0ciron 41 \u03bcg/dL(\u53c3\u8003\u503c50-200)\uff0cTIBC 230 \u03bcg/dL(\u53c3\u8003\u503c260-590)\uff0c\u767d\u8840\u7403\u53ca\u8840\u5c0f\u677f\u6578\u6b63\u5e38\u3002\u9019\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\uff1a\nA. Iron deficiency anemia\nB. Thalassemia\nC. Anemia of chronic disease\nD. Folic acid deficiency anemia\nE. Hemolytic anemia\n": "(C)", "108-2.\n\u4e0b\u5217\u6709\u95dc\u9663\u767c\u6027\u591c\u9593\u8840\u8272\u7d20\u5c3f\u7684\u81e8\u5e8a\u8868\u73fe\u4f55\u8005\u662f\u932f\u7684\uff1f\nA. PIG A gene mutation\nB. CD55 and CD59 deficiency on blood cells\nC. Hypercoagulable state\nD. Intravascular hemolysis\nE. Bilirubinuria\n": "(E)", "108-3.\n\u4e00\u4f4d75\u6b72\u75c5\u4eba\u9577\u671f\u56e0\u9ad8\u8840\u58d3\u4e00\u76f4\u898f\u5247\u770b\u8a3a\u3002\u6700\u8fd1\u62bd\u8840\u6aa2\u67e5\u7121\u610f\u4e2d\u767c\u73fe\u8840\u6e05\u4e2d\u6709IgG/kappa\u55ae\u682a\u7403\u86cb\u767d(monoclonal gammopathy)\uff0cIgG 3700 mg/dL\uff0c\u5176\u4ed6\u8840\u6db2\u6aa2\u67e5\u5982\u8840\u7d05\u7d20\u3001\u767d\u8840\u7403\u53ca\u8840\u5c0f\u677f\u6578\u3001\u8840\u9223\u53ca\u814e\u529f\u80fd\u6b63\u5e38\uff1b\u9aa8\u9ad3\u6aa2\u67e5\u986f\u793a\u6f3f\u7d30\u80de\u70ba35%\uff0c\u9aa8\u9abc\u6aa2\u67e5\u7121\u8755\u9aa8\u75c5\u8b8a\u3002\u6b64\u4f4d\u75c5\u4eba\u6700\u6070\u7576\u7684\u8a3a\u65b7\u70ba\uff1f\nA. Monoclonal gammopathy of undetermined significance\nB. Smoldering multiple myeloma\nC. Symptomatic multiple myeloma\nD. Waldenstrom's macroglobulinemia\nE. Light chain disease\n": "(B)", "108-4.\nIbrutinib\u5c0d\u67d0\u4e9b\u6dcb\u5df4\u60e1\u6027\u75be\u75c5\u5982chronic lymphocytic leukemia, mantle cell lymphoma\u7b49\u975e\u5e38\u6709\u6548\u3002\u5b83\u7684\u4f5c\u7528\u6a5f\u8f49\u70ba\u4f55\uff1f\nA. Phosphoinositide-3 kinase (PI3K) inhibitor\nB. Burton tyrosine kinase (BTK) inhibitor\nC. B-cell lymphoma 2 (BCL-2) inhibitor\nD. Anti-CD79a monoclonal antibody\nE. Anti-CD19 monoclonal antibody\n": "(B)", "108-5.\n\u4e00\u4f4d63\u6b72\u75c5\u4eba\u88ab\u8a3a\u65b7\u70ba\u56b4\u91cd\u578b\u518d\u751f\u4e0d\u826f\u6027\u8ca7\u8840\uff0c\u7d93\u904eAnti-thymocyte globulin\u53cacyclosporine\u6cbb\u7642\u5f8c\u53cd\u61c9\u4e0d\u4f73\uff0c\u4ecd\u5168\u8840\u7403\u4f4e\u4e0b\uff0c\u7d93\u5e38\u9700\u8981\u8f38\u8840\u3002\u6b64\u6642\u6700\u6709\u6548\u4e4b\u6cbb\u7642\u65b9\u5f0f\u70ba\u4f55\uff1f\nA. Eltrombopag\nB. Danazol\nC. Steroid\nD. G-CSF\nE. Erythropoietin\n": "(A)", "108-6.\n\u4e00\u4f4d\u75c5\u4eba\u8840\u6db2\u6aa2\u67e5\u767c\u73fe\u8840\u6db2\u76f8\u7570\u5e38\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\u3002\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u5f97\u4e86\u4ec0\u9ebc\u75c5\uff1f\nA. \u6162\u6027\u6dcb\u5df4\u589e\u751f\u6027\u75be\u75c5\nB. \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\nC. \u6025\u6027\u524d\u9aa8\u9ad3\u7d30\u80de\u767d\u8840\u75c5\nD. \u6025\u6027\u55ae\u6838\u7d30\u80de\u767d\u8840\u75c5\nE. \u6025\u6027\u6dcb\u5df4\u82bd\u7d30\u80de\u767d\u8840\u75c5\n": "(C)", "108-7.\n\u4e00\u4f4d58\u6b72\u75c5\u4eba\u56e0\u5927\u817f\u75bc\u75db\u6709\u786c\u584a\u61c9\u8a3a\uff0c\u8d85\u97f3\u6ce2\u6aa2\u67e5\u986f\u793a\u6709\u808c\u8089\u5167\u8840\u816b\u584a\uff0c\u7d93\u5be6\u9a57\u5ba4\u6aa2\u67e5\u8a3a\u65b7\u70ba\u5f8c\u5929A\u578b\u8840\u53cb\u75c5(acquired hemophilia A)\u3002\u4ee5\u4e0b\u8207\u6b64\u75c5\u76f8\u95dc\u7684\u6558\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f\nA. \u591a\u56e0\u514d\u75ab\u7570\u5e38\u6240\u5f15\u8d77(immune mediated)\nB. Prothrombin time\u6b63\u5e38\nC. Thrombin time\u6b63\u5e38\nD. Mixing test\u5c07\u75c5\u4eba\u8207\u6b63\u5e38\u4eba\u4e4b\u8840\u6f3f\u6df7\u5408\u5f8c2\u5c0f\u6642\u5f8c\u6aa2\u9a57\uff0caPTT\u6703\u6062\u5fa9\u6b63\u5e38\nE. \u53ef\u4ee5\u7528activated prothrombin complex concentrate (aPCC)\u6cbb\u7642\n": "(D)", "108-8.\n\u51b7\u51cd\u6c88\u6fb1(Cryoprecipitate)\u53ef\u7528\u65bc\u6cbb\u7642\u4f55\u7a2e\u75c5\u4eba\uff1f\r(1) Hypofibrinogenemia\r(2) Hypoalbuminemia\r(3) Hemophilia A\r(4) von Willebrand disease\nA. (1)+(2)\nB. (1)+(3)\nC. (1)+(2)+(3)\nD. (1)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(D)", "108-9.\n\u4e0b\u5217\u6709\u95dc\u6dcb\u5df4\u7624\u53ca\u5176\u76f8\u5c0d\u61c9\u4e4b\u67d3\u8272\u9ad4\u8b8a\u7570\uff0c\u4f55\u8005\u662f\u6b63\u78ba\u7684\uff1f\r(1) Follicular lymphoma : t(14;18)\r(2) Mantle cell lymphoma : t(3;14)\r(3) Burkitt lymphoma : t(8;14)\nA. (1)\nB. (3)\nC. (1)+(3)\nD. (2)+(3)\nE. (1)+(2)+(3)\n": "(C)", "108-10.\n\u4e00\u4f4d34\u6b72\u7537\u58eb\u56e0\u70ba\u76ae\u819a\u51fa\u73fe\u7d2b\u6591\u61c9\u8a3a\uff0c\u7121\u670d\u85e5\u75c5\u53f2\u6216\u5176\u4ed6\u4e0d\u9069\u3002\u62bd\u8840\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d2013.2 gm/dL\uff0c\u8840\u5c0f\u677f12000/\u03bcL\uff0c\u767d\u8840\u7403\u6578\u53ca\u5206\u985e\u6b63\u5e38\uff0c\u809d\u3001\u814e\u529f\u80fd\u3001\u5c3f\u6db2\u53ca\u7cde\u4fbf\u6b63\u5e38\u3002\u4e0b\u5217\u4f55\u8005\u662f\u5c0d\u6b64\u75c5\u4eba\u9069\u7576\u7684\u6cbb\u7642\uff1f\r(1)\u8f38\u6ce8\u8840\u5c0f\u677f\u6fc3\u7e2e\u6db2\r(2) \u670d\u7528\u985e\u56fa\u9187\r(3)\u813e\u81df\u5207\u9664\nA. (1)\nB. (2)\nC. (1)+(2)\nD. (2)+(3)\nE. (1)+(2)+(3)\n": "(B)", "108-1.\n\u80ba\u816b\u7624\u7684\u6cbb\u7642\u9078\u9805\uff0c\u4e0a\u76ae\u751f\u9577\u56e0\u5b50\u63a5\u53d7\u9ad4(EGFR, epidermal growth factor receptor)\u7684\u5c0f\u5206\u5b50\u6291\u5236\u5291\u85e5\u7269\u662f\u91cd\u8981\u7684\u9078\u64c7\u3002\u4e0b\u5217\u4f55\u7a2e\u75c5\u4eba\u80ba\u816b\u7624\u6709\u300cEGFR\u7a81\u8b8a\u300d\u7684\u6a5f\u7387\u6700\u9ad8?\nA. A 35-year-old woman with a carcinoid tumor\nB. A 25-year-old man with a hamartoma\nC. A 75-year-old man with squamous cell carcinoma and a history of asbestos exposure\nD. A 58-year-old man with a 100-pack-year history of tobacco use with small-cell lung carcinoma\nE. A 54-year-old woman who has never smoked with an adenocarcinoma\n": "(E)", "108-2.\n\u4e00\u4f4d58\u6b72\u5973\u6027\u56e0\u8173\u4e0a\u6709\u4e00\u9010\u6f38\u9577\u5927\u7684\u9ed1\u75e3\u800c\u81f3\u76ae\u819a\u79d1\u6c42\u8a3a\uff0c\u9ed1\u75e3\u6700\u9577\u76f4\u5f91\u7d049mm\uff0c\u908a\u7de3\u4e0d\u898f\u5247\uff0c\u75c5\u4eba\u81ea\u5df1\u767c\u89ba\u9ed1\u75e3\u9664\u4e86\u9010\u6f38\u8b8a\u5927\u4e4b\u5916\uff0c\u984f\u8272\u4e5f\u6f38\u52a0\u6df1\u8b8a\u9ed1\u3002\u5207\u7247\u6aa2\u67e5\u8b49\u5be6\u662f\u9ed1\u8272\u7d20\u7624(melanoma)\uff0c\u6df1\u5ea6\u7531\u76ae\u819a\u8868\u9762\u4e00\u76f4\u5ef6\u4f38\u5165\u771f\u76ae\u5c64(dermis)\u5171\u6df1\u90540.5mm\uff0c\u8a08\u7b97\u6bcf1mm\u4e4b\u6709\u7d72\u5206\u88c2(mitosis)<1 (<1 mitosis/mm)\u3002\u4e0b\u5217\u56e0\u7d20\u4f55\u8005\u5c0d\u75c5\u4eba\u9ed1\u8272\u7d20\u7624\u7684\u9810\u5f8c(prognosis)\u7684\u5f71\u97ff\u6700\u5927?\nA. Anatomic site\nB. Sex\nC. Number of mitoses\nD. Breslow Depth\nE. Clark level\n": "(D)", "108-3.\n\u4e0069\u6b72\u7537\u6027\uff0c\u75c5\u7406\u5207\u7247\u8a3a\u65b7\u78ba\u8a3a\u7f79\u60a3\u5c0f\u7d30\u80de\u80ba\u764c (SCLC, small-cell lung cancer)\uff0cPET/CT\u6383\u63cf\u7d50\u679c\u986f\u793a\u53f3\u5074\u80ba\u9580(hilar)\u90e8\u4f4d\u6709\u4e004 x 5\u516c\u5206\u816b\u584a\uff0c\u4e14\u540c\u5074\u6709\u4e2d\u7b49\u91cf(moderate)\u7684\u808b\u819c\u7a4d\u6c34\uff0c\u7d93\u808b\u819c\u7a4d\u6c34\u7a7f\u523a\u6aa2\u67e5\uff0c\u808b\u819c\u7a4d\u6c34\u7d30\u80de\u5b78\u8b49\u5be6\u540c\u6a23\u6709SCLC\u764c\u7d30\u80de\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u771f?\nA. Surgical therapy alone has a high curative rate for his stage of SCLC\nB. Radiation plays no palliative role at all in therapy for this disease\nC. Twenty percent of patients with SCLC are diagnosed with the same stage of disease as this patient\nD. The majority of patients with SCLC of this stage respond to chemotherapy alone and go into remission with a very high 3-year survival\nE. This patient has extensive-stage disease\n": "(E)", "108-4.\n\u4e0b\u5217\u5371\u96aa\u56e0\u5b50\uff0c\u4f55\u8005\u8207\u98df\u9053\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c(squamous cell carcinoma)\u8207\u98df\u9053\u817a\u764c(adenocarcinoma)\u5747\u5bc6\u5207\u76f8\u95dc?\nA. Male sex\nB. Chronic gastroesophageal reflux disease\nC. Barrett's esophagus\nD. Lye ingestion\nE. Cigarette smoking\n": "(E)", "108-5.\n\u82e5\u91dd\u5c0d\u300c\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u4e0a\u76ae\u764c\u300d(CUP, carcinoma of unknown primary)\u7684\u816b\u7624\u6aa2\u9ad4\uff0c\u9032\u884c\u6b21\u4e16\u4ee3\u57fa\u56e0\u5b9a\u5e8f\u5206\u6790(NGS, next generation sequencing)\uff0c\u6700\u5e38\u898b\u767c\u751f\u57fa\u56e0\u8b8a\u7570(GA, genetic alterations)\u7684\u57fa\u56e0\u70ba\u4e0b\u5217\u4f55\u8005?\nA. KRAS\nB. CDKN2A\nC. ARID1A\nD. TP53\nE. MTOR\n": "(D)", "108-6.\n\u4e00\u4f4d31\u6b72\u7537\u6027\uff0c\u82e5\u6709\u4e0b\u5217\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u6216\u5bb6\u65cf\u75c5\u53f2\uff0c\u6703\u9700\u8981\u5c07\u300c\u907a\u50b3\u6027\u975e\u591a\u767c\u606f\u8089\u6027\u5927\u8178\u764c\u300d (HNPCC\uff0chereditary nonpolyposis colon cancer) \u7a4d\u6975\u5217\u5165\u7be9\u6aa2(screening)\u7684\u8003\u616e?\nA. Innumerable polyps visualized on routine colonoscopy\nB. Mucocutaneous pigmentation\nC. New diagnosis of ulcerative colitis\nD. (A)+(B)+(C)\nE. Father, paternal uncle, and paternal cousin with colon cancer diagnosed at age 50, 66, and 35 years, respectively\n": "(E)", "108-7.\n\u4e0b\u5217\u75c5\u4eba\u60c5\u5f62\uff0c\u4f55\u8005\u8207\u7f79\u60a3\u982d\u9838\u90e8\u764c\u75c7(head and neck cancers)\u7684\u98a8\u96aa\u589e\u52a0\uff0c\u6700\u7121\u95dc\u9023?\nA. Alcohol consumption\nB. Tobacco consumption\nC. Helicobacter pylori infection\nD. Epstein Barr virus infection\nE. Human papillomavirus infection\n": "(C)", "108-8.\n\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u5e38\u898b\u7684\u60e1\u6027\u6dcb\u5df4\u816b\u7624 (lymphoid malignancy)?\nA. Chronic lymphoid leukemia (CLL)\nB. Acute lymphoid leukemia (ALL)\nC. Hodgkin lymphoma (HD)\nD. Non-Hodgkin lymphoma (NHL)\nE. Multiple myeloma (MM)\n": "(D)", "108-9.\n48\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u7f79\u60a3\u7b2c\u56db\u671f\u5375\u5de2\u764c(ovarian cancer)\uff0c\u63a5\u53d76\u500b\u7642\u7a0bcarboplatin\u5408\u4f75paclitaxel\u5316\u5b78\u6cbb\u7642\u5f8c\uff0c\u6bd4\u8f03\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u524d\u5f8c\u7684\u5dee\u7570\uff0c\u5982\u7642\u6548\u8a55\u4f30\u6839\u64daResponse Evaluation Criteria in Solid Tumors (RECIST), \u7b2c1.1\u7248(Ver. 1.1)\u7684\u5b9a\u7fa9\uff0c\u82e5\u816b\u7624\u6cbb\u7642\u5f8c\u53ef\u6e2c\u91cf\u7684\u816b\u7624\u300c\u6700\u9577\u76f4\u5f91\u300d(longest diameters)\u7684\u7e3d\u548c\uff0c\u5171\u7e2e\u5c0f\u4e8615%\uff0c\u4e14\u6548\u679c\u6301\u7e8c\u81f3\u5c114\u9031\u3002\u53ef\u4ee5\u8a55\u4f30\u5979\u7684\u5375\u5de2\u764c\u5c0d\u5316\u5b78\u6cbb\u7642\u7684\"\u53cd\u61c9\" (response)\u70ba\u4f55?\nA. Complete response (CR)\nB. Partial response (PR)\nC. Stable disease (SD)\nD. Progressive disease (PD)\nE. \u4ee5\u4e0a\u7686\u975e\n": "(C)", "108-10.\n\u6709\u95dc\u81bd\u7ba1\u764c(cholangiocarcinoma)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u4e26\u4e0d\u6b63\u78ba?\nA. The incidence of cholangiocarcinoma has been increasing in recent years\nB. Primary sclerosing cholangitis and hepatitis C virus infection are associated with cholangiocarcinoma\nC. Most patients present due to an abnormal screening ultrasound, without symptoms\nD. Asians infected with liver flukes have an increased risk of cholangiocarcinoma\nE. Surgical resection may achieve 40% 5-year Survival with an R0 resection\n": "(C)", "109-160.\u4e00\u4f4d57\u6b72\u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\u4eba\uff0c\u57fa\u56e0\u6aa2\u6e2c\u767c\u73fe\u6709FLT3-ITD\uff0c\u4e0b\u5217\u4f55\u7a2e\u8a98\u5c0e\u6cbb\u7642\u6700\u70ba\u9069\u7576\uff1f    \nA.Anthracycline \u52a0Cytarabine\nB.Anthracycline \u52a0Cytarabine \u52a0Midostaurin\nC.Anthracycline \u52a0Vetoposide\nD.Anthracycline \u52a0Cytarabine \u52a0Vetoposide\nE.Cyclophosphamide \u52a0Cytarabine\n": "[B]", "109-161.\u4e00\u4f4d65\u6b72\u5973\u6027\u75c5\u4eba\u62bd\u8840\u6aa2\u67e5\u767c\u73feHb \u70ba19.5 gm/dL\uff0cHct 58.5%\uff0cWBC 15400 /\u03bcL\uff0cplatelet 435000 /\u03bcL\u3002\u4ee5\n\u4e0b\u4f55\u7a2e\u57fa\u56e0\u7a81\u8b8a\u53ef\u5e6b\u5fd9\u8a3a\u65b7\u6b64\u75c5\u4eba\u5f97\u4e86\u771f\u6027\u7d05\u8840\u7403\u589e\u591a\u75c7 (PV)\uff1f   \nA.BCR/ABL fusion\nB.ASXL1\nC.CALR\nD.JAK2\nE.RUNX1\n": "[D]", "109-162.Daratumumab\u5df2\u6709\u5065\u4fdd\u7d66\u4ed8\u4f5c\u70ba\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684\u85e5\u7269\uff0c\u5176\u4f5c\u7528\u6a5f\u8f49\u70ba\u4f55\uff1f    \nA.Anti-CD38 antibody\nB.Anti-CD20 antibody\nC.Anti-CD138 antibody\nD.Proteosome inhibitor\nE.Histone deacetylase inhibitor\n": "[A]", "109-163.\u4e00\u4f4d\u6162\u6027\u95dc\u7bc0\u708e\u60a3\u8005\u62bd\u8840\u6aa2\u67e5\u986f\u793a\u6709\u8ca7\u8840 \uff0c\u7d93\u8a73\u7d30\u6aa2\u67e5\u6392\u9664\u5176\u4ed6\u539f\u56e0\u5f8c \uff0c\u88ab\u8a3a\u65b7\u70ba\u6162\u6027\u75be\u60a3\u9020\u6210\u7684\u8ca7\n\u8840(anemia of chronic disease )\uff0c\u4e0b\u5217\u4f55\u8005\u8207\u6b64\u8a3a\u65b7\u4e0d\u7b26\u5408 \uff1f      \nA.Microcytic anemia\nB.Low serum iron\nC.Normal or high serum ferritin\nD.Increased iron stores\nE.Decreased hepcidin production\n": "[E]", "109-164.Double-hit\u5f4c\u6f2b\u6027\u5927 B\u7d30\u80de\u6dcb\u5df4\u7624(DLBCL)\u9810\u5f8c\u5f88\u5dee\uff0c\u9019\u4e9b\u75c5\u4eba\u7684\u6dcb\u5df4\u7624\u7d30\u80de\u6709\u90a3\u5169\u500b\u57fa\u56e0\u91cd\u7d44\uff1f    \nA.MYC, BCL2\nB.BCL2, BCL6\nC.MYC, MCL1\nD.BCL2, MCL1\nE.MYC, BCL1\n": "[A]", "109-165.\u4e0b\u5217\u6a19\u9776\u6cbb\u7642\u8207\u75be\u75c5\u7684\u914d\u5c0d\u4f55\u8005\u662f\u932f\u8aa4\u7684\uff1f    \nA.Eltrombopag- Immune thrombocytopenic purpura\nB.Rituximab- B-cell lymphoma\nC.Brentuximab- Hodgkin\u2019s lymphoma\nD.Ibrutinib- Multiple myeloma\nE.Imatinib- Chronic myeloid leukemia\n": "[D]", "109-166.\u4e0b\u5217\u6709\u95dc\u8f38\u8840\u76f8\u95dc\u4e4b\u6025\u6027\u80ba\u640d\u50b7(Transfusion-related acute lung injury)\u7684\u6558\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f    \nA.\u767c\u751f\u539f\u56e0\u591a\u70ba\u6350\u8840\u8005\u9ad4\u5167\u6709\u9ad8\u6fc3\u5ea6\u4e4bAnti-HLA class II \u6297\u9ad4\nB.\u4e00\u822c\u767c\u751f\u65bc\u8f38\u8840\u5f8c24\u5c0f\u6642\nC.\u75c5\u4eba\u6709\u7f3a\u6c27\u73fe\u8c61\nD.\u6703\u51fa\u73fe\u80ba\u6c34\u816b\nE.\u8f38\u6ce8\u7537\u6027\u6216\u672a\u66fe\u61f7\u5b55\u5a66\u5973\u7684\u8840\u53ef\u6e1b\u5c11\u767c\u751f\u6a5f\u7387\n": "[B]", "109-167.\u4e00\u4f4d75\u6b72\u7537\u58eb \uff0c\u904e\u53bb\u7121\u7279\u6b8a\u75c5\u53f2 \uff0c\u5728\u4f8b\u884c\u62bd\u8840\u6aa2\u67e5\u6642\u767c\u73feHb 9.2 gm/dL\uff0cWBC 2600 /\u03bcL\uff0cblasts \n2%\uff0csegmented neutrophils 35 %\uff0cmonocytes 8%\uff0clymphocytes 55 %\uff0c\u8840\u5c0f\u677f23000 /\u03bcL\uff1b\u9aa8\u9ad3\u6aa2\u67e5\u986f\n\u793a\u9020\u8840\u7d30\u80de\u5316\u751f\u4e0d\u826f (dysplasia )\uff0cblasts 9%\uff0c\u67d3\u8272\u9ad4\u70ba\u8907\u96dc\u8b8a\u5316 \u3002\u6b64\u75c5\u4eba\u6700\u9069\u7576\u7684\u6cbb\u7642\u70ba\u4f55 \uff1f   \nA.Packed RBC transfusion\nB.Platelet concentrate transfusion\nC.Erythropoietin\nD.Azacitidine\nE.Allogeneic hematopoietic stem cell transplantation\n": "[D]", "109-168.Cryoprecipitate\u4e2d\u5e36\u6709\u90a3\u4e9b\u51dd\u8840\u56e0\u5b50 \uff1f\n(1) fibrinogen\n(2) Factor VII\n(3) Factor VIII\n(4) von Willebrand factor   \nA.(1)\nB.(2)   \nC.(1)+(3)\nD.(1)+(3)+(4)\nE.(1)+(2)+(3)\n": "[D]", "109-169.\u4e00\u4f4d55\u6b72\u7537\u58eb\u904e\u53bb\u7121\u7279\u6b8a\u75c5\u53f2 \uff0c\u56e0\u547c\u5438\u6025\u4fc3\u53ca\u76ae\u819a\u7600\u9752\u61c9\u8a3a \uff0c\u8eab\u9ad4\u6aa2\u67e5\u7121\u809d\u813e\u816b\u5927 \uff0c\u9ad4\u6eab\u6b63\u5e38 \u3002\u62bd\u8840\u6aa2\u67e5\n\u986f\u793aHb 7.8 gm/dL\uff0cWBC 1250 /\u03bcL\uff0cneutrophils 20 %\uff0cmonocytes 6%\uff0clymphocytes 74 %\uff0c\u8840\u5c0f\n\u677f13000/\u03bcL\uff1b\u809d\u814e\u529f\u80fd\u6b63\u5e38 \uff0c\u8840\u6e05\u9435\u3001\u7dad\u5316\u547dB12\u53ca\u8449\u9178\u503c\u6b63\u5e38 \uff1b\u9aa8\u9ad3\u6aa2\u67e5\u986f\u793a\u9020\u8840\u7d30\u80de\u4f54\u6709\u6838\u7d30\u80de\n\u4e4b10%\uff0cblasts\u767e\u5206\u6bd4\u6b63\u5e38 \uff0c\u7121\u5316\u751f\u4e0d\u826f (dysplasia) \u8b8a\u5316 \uff0c\u6b64\u6642\u6700\u9069\u7576\u7684\u6cbb\u7642\u70ba\u4f55 \uff1f\n(1) allogeneic hematopoietic stem cell transplantation\n(2) cyclosporine\n(3) anti-thymocyte globulin\n(4) G-CSF   \nA.(1)\nB.(2)\nC.(2)+(3)\nD.(1)+(4)\nE.(2)+(3)+(4)\n": "[C]", "109-170.\u4e0068\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u8a3a\u65b7\u7f79\u60a3\u4e59\u72c0\u7d50\u8178\u764c (adenocarcinoma, sigmoid colon )\uff0c\u4ee5\u6839\u6cbb\u6027\u624b\u8853\u5207\u9664\u5de6\u5074\u4e59\u72c0\u7d50\n\u8178\u8207\u6dcb\u5df4\u7d50\u5ed3\u6e05\u8853 \uff0c\u75c5\u7406\u7d44\u7e54\u78ba\u5b9a\u624b\u8853\u908a\u7de3\u6c92\u6709\u764c\u7d30\u80de \uff0c\u6e05\u9664\u6dcb\u5df4\u7d50\u517125\u9846\u4e2d\u75c5\u7406\u6aa2\u67e5\u6709 6\u9846\u5df2\u6709\u764c\u7d30\n\u80de\uff0c\u6c92\u6709\u9060\u8655\u5668\u5b98\u8f49\u79fb \uff0c\u91ab\u5e2b\u5efa\u8b70\u624b\u8853\u5f8c\u9032\u884c 6\u500b\u6708\u5316\u5b78\u6cbb\u7642\u4ee5\u964d\u4f4e\u5fa9\u767c\u7387\u8207\u589e\u52a0\u5b58\u6d3b \u3002\u5404\u7a2e\u81e8\u5e8a\u6307\u5f15\u5747\n\u4e00\u81f4\u5efa\u8b70\u4e4b\u6700\u9069\u5408\u4e4b\u8f14\u52a9\u6027 (adjuvant )\u6cbb\u7642\u8655\u65b9\u70ba\u4f55\u8005 \uff1f   \nA.Irinotecan added to 5-FU and Leucovorin (FOLFIRI)\nB.Oxaliplatin added to 5-FU and Leucovorin (FOLFOX)\nC.Bevacizumab added to FOLFOX\nD.Cetuximab added to FOLFOX\nE.Panitumumab added to FOLFOX\n": "[B]", "109-171.\u764c\u75c7\u75c5\u4eba\u7684\u8655\u7406\u8a55\u4f30 \uff0c\u9ad4\u80fd\u72c0\u614b (Performance status, PS) \u662f\u4e00\u500b\u91cd\u8981\u7684\u5e38\u7528\u6307\u6a19 \u3002\u9ad4\u80fd\u72c0\u614b\u7684\u8a55\u4f30\u6709\u4e00\n\u500b\u6cbf\u7528\u591a\u5e74\u7684\u6307\u6a19Karnofsky performance status (KPS)\u3002\u4eca\u6709\u4e00\u4f4d60\u6b72\u764c\u75c7\u75c5\u4eba \uff0c\u4ed6\u65e5\u5e38\u751f\u6d3b\u5b8c\u5168\u53ef\u4ee5\n\u81ea\u7406(self-care)\uff0c\u4e0d\u9700\u4eba\u5e6b\u5fd9 \u3002\u4f46\u662f\u4ed6\u5df2\u6c92\u6709\u8fa6\u6cd5\u6b63\u5e38\u7684\u5de5\u4f5c (active work )\uff0c\u4e5f\u6c92\u6709\u8fa6\u6cd5\u53c3\u52a0\u6b63\u5e38\u6d3b\n\u52d5\uff08normal activity )\u3002\u91ab\u5e2b\u4f30\u8a08\u9019\u6a23\u7684\u75c5\u4ebaKPS\u7d04\u70ba\u5e7e\u5206 \uff1f   \nA.KPS 90\nB.KPS 80\nC.KPS 70\nD.KPS 60\nE.KPS 50\n": "[C]", "109-172.\u4e00\u4f4d70\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u7a81\u7136\u56e0\u610f\u8b58\u6df7\u4e82 (confusion )\u88ab\u5bb6\u4eba\u9001\u81f3\u6025\u8a3a\u5ba4 \u3002\u751f\u547d\u5fb5\u8c61 (TPR\u8207\u8840\u58d3 )\u5927\u81f4\u7a69\u5b9a \uff0c\u4e26\n\u6c92\u6709\u5c40\u90e8\u795e\u7d93\u5b78\u5fb5\u8c61 \u3002\u521d\u6b65\u62bd\u8840\u6aa2\u67e5\u767c\u73fe\u8840\u6e05\u9223\u6578\u503c 3.55mmol/L (14.2mg/dL)\uff0cBUN\u8207Cre\u6578\u503c\u8f15\u5fae\u4e0a\n\u5347\u3002\u80f8\u90e8X\u5149\u651d\u5f71(CXR)\u767c\u73fe\u5169\u5074\u80ba\u91ce\u6709\u591a\u767c\u80ba\u7d50\u7bc0 (nodules)\uff0c\u9ad8\u5ea6\u61f7\u7591\u662f\u8f49\u79fb\u7684\u60e1\u6027\u816b\u7624 \u3002\u4e4b\u5f8c\u7684\u5be6\u9a57\n\u5ba4\u6aa2\u67e5\u986f\u793aPTH -rP (parathyroid hormone -related protein )\u6578\u503c\u660e\u986f\u4e0a\u5347 \u3002\u4e0b\u5217\u7684\u9ad8\u8840\u9223\u75c7\u4e4b\u8655\u7f6e\u6700 \"\u4e0d\"\u9700\n\u8981\uff1f   \nA.Normal saline\nB.Pamidronate   \nC.Furosemide\nD.Prednisolone\nE.Calcitonin\n": "[D]", "109-173.\u4e0b\u5217\u75c5\u4eba\u60c5\u5f62\uff0c\u4f55\u8005\u8207\u7f79\u60a3\u809d\u7d30\u80de\u764c(HCC, hepatocellular carcinoma)\u7684\u98a8\u96aa\u589e\u52a0\uff0c\u6700\"\u7121\"\u95dc\u9023\uff1f    \nA.Hepatitis B infection\nB.Nonalcoholic steatohepatitis (NASH)\nC.Hepatitis C infection\nD.Liver flukes (Clonorchis sinensis, Opisthorchis viverrini)\nE.Cirrhosis from any cause\n": "[D]", "109-174.\u81ea2012\u5e74\u4ee5\u4f86 \uff0c\u514d\u75ab\u6cbb\u7642\u7684\u9032\u5165\u5fa9\u8208\u65b0\u6642\u4ee3 \uff0c\u6709\u4e9b\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291 (immune checkpoint inhibitors )\u8b49\u5be6\n\u53ef\u4ee5\u6709\u6548\u6cbb\u7642\u764c\u75c7 \uff0c\u4e14\u9032\u5165\u81e8\u5e8a\u5be6\u7528\u968e\u6bb5 \uff0c\u9032\u4e00\u6b65\u6709\u4e9b\u764c\u75c7\u6cbb\u7642\u6642\u4e5f\u767c\u73fe\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291\u91cd\u8981\u7684 \"\u9810\u6e2c\n\u6027\u751f\u7269\u6a19\u8a18 \"\u3002\u8f49\u79fb\u6027\u5927\u8178\u764c\u75c5\u4eba\u5728\u63a5\u53d7PD -1\u6297\u9ad4\u85e5\u5291Pembrolizumab (Kytruda)\u6cbb\u7642\u6642\uff0c\u5df2\u77e5\u4e0b\u5217\u4f55\n\u7a2e\"\u9810\u6e2c\u6027\u751f\u7269\u6a19\u8a18 \"\u60c5\u5f62\u4e0b\uff0cPembrolizumab (Kytruda)\u6cbb\u7642\u8f03\u70ba\u6709\u6548 \uff1f   \nA.MSI-H (microsatellite instability -high, \u5fae\u5c0f\u885b\u661f\u9ad4\u9ad8\u5ea6\u4e0d\u7a69\u5b9a\u6027 )\uff0cdefective MMR (\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\u7d20\n\u7f3a\u9677)\nB.MSS (microsatellite stable, \u5fae\u5c0f\u885b\u661f\u9ad4\u7a69\u5b9a\u6027)\uff0cdefective MMR (\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\u7d20\u7f3a\u9677)\nC.MSI-H (microsatellite instability -high, \u5fae\u5c0f\u885b\u661f\u9ad4\u9ad8\u5ea6\u4e0d\u7a69\u5b9a\u6027 )\uff0cproficient MMR (\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\n\u7d20\u5b8c\u6574)\nD.MSS (microsatellite stable, \u5fae\u5c0f\u885b\u661f\u9ad4\u7a69\u5b9a\u6027)\uff0cproficient MMR (\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\u7d20\u5b8c\u6574)\nE.\u4ee5\u4e0a\u7686\u975e\n": "[A]", "109-175.\u8f49\u79fb\u6027\u5927\u8178\u764c\u5728\u4f7f\u7528\u6297\u764c\u85e5\u7269\u6cbb\u7642\u6642 \uff0c\u5df2\u77e5\u6709\u4e00\u91cd\u8981\u7684\u9810\u6e2c\u6027\u751f\u7269\u6a19\u8a18 (predictive biomarker )\u3002\u8b6c\u5982\uff1a\u7576\n\u5927\u8178\u764c\u6aa2\u9ad4\u57fa\u56e0\u578bExpanded RAS (KRAS, NRAS\u57fa\u56e0\u7684exons 2, 3, 4)\u5c6c\u300c\u91ce\u751f\u578b\u300d(wild-type)\u6642\uff0c\u662f\u5c0d\n\u4e0b\u5217\u54ea\u500b\u85e5\u5291\u6709\u6548 (responsiveness )\u7684\u9810\u6e2c\u56e0\u5b50predictive biomarker \uff0c\u56e0\u6b64\u5efa\u8b70\u53ef\u9078\u7528\u8a72\u85e5\u5291\u6cbb\u7642 \u3002   \nA.5-Fluorouracil (5-FU)\nB.Irinotecan\nC.Oxaliplatin\nD.Cetuximab\nE.Bevacizumab\n": "[D]", "109-176.\u4e0070\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u4e3b\u8a34\u4e00\u500b\u6708\u7684\u7121\u75db\u6027\u9ec3\u75b8\u5408\u4f75\u9ad4\u91cd\u6e1b\u8f15 4\u81f35\u516c\u65a4\u3002\u986f\u5f71\u6ce8\u5c04\u7684\u96fb\u8166\u65b7\u5c64CT\u6383\u63cf \uff0c\u767c\u73fe\n\u80f0\u81df\u982d\u90e8 (head of pancreas )\u6709\u4e00\u7591\u4f3c\u816b\u584a\u4e14\u5408\u4f75\u81bd\u7ba1\u64f4\u5f35 \u3002\u4e0b\u5217\u4f55\u8005\u662f\u70ba\u6b64\u75c5\u4eba\u78ba\u8a3a\u662f\u5426\u70ba\u80f0\u81df\u764c\u7684\u6700\n\u4f73\u8a3a\u65b7\u65b9\u5f0f \uff1f   \nA.CT-guided percutaneous needle biopsy\nB.Endoscopic ultrasound (EUS)-guided needle biopsy\nC.Endoscopic retrograde cholangiopancreatography (ERCP) with pancreatic juice sampling for \ncytopathology\nD.FDG-PET imaging\nE.Serum CA 19-9\n": "[B]", "109-177.\u6709\u95dc\u524d\u5217\u817a\u7279\u7570\u6297\u539f\uff08PSA\uff0cprostate specific antigen\uff09\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u771f?    \nA.Most prostate cancer deaths occur in men with PSA levels below the top quartile.   \nB.PSA is produced by malignant and non-malignant prostate cells.\nC.The US Preventive Services Task Force (USPSTF) recommends PSA screening in men between \n55 and 69 years of age .\nD.The American Urological Association (AUA) recommends PSA screening in men 40 -55 years of \nage.\nE.Asymptomatic men with an elevated PSA should receive a 2-week course of antibiotics before \nrepeating PSA and considering biopsy .\n": "[B]", "109-178.\u764c\u75c7\u7684\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291 (immune checkpoint inhibitors )\u6216\u6a19\u9776\u6cbb\u7642\u85e5\u5291 (molecular targeted agents )\u901a\u5e38\n\u91dd\u5c0d\u7279\u5b9a\u7684\u8a0a\u606f\u50b3\u905e\u8def\u5f91\u6216\u5206\u5b50\u6a19\u9776\u9032\u884c\u6291\u5236 \uff0c\u4ee5\u9054\u5230\u6cbb\u7642\u764c\u75c7\u7684\u76ee\u7684 \u3002\u6cbb\u7642\"\u85e5\u5291\"\u8207\u514d\u75ab\u6216\u5206\u5b50 \"\u6a19\n\u9776\"\u7684\u914d\u5c0d\uff0c\u4e0b\u5217\u90a3\u4e9b\u70ba\u771f \uff1f\n(1) Ipilimumab \u8207 CTLA -4\n(2) Afatinib \u8207 EGFR\n(3) Rituximab \u8207 CD20\n(4) Trastuzumab \u8207 HER -2\n(5) Nivolumab \u8207 PD -L1   \nA.(1)+(2)+(3)+(4)\nB.(1)+(3)+(4)+(5)\nC.(2)+(3)+(4)+(5)\nD.(2)+(4)+(5)\nE.(1)+(2)+(3)+(4)+(5)\n": "[A]", "109-179.\u4e0064\u6b72\u5973\u6027\u75c5\u4eba \uff0c\u904e\u53bb\u5341\u591a\u5e74\u9678\u7e8c\u6709\u9593\u6b47\u6027\u8179\u7009\u7684\u75c7\u72c0 \uff0c\u5747\u50c5\u88ab\u8a3a\u65b7\u70ba\u8178\u8e81\u75c7 (irritable bowel \nsyndrome )\uff0c\u7d66\u4e88\u75c7\u72c0\u6cbb\u7642 \u3002\u6700\u8fd1\u4e00\u5e74\u4f86 \uff0c\u5979\u958b\u59cb\u6709\u8173\u8e1d\u6c34\u816b \uff0c\u4e14\u6f38\u6709\u60e1\u5316\u8da8\u52e2 \uff0c\u6f38\u6f38\u9700\u53e3\u670d\u5229\u5c3f\u5291\u624d\u80fd\n\u7de9\u89e3\u3002\u4ed4\u7d30\u8a62\u554f\u75c5\u53f2 \uff0c\u5979\u9593\u65b7\u6709\u71b1\u6f6e\u7d05\u7684\u60c5\u5f62\u5df2\u6709\u591a\u5e74 \uff0c\u4f46\u4e00\u76f4\u7576\u4f5c\u662f\u505c\u7d93\u75c7\u5019\u7fa4\u7684\u4e00\u90e8\u5206\u75c7\u72c0 \u3002\u7406\u5b78\u6aa2\n\u67e5\u6240\u898b\u75c5\u4eba\u767c\u80b2\u8207\u71df\u990a\u72c0\u614b\u826f\u597d \uff0c\u7121\u9ec3\u75b8\uff0c\u7121\u5468\u908a\u6dcb\u5df4\u7d50\u816b\u5927 \uff0chepatojugular reflux\u967d\u6027 \uff0c\u5fc3\u81df\u807d\u8a3a\u6709\u660e\n\u986fS3\u5fc3\u97f3\uff0c\u809d\u816b\u5927\u81f3\u53f3\u808b\u7de3\u4e0b\u7d04 3\u6307\u5e45\uff0c\u4e14\u660e\u986f\u5169\u5074\u8db3\u8e1d\u6c34\u816b \u3002\u4f60\u5efa\u8b70\u9032\u4e00\u6b65\u70ba\u6b64\u75c5\u4eba\u5b89\u6392\u4ee5\u4e0b\u7684\u6aa2\n\u67e5\uff0c\u4f55\u8005\u9069\u5b9c \uff1f\n(1) 24-hour urine for 5-HIAA (5-hydroxyindoleacetic acid )\n(2) Echocardiogram\n(3) 18-FDG-PET scan\n(4) CT scan of abdomen and pelvis\n(5) Octreoscan   \nA.\u50c51\u9069\u5b9c\nB.\u50c51\u30012\u9069\u5b9c\nC.\u50c51\u30012\u30013\u9069\u5b9c\nD.1\u30012\u30013\u30014\u5747\u9069\u5b9c\nE.1\u30012\u30014\u30015\u5747\u9069\u5b9c\n": "[E]", "110-129.\u76ee\u524dAnti-CD22\u85e5\u7269Inotuzumab\u5df2\u88ab\u6838\u51c6\u7528\u65bc\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\uff1f    \nA.\u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\u3002\nB.B\u7d30\u80de\u6025\u6027\u6dcb\u5df4\u82bd\u7d30\u80de\u767d\u8840\u75c5\u3002\nC.\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u3002\nD.\u975e\u4f55\u6770\u91d1\u6c0f\u6dcb\u5df4\u7624\u3002\nE.\u514d\u75ab\u6027\u8840\u5c0f\u677f\u4f4e\u4e0b\u6027\u7d2b\u6591\u75c7\u3002\n": "[B]", "110-130.Venetoclax\u7528\u65bc\u8001\u5e74\u4e0d\u9069\u5408\u63a5\u53d7\u589e\u5f37\u5316\u7642\u7684\u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\u75c5\u4eba\u5df2\u6709\u5065\u4fdd\u7d66\u4ed8\uff0c\u5b83\u7684\u4f5c\u7528\u6a5f\u8f49\u70ba\u4f55\uff1f    \nA.BCL-2 inhibitor\u3002\nB.MCL-1 inhibitor\u3002\nC.Bruton tyrosine kinase inhibito\u3002\nD.RAS inhibitor\u3002\nE.Immunomudulatory agent\u3002\n": "[A]", "110-131.\u4e00\u4f4d25\u6b72\u5973\u6027\u7121\u7279\u6b8a\u4e0d\u9069 \u3002\u5728\u9ad4\u6aa2\u6642\u767c\u73feHb 9.1 gm/dL\uff0cRBC 4.43 M/\u03bcL\uff0cMCV 68 fL \uff0c\u767d\u8840\u7403\u6578\u53ca\u5206\u985e\n\u6b63\u5e38\uff0c\u8840\u5c0f\u677f\u6578\u6b63\u5e38 \uff0c\u7db2\u72c0\u7d05\u8840\u7403 3.1%\uff1b\u8840\u9435\u8cea185 ng /mL (\u6b63\u5e385~148)\uff0ciron 145 \u03bcg/dL (\u6b63\n\u5e3851~209)\uff0cTIBC 420 \u03bcg/dL (\u6b63\u5e38268~593)\u3002\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55 \uff1f   \nA.Iron deficiency anemia\u3002\nB.Anemia of chronic disorder\u3002\nC.Thalassemia\u3002\nD.Myelodysplastic syndrome with ring sideroblasts\u3002\nE.Lead poisoning\u3002\n": "[C]", "110-132.\u4e0b\u5217\u6709\u95dc\u9663\u767c\u6027\u591c\u9593\u8840\u8272\u7d20\u5c3f(PNH)\u7684\u6558\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f    \nA.Intravascular hemolysis\u3002\nB.Elevation of LDH levels\u3002\nC.Reduced haptoglobin levels\u3002\nD.Loss of membrane CD55 and CD56 expression on RBC\u3002\nE.Responsive to complement 5 (C5) inhibitor treatment\u3002\n": "[D]", "110-133.\u4e00\u4f4d35\u6b72\u7537\u6027\u75c5\u4eba\u767c\u73fe\u624b\u8173\u78b0\u649e\u6642\u5076\u6709\u7d2b\u6591 \uff0c\u4f46\u7121\u5176\u4ed6\u51fa\u8840\u73fe\u8c61 \uff0c\u8840\u6db2\u6aa2\u67e5\u986f\u793aHb 13 .2 gm/dL\uff0c\u767d\u8840\u7403 \n5650/\u03bcL\uff0c\u5206\u985e\u6b63\u5e38 \uff0c\u8840\u5c0f\u677f 36000 /\u03bcL\uff0c\u4e0b\u5217\u6aa2\u67e5\u4f55\u8005\u662f\u6700\u4e0d\u9700\u8981\u7684 \uff1f   \nA.Hepatitis C\u3002\nB.Autoimmune profile\u3002\nC.Helicobacter pylori\u3002\nD.Antiphospholipid antibodies\u3002\nE.Bone marrow\u3002\n": "[E]", "110-134.\u4e0b\u5217\u4f55\u8005\u662f\u539f\u767c\u6027\u591a\u8840\u75c7(polycythemia vera)\u6700\u5e38\u898b\u7684\u57fa\u56e0\u7a81\u8b8a\uff1f    \nA.JAK2\u7a81\u8b8a\u3002\nB.CALR\u7a81\u8b8a\u3002   \nC.MPL\u7a81\u8b8a\u3002\nD.DNMT3A\u7a81\u8b8a\u3002\nE.IDH\u7a81\u8b8a\u3002\n": "[A]", "110-135.\u4e00\u4f4d45\u6b72\u75c5\u4eba\u62bd\u8840\u767c\u73feaPTT\u5ef6\u9577 \uff0c\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55 \uff1f\n(1) hemophilia  (2) antiphospholipid syndrome  (3) heparin use  (4) von Willebramd disease   \nA.(1)\u3002\nB.(1)+(4)\u3002\nC.(1)+(3)\u3002\nD.(1)+(3)+(4)\u3002\nE.(1)+(2)+(3)+(4)\u3002\n": "[E]", "110-136.\u4e0b\u5217\u4f55\u8005\u70batumor lysis\u7684\u8868\u73fe \uff1f(1) Hyperkalemia  (2) Hypercalcemia  (3) Hyperuricemia  (4) renal \nfunction impairment   \nA.(1)+(3)\u3002\nB.(1)+(2)+(3)\u3002\nC.(1)+(3)+(4)\u3002\nD.(2)+(3)+(4)\u3002\nE.(1)+(2)+(3)+(4)\u3002\n": "[C]", "110-137.\u4e0060\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u8a3a\u65b7\u7f79\u60a3\u4e59\u72c0\u7d50\u8178\u764c (adenocarcinoma, sigmoid colon )\uff0c\u4ee5\u6839\u6cbb\u6027\u624b\u8853\u5207\u9664\u5de6\u5074\u4e59\u72c0\u7d50\n\u8178\u8207\u6dcb\u5df4\u7d50\u5ed3\u6e05\u8853 \uff0c\u75c5\u7406\u7d44\u7e54\u78ba\u5b9a\u624b\u8853\u908a\u7de3\u6c92\u6709\u764c\u7d30\u80de \uff0c\u6e05\u9664\u6dcb\u5df4\u7d50\u517121\u9846\u4e2d\u75c5\u7406\u6aa2\u67e5\u6709 8\u9846\u5df2\u6709\u764c\u7d30\n\u80de\uff0c\u6c92\u6709\u9060\u8655\u5668\u5b98\u8f49\u79fb \u3002\u91ab\u5e2b\u5efa\u8b70\u624b\u8853\u5f8c \uff0c\u518d\u7d66\u4e886\u500b\u6708\u300c\u8f14\u52a9\u6027(adjuvant) \u5316\u5b78\u6cbb\u7642 \u300d\u4ee5\u964d\u4f4e\u5fa9\u767c\u7387\u8207\n\u589e\u52a0\u5b58\u6d3b \u3002\u4f9d\u64da\u5404\u7a2e \u300c\u81e8\u5e8a\u6307\u5f15\u300d\uff0c \u91ab\u5e2b\u5efa\u8b70\u4e0b\u5217\u4f55\u8005 \u300c\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642 \u300d\u8655\u65b9\u8f03\u70ba\u5408\u9069 \uff1f   \nA.Oxaliplatin plus 5-FU or Capecitabine (FOLFOX or CAPOX)\u3002\nB.Irinotecan plus 5-FU or Capecitabine (FOLFIRI or CAPIRI)\u3002\nC.Bevacizumab added to (FOLFOX or CAPOX)\u3002\nD.Cetuximab added to (FOLFIRI or CAPIRI)\u3002\nE.Panitumumab added to (FOLFIRI or CAPIRI)\u3002\n": "[A]", "110-138.\u4e00\u4f4d65\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\u8207\u5207\u7247\u78ba\u5b9a\u7f79\u60a3\u80c3\u7684 \u300c\u795e\u7d93\u5167\u5206\u6ccc\u7624 (Neuroendocrine \ntumor, NET) \u300d\u3002 \u96fb\u8166\u65b7\u5c64\u6383\u63cf\u986f\u793a\u809d\u81df\u5df2\u6709\u591a\u767c\u8f49\u79fb\u75c5\u7076 \u3002\u75c5\u7406\u7d44\u7e54\u9664\u4e86\u78ba\u5b9a\u70ba\u795e\u7d93\u5167\u5206\u6ccc\u7624\u4e4b\u5916 \uff0c\u816b\n\u7624\u7684\u300c\u5206\u5316\u300d(grading)\u5c0d\u75c5\u4eba\u81e8\u5e8a\u9810\u5f8c (prognosis )\u7684\u5224\u5b9a\u8207\u6cbb\u7642\u9078\u9805\u7684\u9078\u64c7 \uff0c\u6709\u91cd\u8981\u7684\u53c3\u8003\u50f9\u503c \u3002\n\u5018\u82e5\u75c5\u7406\u7d44\u7e54\u986f\u5fae\u93e1\u6aa2\u67e5 \uff0c\u6bcf10\u500b\u9ad8\u500d\u6578\u8996\u91ce (10 HPF, high power field ), \u5e73\u5747\u670912\u500b\u6709\u7d72\u5206\u88c2 (mitotic \ncount)\uff0c\u8207Ki-67\u6307\u6578(Ki-67 index )\u8a08\u7b97\u70ba11 %\u3002\u4f9d\u7167\u4e16\u754c\u885b\u751f\u7d44\u7e54 (WHO) NET\u5206\u985e\u7cfb\u7d71\u7684grading \u5efa\n\u8b70\uff0c\u9019\u6a23\u7684\u75c5\u7406\u7d44\u7e54\u7684 \u300c\u5206\u5316\u300d(grading)\u5c6c\u65bc\u7b2c\u5e7e\u7d1a ?   \nA.Gr. 1\u3002\nB.Gr. 2\u3002\nC.Gr. 3\u3002\nD.Gr. 4\u3002\nE.Neuroendocrine carcinoma (NEC)\u3002\n": "[B]", "110-139.\u6709\u4e00\u7814\u7a76\u4f7f\u7528200 \u500b\u300c\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u4e0a\u76ae\u764c \u300d(CUP, carcinoma of unknown primary )\u75c5\u4eba\u7684\u816b\u7624\u6aa2\u9ad4 \uff0c\u9032\n\u884c\u300c\u6b21\u4e16\u4ee3\u57fa\u56e0\u5b9a\u5e8f\u5206\u6790 \u300d(NGS, next generation sequencing )\u3002\u60a8\u63a8\u6e2c\u6700\u5e38\u898b\u767c\u751f\u57fa\u56e0\u8b8a\u7570 (genetic \nalterations )\u7684\u57fa\u56e0\u70ba\u4e0b\u5217\u4f55\u8005 ?      \nA.KRAS\u3002\nB.TP53\u3002\nC.ARID1A\u3002\nD.CDKN2A\u3002\nE.mTOR\u3002\n": "[B]", "110-140.67\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u4e3b\u8a34\u4e8c\u500b\u6708\u9010\u6f38\u52a0\u91cd\u7684\u53f3\u8170\u75db \uff0c\u5408\u4f75\u4e00\u500b\u6708\u9010\u6f38\u52a0\u91cd\u7684\u8840\u5c3f (hematuria )\u3002\u4e14\u81ea\u89ba\u6c92\u6709\u80c3\n\u53e3\uff0c\u5728\u4e8c\u500b\u6708\u5167\u9ad4\u91cd\u6e1b\u8f15\u7d04 3\u516c\u65a4\u3002\u75c5\u4eba\u8f49\u81f3\u5927\u91ab\u9662\u6c42\u8a3a \uff0c\u7406\u5b78\u6aa2\u67e5\u89f8\u8a3a\u5df2\u767c\u73fe\u53f3\u8170\u90e8\u6709\u81f3\u5c11 5\u516c\u5206\u5927\u5c0f\u816b\n\u584a\uff0c\u814e\u529f\u80fd\u5927\u81f4\u6b63\u5e38 \u3002\u5f71\u50cf\u6aa2\u67e5\u767c\u73fe\u53f3\u814e\u6709\u4e0010\u516c\u5206\u5be6\u9ad4\u816b\u584a \uff0c\u5169\u5074\u80ba\u91ce\u6709\u591a\u767c\u7684\u80ba\u7d50\u7bc0 \uff0c\u986f\u793a\u5df2\u6709\u591a\u767c\n\u80ba\u81df\u8f49\u79fb \u3002\u7d30\u91dd\u7a7f\u523a\u5207\u7247\u75c5\u7406\u8b49\u5be6\u70ba\u814e\u7d30\u80de\u764c (renal cell carcinoma )\u4e4b\u4eae\u7d30\u80de (clear cell )\u4e9e\u578b\u3002\u5efa\u8b70\u4e0b\u4e00\n\u6b65\u5982\u4f55\u8655\u7f6e\u6700\u70ba\u5408\u9069 ?   \nA.Radical nephrectomy\u3002\nB.Gemcitabine\u3002\nC.Sunitinib\u3002\nD.Interleukin-2\u3002\nE.Interferon-\u03b3\u3002\n": "[C]", "110-141.58\u6b72\u5973\u6027\u75c5\u4eba \uff0c\u7f79\u60a3\u8f49\u79fb\u6027\u80ba\u817a\u764c (NSCLC, adenocarcinoma )\uff0c\u5df2\u63a5\u53d7\u7b2c\u4e00\u7ddacarboplatin \u3001paclitaxel \uff0c\u5408\n\u4f75bevacizumab\u6cbb\u7642 \uff0c\u6709\u6548\u201d\u7de9\u89e3\u201d(partial response )\u4e00\u6bb5\u671f\u9593\u4e4b\u5f8c \u201d\u60e1\u5316\u201d(disease progression )\u3002\u75c5\u4eba\n\u7684ECOG\u9ad4\u80fd\u72c0\u614b (performance status, PS )\u70ba1\uff0c\u91dd\u5c0d\u75c5\u4eba\u5468\u908a\u80ba\u91ce\u7684\u8f03\u5927\u75c5\u7076\u5b89\u6392\u91cd\u65b0\u5207\u7247 \uff0c\u5206\u5b50\u6aa2\u6e2c\n\u767c\u73feROS 1\u57fa\u56e0rearrangement\u967d\u6027 \u3002\u4f60\u5efa\u8b70\u4e0b\u4e00\u6b65\u7684\u6cbb\u7642 \uff0c\u4f55\u8005\u6700\u70ba\u9069\u5b9c ?   \nA.Pemetrexed\u3002\nB.Docetaxel\u3002\nC.Gemcitabine\u3002\nD.Erlotinib\u3002\nE.Crizotinib\u3002\n": "[E]", "110-142.\u81ea2012\u5e74\u4ee5\u4f86 \uff0c\u514d\u75ab\u6cbb\u7642\u7684\u9032\u5165\u5fa9\u8208\u65b0\u6642\u4ee3 \uff0c\u6709\u4e9b\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291 (Immune checkpoint inhibitors) \u8b49\n\u5be6\u53ef\u4ee5\u6709\u6548\u6cbb\u7642\u764c\u75c7 \uff0c\u4e14\u9032\u5165\u81e8\u5e8a\u5be6\u7528\u968e\u6bb5 \uff0c\u9032\u4e00\u6b65\u6709\u4e9b\u764c\u75c7\u6cbb\u7642\u6642\u4e5f\u767c\u73fe\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291\u91cd\u8981\u7684 \u300c\u9810\n\u6e2c\u6027\u751f\u7269\u6a19\u8a18\u300d\u3002 \u8f49\u79fb\u6027\u5927\u8178\u764c\u75c5\u4eba\u5728\u63a5\u53d7PD -1\u6297\u9ad4\u85e5\u5291Pembrolizumab (Kytruda)\u6cbb\u7642\u6642\uff0c\u5df2\u77e5\u4e0b\u5217\u4f55\n\u7a2e\u201d\u9810\u6e2c\u6027\u751f\u7269\u6a19\u8a18 \u201d\u60c5\u5f62\u4e0b, Pembrolizumab (Kytruda)\u6cbb\u7642\u8f03\u70ba\u6709\u6548 \uff1f   \nA.MSS (microsatellite stable, \u5fae\u5c0f\u885b\u661f\u9ad4\u7a69\u5b9a\u6027 )\uff0cdefective MMR (mismatch repair \u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\n\u7d20\u7f3a\u9677)\u3002\nB.MSI-H (microsatellite instability -high, \u5fae\u5c0f\u885b\u661f\u9ad4\u9ad8\u5ea6\u4e0d\u7a69\u5b9a\u6027 )\uff0cproficient MMR (mismatch repair \n\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\u7d20\u5b8c\u6574 )\u3002\nC.MSI-H (microsatellite instability -high, \u5fae\u5c0f\u885b\u661f\u9ad4\u9ad8\u5ea6\u4e0d\u7a69\u5b9a\u6027 )\uff0cdefective MMR (mismatch repair \n\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\u7d20\u7f3a\u9677 )\u3002\nD.MSS (microsatellite stable, \u5fae\u5c0f\u885b\u661f\u9ad4\u7a69\u5b9a\u6027 )\uff0cproficient MMR (mismatch repair \u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\n\u7d20\u5b8c\u6574)\u3002\nE.\u4ee5\u4e0a\u7686\u975e\u3002\n": "[C]", "110-143.\u764c\u75c7\u7684\u6a19\u9776\u6cbb\u7642\u85e5\u5291 (molecular targeted agents )\u6216\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291 (immune checkpoint inhibitors )\u901a\u5e38\n\u91dd\u5c0d\u7279\u5b9a\u7684\u5206\u5b50\u6a19\u9776\u6216\u514d\u75ab\u8def\u5f91\u9032\u884c\u6291\u5236 \uff0c\u4ee5\u9054\u5230\u6cbb\u7642\u764c\u75c7\u7684\u76ee\u7684 \u3002\u6cbb\u7642\u300c\u85e5\u5291\u300d\u8207\u5206\u5b50\u6216\u514d\u75ab \u300c\u6a19\n\u9776\u300d\u7684\u914d\u5c0d\uff0c\u4e0b\u5217\u90a3\u4e9b\u70ba\u771f ?(1)Nivolumab \u8207PD-L1 (2)Afatinib\u8207EGFR (3)Trastuzumab \u8207HER-2 \n(4)Rituximab \u8207CD20 (5)Ipilimumab \u8207CTLA-4      \nA.(1)+(2)+(3)+(4)\u3002\nB.(1)+(3)+(4)+(5)\u3002\nC.(2)+(3)+(4)+(5)\u3002\nD.(1)+(2)+(4)+(5)\u3002\nE.(1)+(2)+(3)+(4)+(5)\u3002\n": "[C]", "110-144.\u4e0b\u5217\u90a3\u4e9b\u75c5\u75c7\u6216\u75c7\u5019\u7fa4 (syndrome )\uff0c\u53ef\u80fd\u6703\u589e\u52a0\u75c5\u4eba\u7f79\u60a3\u764c\u75c7\u7684\u98a8\u96aa? (1)Fanconi's anemia (2)Down \nsyndrome (3)Fragile X syndrome (4)von Hippel -Lindau syndrome (5)Neurofibromatosis   \nA.(1)+(3)+(4)\u3002\nB.(2)+(3)+(4)\u3002\nC.(1)+(2)+(3)+(5)\u3002\nD.(1)+(2)+(4)+(5)\u3002\nE.(1)+(2)+(3)+(4)+(5)\u3002\n": "[D]", "111-129.\u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\u4eba\u5e36\u6709\u4e0b\u5217\u67d3\u8272\u9ad4\u6216\u57fa\u56e0\u8b8a\u7570\u7684\u9810\u5f8c\u5f88\u5dee\uff0c\u4f55\u8005\u70ba\u4f8b\u5916\uff1f    \nA.t(6;9)\u3002\nB.t(3;3)\u3002\nC.NPM1 mutation without FLT3-ITD\u3002\nD.TP53 mutation\u3002\nE.ASXL1 mutation\u3002\n": "[C]", "111-130.Ibrutinib\u5065\u4fdd\u53ef\u7d66\u4ed8\u7528\u65bc\u5e36\u670917 p\u7f3a\u640d\u4e14\u5148\u524d\u66fe\u63a5\u53d7\u6cbb\u7642\u4ecd\u60e1\u5316\u6216\u5fa9\u767c\u7684\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u75c5\u4eba \uff0c\u5b83\u7684\n\u4f5c\u7528\u6a5f\u8f49\u70ba\u4f55 \uff1f   \nA.Bruton tyrosine kinase inhibitor\u3002\nB.BCL-2 inhibitor\u3002\nC.MCL-1 inhibitor\u3002\nD.RAS inhibitor\u3002\nE.Immunomudulatory agent\u3002\n": "[A]", "111-131.\u4e00\u4f4d65\u6b72\u75c5\u60a3\u56e0\u75b2\u618a \u3001\u5931\u53bb\u5473\u89ba \u3001\u624b\u8173\u767c\u9ebb\u4f86\u8a3a \uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u767c\u73fevibration sensation\u7570\u5e38 \uff0c\u820c\u982d\u5149\n\u6ed1\u3001\u5473\u857e\u840e\u7e2e \uff1b\u62bd\u8840\u7d50\u679c\u767c\u73feHb 6.1 gm/dL\uff0cMCV 118 fL \uff0c\u767d\u8840\u74033150 /\u00b5L\uff0c\u5206\u985e\u6b63\u5e38 \uff0c\u8840\u5c0f\n\u677f116,000/\u00b5L\uff0c\u7db2\u72c0\u7d05\u8840\u7403 1.1%\u3002\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba \uff1f   \nA.Aplastic anemia\u3002\nB.VitB12 deficiency anemia\u3002\nC.Folic acid deficiency anemia\u3002\nD.Hemolytic anemia\u3002\nE.Lead poisoning\u3002\n": "[B]", "111-132.\u4e0b\u5217\u6709\u95dc\u9663\u767c\u6027\u591c\u9593\u8840\u8272\u7d20\u5c3f(PNH)\u7684\u6558\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f    \nA.PIG-A gene mutation\u3002\nB.Tendency to venous thrombosis\u3002\nC.Reduced haptoglobin levels\u3002\nD.Bilirubinuria\u3002\nE.Responsive to complement 5 (C5) inhibitor treatment\u3002\n": "[D]", "111-133.\u672a\u66fe\u6ce8\u5c04\u904eheparin\u4e4b\u75c5\u4eba \uff0c\u6ce8\u5c04heparin\u5f8c\u5f15\u767c\u8840\u5c0f\u677f\u4f4e\u4e0b (Heparin induced thrombocytopenia )\u6700\u5e38\u51fa\u73fe\n\u7684\u6642\u9593\u70baheparin \u6ce8\u5c04\u5f8c   \nA.1\u5929\u5167\u3002\nB.1\u81f33\u5929\u3002\nC.5\u81f310\u5929\u3002\nD.14\u81f328\u5929\u3002\nE.1\u500b\u6708\u5f8c\u3002\n": "[C]", "111-134.\u4e0b\u5217\u8b8a\u5316\u80fd\u5e6b\u5fd9\u9451\u5225\u75c5\u4eba\u70ba\u539f\u767c\u6027\u591a\u8840\u75c7\u800c\u975e\u6b21\u767c\u6027\u591a\u8840\u75c7\uff0c\u4f55\u8005\u4f8b\u5916?       \nA.JAK2 gene mutation\u3002\nB.Splenomegaly\u3002\nC.Expansion of plasma volume\u3002\nD.Leukocytosis and thrombocytosis\u3002\nE.Elevated erythropoietin level\u3002\n": "[E]", "111-135.\u4e00\u4f4d65\u6b72\u75c5\u4eba\u62b1\u6028\u80c3\u75db \uff0c\u5167\u8996\u93e1\u6aa2\u67e5\u767c\u73fe\u80c3\u7ac7\u6709\u4e00\u816b\u7624 \uff0c\u75c5\u7406\u5207\u7247\u6aa2\u67e5\u986f\u793a\u70bamucosa associated \nlymphoid tissue lymphoma \uff0cCD20\u967d\u6027\u53ca H. Pylori\u967d\u6027 \uff0c\u5206\u671f\u6aa2\u67e5\u672a\u767c\u73fe\u5176\u4ed6\u7570\u5e38 \u3002\u4e0b\u5217\u4f55\u8005\u70ba\u6b64\u75c5\u4eba\u6700\n\u9069\u7576\u7684\u7b2c\u4e00\u7dda\u6cbb\u7642 \uff1f   \nA.Eradication of H. Pylori\u3002\nB.Chemotherapy\u3002\nC.Rituximab\u3002\nD.Rituximab + Chemotherapy\u3002\nE.Watchful waiting\u3002\n": "[A]", "111-136.\u4e0b\u5217\u6709\u95dcTRALI (transfusion -related acute lung injury )\u7684\u654d\u8ff0\u4f55\u8005\u662f\u6b63\u78ba\u7684 ?\n(1) \u591a\u5728\u8f38\u8840 3\u5929\u5f8c\u767c\u751f \n(2) \u767c\u751f\u7684\u539f\u56e0\u5e38\u8207\u6350\u8840\u8005\u9ad4\u5167\u6709\u6297\u53d7\u8840\u8005HLA class II\u4e4b\u6297\u9ad4\u6709\u95dc  \n(3) \u75c5\u4eba\u7684\u80f8\u90e8 X\u5149\u6703\u51fa\u73fe\u5169\u908a\u80ba\u8449\u7684\u6d78\u6f64   \nA.(1)\u3002\nB.(3)\u3002\nC.(2)+(3)\u3002\nD.(1)+(3)\u3002\nE.(1)+(2)+(3)\u3002\n": "[C]", "111-137.\u816b\u7624\u95dc\u806f\u75c7\u5019\u7fa4 (Paraneoplastic syndromes )\u6709\u6642\u7531\u65bc\u816b\u7624\u7522\u88fd \u300c\u7570\u4f4d\u6027\u7684\u8377\u723e\u8499 \u300d(ectopic hormone )\u6240\n\u9020\u6210\u3002\u8b6c\u5982:\u300cSyndrome of inappropriate antidiuretic hormone secretion (SIADH)\u300d\u5e38\u5f15\u767c\u81e8\u5e8a\u7684\u4f4e\u8840\u9209\n\u75c7(hyponatremia )\u3002SIADH\u5e38\u7531\u4e0b\u5217\u4f55\u7a2e \u300c\u7570\u4f4d\u6027\u7684\u8377\u723e\u8499 \u300d(ectopic hormone) \u7522\u88fd\u8207\u5206\u6ccc\u904e\u591a\u6240\u9020\u6210 ?   \nA.Parathyroid hormone-related protein (PTHrP)\u3002\nB.1,25-Dihydroxyvitamin D\u3002\nC.Vasopressin\u3002\nD.Adrenocorticotropic hormone (ACTH)\u3002\nE.Insulin-like growth factor type II (IGF-II)\u3002\n": "[C]", "111-138.\u6709\u95dc\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u7684\u4e0a\u76ae\u764c (Carcinoma of unknown primary, CUP )\uff0c\u9664\u4e86\u75c5\u7406\u7d44\u7e54\u7684 H&E\u67d3\u8272\u578b\u614b\u4e4b\n\u5916\uff0c\u6709\u6642\u9700\u501f\u52a9\u65bc\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u67d3\u8272\u4f86\u5354\u52a9\u5224\u65b7CUP\u7684\u539f\u767c\u5668\u5b98 \u3002\u4e0b\u5217\u54ea\u4e00\u7a2e\u6a19\u8a18\u7684\u6297\u9ad4\u6838\u67d3\u8272 \uff0c\u7d04\n\u670968%\u80ba\u817a\u764c(adenocarcinoma of lung) \u5448\u967d\u6027 \uff0c\u7d04\u6709 25%\u7684\u80ba\u9c57\u72c0\u4e0a\u76ae\u764c (squamous cell carcinoma of \nlung)\u5448\u967d\u6027\uff0c\u7d93\u5e38\u505a\u70ba\u80ba\u81df (lung)\u70baCUP\u539f\u767c\u5668\u5b98\u4e4b\u9451\u5225\u8a3a\u65b7\u8f14\u52a9\u6a19\u8a18\u4e4b \u3127\uff1f   \nA.CDX-2 transcription factor (CDX-2)\u3002\nB.Thyroglobulin\u3002\nC.Thyroid transcription factor 1 (TTF-1)\u3002\nD.Cytokeratin (CK)\u3002\nE.Leucocyte common antigen (LCA)\u3002   \n": "[C]", "111-139.\u5728 COVID -19 \u65b0\u51a0\u75ab\u60c5\u5927\u6d41\u884c (pandemic )\u5371\u6a5f\u671f\u9593 \uff0c\u95dc\u65bc\u764c\u75c7\u75c5\u4eba\u5373\u6642\u63d0\u4f9b\u6cbb\u7642\u7684\u5efa\u8b70\u6307\u5f15 \uff0c\u767c\u8868\u65bc \n(Kutikov A, et al. Ann Intern Med. 2020, DOI: 10 .7326/M20-1133)\u3002\u8a72\u4e00\u6307\u5f15\u5efa\u8b70\u5c0d\u4e0b\u5217\u764c\u75c7\u75c5\u4eba \u201c\u9ad8\u5ea6\n\u512a\u5148\uff08\u7406\u60f3\u60c5\u6cc1\u4e0b, \u4e0d\u61c9\u5ef6\u9072 \uff09\u201d\u5373\u6642\u63d0\u4f9b\u764c\u75c7\u6cbb\u7642 \uff0c\u4f46\u4ee5\u4e0b\u60c5\u6cc1\u53ef\u80fd\u9664\u5916 \uff1a   \nA.Chemotherapy for testicular cancers\u3002\nB.Chronic lymphocytic leukemia\u3002\nC.Small cell lung cancer\u3002\nD.Colon cancer with imminent obstruction\u3002\nE.High-grade soft tissue sarcomas\u3002\n": "[B]", "111-140.\u4e0066\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u8a3a\u65b7\u7f79\u60a3\u4e59\u72c0\u7d50\u8178\u764c (adenocarcinoma, sigmoid colon )\uff0c\u4ee5\u6839\u6cbb\u6027\u624b\u8853\u5207\u9664\u5de6\u5074\u4e59\u72c0\u7d50\n\u8178\u8207\u6dcb\u5df4\u7d50\u5ed3\u6e05\u8853 \uff0c\u75c5\u7406\u7d44\u7e54\u78ba\u5b9a\u624b\u8853\u908a\u7de3\u6c92\u6709\u764c\u7d30\u80de \uff0c\u6e05\u9664\u6dcb\u5df4\u7d50\u517122\u9846\u4e2d\u75c5\u7406\u6aa2\u67e5\u670910\u9846\u5df2\u6709\u764c\u7d30\n\u80de\uff0c\u6c92\u6709\u9060\u8655\u5668\u5b98\u8f49\u79fb \u3002\u91ab\u5e2b\u5efa\u8b70\u624b\u8853\u5f8c \uff0c\u518d\u7d66\u4e886\u500b\u6708\u300c\u8f14\u52a9\u6027(adjuvant) \u5316\u5b78\u6cbb\u7642 \u300d\u4ee5\u964d\u4f4e\u5fa9\u767c\u7387\u8207\n\u589e\u52a0\u5b58\u6d3b \u3002\u4f9d\u64da\u5404\u7a2e \u300c\u81e8\u5e8a\u6307\u5f15\u300d\uff0c \u91ab\u5e2b\u5efa\u8b70\u4e0b\u5217\u4f55\u8005 \u300c\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642 \u300d\u8655\u65b9\u8f03\u70ba\u5408\u9069 \uff1f   \nA.Irinotecan plus 5-FU or Capecitabine (FOLFIRI or CAPIRI/XELIRI)\u3002\nB.Oxaliplatin plus 5-FU or Capecitabine (FOLFOX or CAPOX/XELOX)\u3002\nC.Cetuximab, combined with (FOLFIRI or CAPIRI//XELIRI)\u3002\nD.Bevacizumab, combined with (FOLFOX or CAPOX/XELOX)\u3002\nE.Panitumumab, combined with (FOLFIRI or CAPIRI/XELIRI)\u3002\n": "[B]", "111-141.\u81ea2012\u5e74\u4ee5\u4f86 \uff0c\u514d\u75ab\u6cbb\u7642\u7684\u9032\u5165\u5fa9\u8208\u65b0\u6642\u4ee3 \uff0c\u6709\u4e9b\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291 (Immune checkpoint inhibitors) \u8b49\n\u5be6\u53ef\u4ee5\u6709\u6548\u6cbb\u7642\u764c\u75c7 \uff0c\u4e14\u9032\u5165\u81e8\u5e8a\u5be6\u7528\u968e\u6bb5 \uff0c\u9032\u4e00\u6b65\u6709\u4e9b\u764c\u75c7\u6cbb\u7642\u6642\u4e5f\u767c\u73fe\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291\u91cd\u8981\u7684 \u300c\u9810\n\u6e2c\u6027\u751f\u7269\u6a19\u8a18\u300d\u3002 \u8f49\u79fb\u6027\u5927\u8178\u764c\u75c5\u4eba\u5728\u63a5\u53d7PD -1\u6297\u9ad4\u85e5\u5291Pembrolizumab (Kytruda)\u6cbb\u7642\u6642\uff0c\u5df2\u77e5\u4e0b\u5217\u4f55\n\u7a2e\"\u9810\u6e2c\u6027\u751f\u7269\u6a19\u8a18 \"\u60c5\u5f62\u4e0b, Pembrolizumab (Kytruda)\u6cbb\u7642\u8f03\u70ba\u6709\u6548 \uff1f   \nA.MSS (microsatellite stable, \u5fae\u5c0f\u885b\u661f\u9ad4\u7a69\u5b9a\u6027)\uff0cproficient MMR (\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\u7d20\u5b8c\u6574)\u3002\nB.MSS (microsatellite stable, \u5fae\u5c0f\u885b\u661f\u9ad4\u7a69\u5b9a\u6027)\uff0cdefective MMR (\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\u7d20\u7f3a\u9677)\u3002\nC.MSI-H (microsatellite instability -high, \u5fae\u5c0f\u885b\u661f\u9ad4\u9ad8\u5ea6\u4e0d\u7a69\u5b9a\u6027 )\uff0cproficient MMR (\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\n\u7d20\u5b8c\u6574)\u3002\nD.MSI-H (microsatellite instability -high, \u5fae\u5c0f\u885b\u661f\u9ad4\u9ad8\u5ea6\u4e0d\u7a69\u5b9a\u6027 )\uff0cdefective MMR (\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\u7d20\n\u7f3a\u9677)\u3002\nE.\u4ee5\u4e0a\u7686\u662f\u3002\n": "[D]", "111-142.51\u6b72\u5973\u6027\u75c5\u4eba \uff0c3\u5e74\u534a\u4e4b\u524d \uff0c\u56e0\u5f8c\u4e0a\u80cc\u90e8\u9ed1\u8272\u7d20\u7624 (melanoma )\u624b\u8853\u5207\u9664 \uff0c\u764c\u75c7\u5206\u671f\u7b2cIIB \u671f\u3002\u6700\u8fd1\u56e0\u547c\u5438\n\u6025\u4fc3\u81f3\u6025\u8a3a\u5c31\u91ab \uff0c\u767c\u73fe\u5169\u5074\u80ba\u91ce\u591a\u767c\u75c5\u7076 \uff0c\u5f8c\u7e8c\u6aa2\u67e5\u8b49\u5be6\u60e1\u6027\u9ed1\u8272\u7d20\u7624\u591a\u767c\u5169\u5074\u80ba\u8f49\u79fb \u3002\u5728\u6c7a\u5b9a\u9078\u64c7\u6a19\u9776\n\u6cbb\u7642\u3001\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291 \u3001\u6216\u5316\u5b78\u6cbb\u7642\u4e4b\u524d \uff0c\u61c9\u6aa2\u9a57\u4f55\u7a2e\u57fa\u56e0\u7a81\u8b8a (genetic mutation )\u7684\u6709\u7121\uff0c\u5c0d\u65bc\u9078\u64c7\u4f55\n\u7a2e\u6a19\u9776\u6cbb\u7642\u6709\u6700\u91cd\u8981\u7684\u53c3\u8003\u50f9\u503c ?   \nA.C-KIT\u3002\nB.NRAS\u3002\nC.HRAS\u3002\nD.ERK\u3002\nE.BRAF\u3002   \n": "[E]", "111-143.\u764c\u75c7\u5206\u671f\u5c6cBCLC (Barcelona Clinic Liver Cancer staging) \u7b2cC \u671f\u7684\u665a\u671f\u809d\u764c (HCC)\u75c5\u4eba\uff0c\u5df2\u77e5\u53d7\u76ca\u65bc\u5168\n\u8eab\u6027\u85e5\u5291\u6cbb\u7642 \u3002\u5df2\u6709\u6578\u500b\u809d\u764c\u7684\u6a19\u9776\u6cbb\u7642\u85e5\u5291 (molecular targeted agents, MTAs )\u6216\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\n\u5291(immune checkpoint inhibitors, ICIs )\uff0c\u55ae\u7368\u6216\u7d44\u5408\u4f7f\u7528 \uff0c\u7b2c\u4e00\u7dda\u6216\u7b2c\u4e8c\u7dda\u4f7f\u7528 \uff0c\u7531\u81e8\u5e8a\u8a66\u9a57\u8b49\u5be6\u53ef\u6709\u6548\n\u5ef6\u9577\u4e2d\u4f4d\u6578\u7e3d\u5b58\u6d3b\u671f (median overall survival )\u7684\u76ee\u7684\u3002(1) Sorafenib (2)Lenvatinib (3)Atezolizumab \n(4)Bevacizumab (5)Regorafenib \u3002\u4e0b\u5217\u6a19\u9776\u6cbb\u7642\u85e5\u5291 (MTAs)\u8207\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291 (ICIs)\u7684\u54ea\u4e00\u500b \u300c\u7d44\n\u5408\u300d\uff0c  \u91dd\u5c0d\u7121\u6cd5\u624b\u8853\u6210\u529f\u5207\u9664\u7684\u809d\u764c (unresectable HCC )\u75c5\u4eba\uff0c\u5df2\u7531\u81e8\u5e8a\u8a66\u9a57\u8b49\u5be6 \uff0c\u7b2c\u4e00\u7dda(1st-line)\u7684\u5168\n\u8eab\u6027\u85e5\u5291\u6cbb\u7642 \uff0c\u53ef\u9054\u7d71\u8a08\u4e0a\u986f\u8457\u5ef6\u9577\u4e4b\u4e2d\u4f4d\u6578\u7e3d\u5b58\u6d3b\u671f (\u7d0419.2\u500b\u6708) \u7684\u76ee\u7684 \uff0c\u767c\u8868\u65bc (N Engl J Med \n2020 May 14 ;382(20):1894 -1905)\u3002   \nA.(1)+(3)\u3002\nB.(2)+(3)\u3002\nC.(3)+(4)\u3002\nD.(3)+(5)\u3002\nE.(1)+(5)\u3002\n": "[C]", "111-144.\u764c\u75c7\u7684\u6a19\u9776\u6cbb\u7642\u85e5\u5291 (molecular targeted agents )\u6216\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291 (immune checkpoint inhibitors )\u901a\u5e38\n\u91dd\u5c0d\u7279\u5b9a\u7684\u5206\u5b50\u6a19\u9776\u6216\u514d\u75ab\u8def\u5f91\u9032\u884c\u6291\u5236 \uff0c\u4ee5\u9054\u5230\u6cbb\u7642\u764c\u75c7\u7684\u76ee\u7684 \u3002\u6cbb\u7642\u300c\u85e5\u5291\u300d\u8207\u5206\u5b50\u6216\u514d\u75ab \u300c\u6a19\n\u9776\u300d\u7684\u914d\u5c0d\uff0c\u4e0b\u5217\u90a3\u4e9b\u70ba\u771f ?\n(1) Rituximab \u8207CD20\n(2) Osimertinib \u8207EGFR\n(3) Trastuzumab \u8207HER-2\n(4) Nivolumab \u8207PD-1\n(5) Ipilimumab \u8207CTLA-4   \nA.(1)+(2)+(3)+(4)\u3002\nB.(2)+(3)+(4)+(5)\u3002\nC.(2)+(3)+(4)\u3002\nD.(3)+(4)+(5)\u3002\nE.(1)+(2)+(3)+(4)+(5)\u3002\n": "[E]"}